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molecular tweezers with different guest molecules will be discussed. In the final part, the 
anticancer potential of dinuclear ruthenium, rhodium and iridium complexes are evaluated 
with different cancer cell lines. 
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1. General Introduction 
1.1. Metal carbonyl complexes 
Families of metal carbonyls are well known for their interesting structural features and 
for their versatile applications not only in the field of catalysis like Monsanto and Cativa 
processes but also in biological and supramolecular chemistry. The remarkable stability of 
metal carbonyl complexes is achieved by the “π back-bonding” involvement of the metal d-
orbitals and carbonyl ligands (Fig. 1). 
 
        
 
Fig. 1. The p-orbital of carbonyl ligand gives an unshared pair of electrons to the vacant d-orbital of 
the metal through σ-bonding. The filled d-orbital of the metal gives back an electron to the anti-
bonding p-orbital of CO through π back-bonding (dπ → pπ*). (Picture taken from1) 
 
Two different kinds of metal carbonyls exist, namely the homoleptic and the 
heteroleptic. The homoleptic is metal carbonyl complexes containing identical ligands for 
example, Ni(CO)4, Fe(CO)5, Cr(CO)6, Fe3(CO)12, Ru3(CO)12 and Os3(CO)12. The heteroleptic 
is metal carbonyl complexes containing more than one type of ligands for example, 
Re(CO)3(2,2’-bpy)Cl (bpy = 2,2’-bipyridine) and IrCl(CO)2. 
The most straightforward way to synthesize metal carbonyls is through reduction of 
the corresponding metallic salt under a high pressure of carbon monoxide. Among the 
transition metal catalysts, ruthenium carbonyl clusters have played an important role in 
catalysis due to the plethora of applications that were made since its discovery. The 
production of the ruthenium carbonyl cluster, dodecacarbonyltriruthenium {Ru3(CO)12}, 
involves high temperature and high pressure (120 ºC, 65 bar of CO), which yields modest 
σ-bonding π back-bonding 
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amounts of Ru3(CO)12.
2
 Fauré et al.
3
 have produced Ru3(CO)12 in one pot in ethylene glycol 
under milder conditions with a relatively moderate yield. Since then, other methods have also 
been reported for the synthesis of Ru3(CO)12.
4
 Notably, the recent method using microwave 
gave very high yield up to 90 % of Ru3(CO)12 even under very low CO pressure (3.5 bar).
5
 
Ru3(CO)12 was characterized by IR spectroscopy which showed the corresponding CO 
absorption bands [ν(CO), 2011 (m), 2030 (s), 2060 (vs) cm
-1
].
3
 X-ray structure of Ru3(CO)12 
was reported by Mason et al.
6
 which demonstrated that the trinuclear ruthenium was 
coordinated to 12 carbonyl ligands in terminal positions to form a symmetrical ruthenium 
cluster (Fig. 2). 
 
 
Fig. 2. Structural representation of dodecacarbonyltriruthenium Ru3(CO)12. 
 
1.2. Sawhorse-type diruthenium tetracarbonyl complexes 
 Among ruthenium carbonyls, complexes having Ru2(CO)4 backbone with a typical 
sawhorse-type geometry are well known for their applications in catalysts, liquid crystals, 
bioactive substances and also as supramolecular materials.
7
 Sawhorse-type diruthenium 
tetracarbonyl complexes are synthesized from the precursor Ru3(CO)12. In 1969, Lewis et al.
8
 
introduced a method for the synthesis of sawhorse-type diruthenium tetracarbonyl complexes. 
Refluxing Ru3(CO)12 with carboxylic acids, RCOOH (R = H, CH3, C2H4 or n-C9H19) gave 
yellow-orange polymeric material, [Ru2(CO)4(OOCR)2]n (R = H, CH3, C2H4 or n-C9H19). 
Depolymerization of this material can be achieved using coordinating solvents 
{tetrahydrofuran (thf) or acetonitrile}. Addition of monodentate ligands such as pyridine, 
acetonitrile or phosphine affords stable dinuclear tetracarbonyl complexes (Fig. 3). 
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2/3 Ru3(CO)12 + 2 RCOOH + 2 L → Ru2(CO)4(OOCR)2L2 + 4 CO + H2               (eq. 1) 
 
                         
Fig. 3. The sawhorse geometry of [Ru2(CO)4(OOCR)2L2] complexes. 
 
 
Fig. 4. IR-spectrum of Ru2(CO)4(OOCEt)2(N2C3H4)2. (Picture taken from
7
) 
 
The structure of Ru2(CO)4 sawhorse-type complexes can be easily recognized by their 
characteristic three IR band patterns (very strong-medium-very strong) between 1900 to 2050 
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cm
-1
. Asymmetric and symmetric absorption stretching frequencies of the bridging µ2-η
2
-O,O 
carboxylato groups are observed between 1550 and 1400 cm
-1 
(Fig. 4). 
In 1977, Schumann et al.
9
 reported the single crystal X-ray structure of tri(t-
butyl)phosphine derivative of the sawhorse-type complex, Ru2(CO)4(OOCBu
n
)2(PBu
t
3)2, 
which clearly showed the dinuclear ruthenium-ruthenium backbone, and each ruthenium 
atom having two carbonyl ligands in the remaining equatorial positions. The Ru2(CO)4 unit 
carries two µ2-η
2
-O,O carboxylato groups coordinated in four equatorial positions of the two 
ruthenium atoms and the two tri(t-butyl)phosphine ligands are coordinated in the axial 
position of ruthenium atoms. Later, Jones and co-workers
10
 also obtained the crystal structure 
of di(t-butyl)phosphine derived diruthenium tetracarbonyl complex, Ru2(CO)4(OOCMe)2-
(PBu
t
2H)2 which displayed a similar structure as Ru2(CO)4(OOCBu
n
)2(PBu
t
3)2 (Fig. 5). 
 
           
[Ru2(CO)4(OOCBu
n
)2(PBu
t
3)2]                                  [Ru2(CO)4(OOCMe)2(PBu
t
2H)2] 
Fig. 5. ORTEP representation of diruthenium complexes Ru2(CO)4(OOCBu
n
)2(PBu
t
3)2,
7,9
 and 
Ru2(CO)4(OOCMe)2(PBu
t
2H)2.
7,10
 (Picture taken from
7
) 
 
 In 1985, Süss-Fink and co-workers
11
 analysed the polymeric propionato dinuclear 
tetracarbonyl material derived from propionic acid on refluxing with Ru3(CO)12 in thf 
medium. Infrared and raman spectroscopic analyses showed that diruthenium unit 
coordinates with propionato ligand in equatorial position and the dinuclear units were held 
together by a strong interaction between an oxygen atom of carboxylato bridge and a 
ruthenium atom of the neighboring dinuclear unit (Ru-O) (Fig. 6). This model is widely 
accepted for the polymeric nature of [Ru2(CO)4(OOCR)2]n.  
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Fig. 6. The polymeric chain of sawhorse units [Ru2(CO)4(OOCEt)2]n.
7
 
 
Süss-Fink and co-workers
12
 have used a variety of carboxylic acids for the synthesis 
of sawhorse-type diruthenium complexes from Ru3(CO)12. All reactions were carried out in a 
pressure Schlenk tube at 120 ºC using thf as solvent. They further extended their synthesis to 
other ligands such as carboamido (RCONH2),
13
 pyrazolato (C3R1R2R3N2H),
14
 oxinato 
(R1R2CNOH)
15
 and sulfanato (R2SO3H)
16
 derivatives to get access to other sawhorse-type 
diruthenium complexes. The only drawback of this method is that, for the high temperature 
reactions (120 ºC) in the presence of low boiling solvent like thf (b.p. 66 ºC), a pressure 
Schlenk tube or an autoclave is required, which is not always readily available in most 
synthetic laboratories. This difficulty could be overcome by performing the reaction in 
anhydrous methanol, which requires only reflux conditions. It was observed that even under 
these mild conditions, the yields of the reaction were almost identical to those of the reaction 
at high temperature in a pressure Schlenk tube.
12a,12d
 
2 [Ru(CO)2Cl2]n + 4 RCOONa + 2 L → [Ru(CO)2(OOCR)L]2 + CO2 + 4 NaCl             (eq. 2) 
 Spiccia and co-workers
17
 reported a benign and efficient alternative method for the 
synthesis of sawhorse-type diruthenium complexes. Refluxing ruthenium trichloride hydrate 
(RuCl3 · xH2O) with formic acid, which provided a polymeric ruthenium dichloride 
[Ru(CO)2Cl2]n material
18
 that can be isolated. Addition of sodium carboxylate and a two-
electron donor ligand to this material in methanol at reflux condition for 2.5 h afforded 
diruthenium complexes [Ru2(CO)4(OOCR)2(L)2] (eq. 2). Notably, the yields were found to be 
lower than those obtained from Ru3(CO)12. However this method was found to have more 
advantageous, for example, the starting precursor RuCl3 · xH2O is less expensive than 
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Ru3(CO)12 and shorter reaction time and milder synthesis conditions are surely interesting 
enough to consider this as an effective alternative method.  
 
1.3. Catalytic activity of sawhorse-type diruthenium tetracarbonyl complexes 
Diruthenium tetracarbonyl complexes of the type [Ru2(CO)4(OOCR)2L2] and their 
polymeric derivatives [Ru2(CO)4(OOCR)2]n have been extensively studied for 
hydrogenation,
19
 isomerization,
20
 carbonylation,
21
 carbon-carbon
22
 and carbon-oxygen 
coupling
23
 reactions. Recent review from Therrien et al.
7
 summarized all the different 
catalytic applications of the sawhorse-type Ru2(CO)4 complexes. 
Frediani et al.
19a
 reported the hydrogenation of hex-1-ene using dinuclear catalyst 
[Ru2(CO)4(OOCCH3)2(biisoq)2][CH3COO] (biisoq = 1,1’-biisoquinoline) (Fig. 7) under H2 
(100 bar) in a methanol/water mixture (catalyst/substrate ratio of 1:1000 at 60 ºC for 6 h) 
resulted in 87 % of hexane (eq. 3). Similar type of catalyst [Ru2(CO)4(OOCCH3)(bpy)2]-
[CH3COO] (bpy = 2,2’-bipyridine) was used for the catalytic hydrogenation of acetone under 
100 bar pressure of H2 {100 ºC, methanol/water (2:1), catalyst/substrate (1:3800)} with 
catalytic turnover frequencies (TOF) up to 142 h
-1 
and provided 89 % yield of isopropanol.
19b
 
The dinuclear complexes such as [Ru2(CO)4(OOCCH3)2(PBu3)2] and [Ru2(CO)4-
{OOCCH(OH)CH(OH)COO}(bipy)2] were reported as catalysts for hydrogenation of 
cyclohexene and of styrene, respectively. In the first case, catalyst [Ru2(CO)4-
(OOCCH3)2(PBu3)2] reduced cyclohexene under 130 bar of H2 at 60 ºC for 22 h with a 
catalyst/substrate ratio of 1:2300 to provide cyclohexane with 22 % yield.
24
 The same catalyst 
is also efficient for the hydrogenation of ketone to alcohol for example, 1-phenylethanol was 
prepared from acetophenone at 120 ºC with 66 % conversion (catalyst/substrate 1:2300, H2 = 
130 atm).
24
 In the second case, the catalyst [Ru2(CO)4{OOCCH(OH)CH(OH)COO}(bipy)2] 
gave ethyl benzene by the hydrogenation of styrene with a catalyst/substrate ratio of 1:100 
under 100 bar of H2 using methanol/water as solvent at 100 ºC for 6 h with 91 % yield.
25
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Fig. 7. Suggested chemical structure of catalyst [Ru2(CO)4(OOCCH3)(biisoq)2][CH3COO]. 
 
In 1989, Süss-Fink and co-workers
26
 synthesized dinuclear Ru2(CO)4 complexes 
using bisphosphines such as dppe {1,2-bis(diphenylphosphino)ethane} (i), cyclop {1,2-
bis(diphenylphosphinomethyl)cyclohexane} (ii), diop {4,5-bis(diphenyl-phosphinomethyl)-
2,2-dimethyl-1,3-dioxolane} (iii) (Fig. 8) which were used for hydrogenation of 
hydroxyacetone. These chiral catalysts showed satisfactory catalytic turnovers, but with very 
low enantioselectivity. 
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Fig. 8. Chiral bis-phosphine derived sawhorse-type Ru2(CO)4 complexes. 
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The chiral dinuclear complex [Ru2(CO)4(OOCCH3)2(diop)] converts hydroxyacetone 
to 1,2-propanediol (eq. 4) under 40 bar of H2 in tetrahydrofuran at 120 ºC, which results in 14 
% enantiomeric exess with 67 % conversion (catalyst/substrate ratio 1:1000).
27
 2-Methyl-
butanoic acid was obtained by the hydrogenation of tiglic acid in the presence of 
[Ru2(CO)4(OOCCH(CH3)CH2CH3)2(diop)] as catalyst (eq. 5). The hydrogenation reaction 
was carried out under a H2 pressure of 130 atm, in toluene/ethanol (1:1) as solvent mixture at 
100 ºC for 4 h with catalyst/substrate ratio 1:655, providing 95 % conversation with 37 % of 
optical purity.
28
 
 
 
Diruthenium carbonyl complexes efficiently catalyze the reduction of saturated 
aliphatic carboxylic acids, which are one of the industrially important bulk chemicals. 
[Ru4H4(CO)8(PBu3)4] could reduce the easily available acetic acid to ethyl acetate (eq. 6) 
under H2 (130 atm) at 180 ºC for 48 h with 37 % conversion; while the conversion has been 
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increased up to 69 % with an increase in temperature to 200 ºC  also with the formation of 
ethyl alcohol as a side product.
29
 The phosphine-substituted ruthenium carbonyl carboxylate 
[Ru2(CO)4(OOCCH3)2(PBu3)2] catalyzed the hydrogenation of dimethyl oxalate under H2 
(130 atm) at 180 ºC for 50 h affording 100 % conversion to methyl glycolate in benzene (eq. 
7).
30
 
 
1.4. Arene ruthenium complexes 
In 1967, Winkhaus and Singer discovered the first arene ruthenium complex by 
dehydrogenation of 1,3-cyclohexadiene (C6H8) with ruthenium trichloride hydrate (RuCl3· 
xH2O) in ethanolic medium under reflux condition. The obtained orange-red precipitate of 
the neutral diamagnetic complex was considered to be a polymeric material and they 
proposed an empirical formula for the polymeric structure [(C6H6)RuCl2]n (eq. 8).
31
  
 
 
 
However, the structure was considered to be a polymer until Baird
32
 and Bennett
33
 
revealed that the proposed polymeric structure was erroneous and showed that this complex 
actually had a dimeric structure [(η6-C6H6)Ru(µ-Cl)Cl]2, where each ruthenium atom is in +2 
oxidation state. The arene hapticity (η) is six and two units of (C6H6)RuCl are linked by the 
chloro bridge. Later, Canivet et al.
34
 showed the X-ray crystal structure of di-µ-chloro-
bis[(η6-benzene)chlororuthenium(II)] (Fig. 9). 
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Fig. 9. Structure of [(η6-C6H6)Ru(µ-Cl)Cl]2. (crystal structure taken from
34
) 
 
After the discovery of the of arene ruthenium dimeric structure, a remarkable number 
of arene ruthenium complexes has been synthesized. The dimeric p-cymene di-ruthenium 
complex [(η6-p-MeC6H4Pr
i
)Ru(µ-Cl)Cl]2 was synthesized by the dehydrogenation of the 
electron poor diene (α)-phellandrene with ruthenium(III) trichloride hydrate in refluxing 
ethanol (eq. 9).
33,35
 
 
 
1.5. Pentamethylcylopentadienyl rhodium and iridium complexes 
Kang et al.
36
 showed the synthesis of dichloro(η5-pentamethylcyclopentadienyl)-
rhodium and iridium dimers from methanol solution of rhodium trichloride hydrate (RhCl3 · 
xH2O) or iridium trichloride hydrate (IrCl3 · xH2O) with hexamethylbicyclo[2,2,0]hexadiene 
(HMDB). The HMDB undergoes ring-contraction under acidic condition and leads to the 
formation of pentamethylcyclopentadienylrhodium and iridium dimers (eq. 10). 
Subsequently, White et al. 
37
 developed another synthetic route to prepare Rh(III) and Ir(III) 
dimers by the reaction of pentamethylcyclopentadiene with metal hydrates in reagent-grade 
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methanol under nitrogen atmosphere for 48 h which resulted in air stable red crystalline 
powders [(η5-C5Me5)M(µ-Cl)Cl]2 (M = Rh and Ir)] (eq. 11). 
 
 
 
1.6. Reactivity of dinuclear Ru, Rh and Ir sulfur bridged complexes 
 Transition metal complexes with sulfur ligands especially thiol derivatives, have 
interesting structural properties and excellent reactivity.
38
 The thiolato bridged dinuclear 
cationic complexes are synthesized from the starting precursors, such as [(η6-p-
MeC6H4Pr
i
)Ru(µ-Cl)Cl]2 or [(η
5
-C5Me5)M(µ-Cl)Cl]2 (M = Rh and Ir)]. The dimeric arene-
ruthenium dichloride complexes were found to react with thiols to give cationic thiolato-
bridged arene-ruthenium complexes of the type [(η6-arene)2Ru2(µ-SR)3]
+
. Schacht et al.
39
 
reported the first thiolato-bridged complex [(η6-C6Me6)2Ru2(µ-SC6H5)3]
+
, which was derived 
from hexamethylbenzene ruthenium dimer [(η6-C6Me6)Ru2(µ-Cl)Cl]2 (Fig. 10). Mashima et 
al.
40
 reported another complex of this type [(η6-p-MeC6H4Pr
i
)2Ru2(µ-SC6H5)3]
+
 derived from 
p-cymene ruthenium dimer (Fig. 10). 
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Fig. 10. Structures of cationic [(η6-C6Me6)2Ru2(µ-SC6H5)3]
+
 (left) and [(η6-p-MeC6H4Pr
i
)2Ru2(µ-
SC6H5)3]
+
 (right) complexes. 
 
Similarly, Nishio et al.
41
 reported the neutral [(η5-C5Me5)Ir(µ-SCH2C6H5)Cl]2 (Fig. 
11) and the cationic [(η5-C5Me5)2Ir2(µ-SCH2CH3)3]
+
 (Fig. 11) dinuclear Ir complexes 
containing bridging thiolato ligands. Complex [(η5-C5Me5)Ir(µ-SCH2C6H5)Cl]2 was 
synthesized from the reaction of [(η5-C5Me5)Ir(µ-Cl)Cl]2 with benzyl mercaptan 
(C6H5CH2SH) in CH2Cl2 at room temperature for 12 h. While, [(η
5
-C5Me5)Ir(µ-Cl)Cl]2 
reacted with ethanethiol (CH3CH2SH) in CH2Cl2 at room temperature for 6 h to give the 
cationic complex [(η5-C5Me5)2Ir2(µ-SCH2CH3)3]
+
.  
 
 
Fig. 11. Structures of dinuclear Ir complexes [(η5-C5Me5)2Ir2(µ-SCH2Ph)2Cl2] (left) and [(η
5
-
C5Me5)2Ir2(µ-SCH2CH3)3]
+
(right). 
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Süss-Fink and co-workers
42
 reported the star-like tris-thiobromo dinuclear(II) cationic 
complexes [(η6-p-MeC6H4Pr
i
)2Ru2(µ-SC6H4-p-Br)3]
+
 (Fig. 12) and [(η5-C5Me5)2Rh2(µ-
SC6H4-p-Br)3]
+
 synthesized from ruthenium [(η6-p-MeC6H4Pr
i
)Ru(µ-Cl)Cl]2 and rhodium 
[(η5-C5Me5)Rh(µ-Cl)Cl]2 dimers, respectively. The star-like trisbromo cationic complexes 
undergo a triple Suzuki coupling with oligophenylene boronic acids (thiophene boronic 
acids) to give [(η6-p-MeC6H4Pr
i
)2Ru2(µ-SC6H4-p-C4H3S)3]
+
 and [(η5-C5Me5)2Rh2(µ-SC6H4-
p-C4H3S)3]
+
 (Fig. 12). The electrochemical and optical properties of these complexes have 
been studied. 
 
 
Fig. 12. Structures of star-like cationic [(η6-p-MeC6H4Pr
i
)2Ru2(µ-SC6H4-p-Br)3]
+
 (left) and [(η5-
C5Me5)2Rh2(µ-SC6H4-p-C4H3S)3]
+
 (right) complexes. 
 
They also reported a series of cationic diruthenium trithiolato complexes [(η6-
arene)2Ru2(µ-SR)3]
+
 which were tested for anticancer activity. The water soluble cationic 
trithiolato complexes showed high cytotoxicity against human ovarian cancer cells even in 
the submicromolar range. From the in vitro studies, it was shown that the cationic complex 
[(η6-p-MeC6H4Pr
i
)2Ru2(µ-SC6H4-CH3)3]
+
 (Fig. 13) has IC50 of 0.13 µM on A7280 and 0.08 
µM on A2780cisR ovarian cancer cell lines.
43
 The neutral dithiolato complexes were also 
obtained from the reaction of [(η6-p-MeC6H4Pr
i
)Ru(µ-Cl)Cl]2 with thiolates at 0 ºC in 
technical-grade ethanol. The antiproliferative activities of the dithiolato complexes were 
evaluated against human ovarian cancer cell lines. Following in vitro studies, the neutral 
dithiolato complex [(η6-p-MeC6H4Pr
i
)2Ru2(µ-SCH2CH2Ph)2Cl2] (Fig. 13) has shown very 
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high cytotoxicity (IC50 values of 0.02 µM on A2780 and 0.31 µM on A2780cisR ovarian 
cancer cell lines).
38a
  
 
 
Fig. 13. Highly cytotoxic thiolato complexes [(η6-p-MeC6H4Pr
i
)2Ru2(µ-SC6H4-CH3)3]
+
 (left) and [(η6-
p-MeC6H4Pr
i
)2Ru2(µ-SCH2CH2Ph)2Cl2] (right). 
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1.7. Aim of the present work 
The aim of this thesis was to develop a novel series of dinuclear metal complexes, for 
catalytic, supramolecular and biological applications. The first part of the work deals with the 
synthesis, characterization and exploration of the hydrogenation potential of sawhorse-type 
diruthenium tetracarbonyl complexes in supercritical carbon dioxide (scCO2) medium. The 
second part of the thesis highlights the possible supramolecular applications of sawhorse-type 
diruthenium complexes, and in the final part we explored the anticancer activity of dinuclear 
Ru, Rh and Ir complexes. 
The catalytic activity in scCO2 was studied in collaboration with Dr. L. Plasseraud, 
UMR CNRS 6302, Université de Bourgogne, France. During a collaboration with Dr. N. 
Armaroli at the CNR-ISOF, Bologna, Italy, molecular tweezer applications of dinuclear 
complexes were explored. Dr. F. Schmitt from the CHUV in Lausanne, Switzerland and Dr. 
N. Nagesh from CCMB, Hyderabad, India helped us with the biological studies and related 
applications. 
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2. Catalytically active dinuclear ruthenium complexes 
2.1. Supercritical carbon dioxide in catalysis 
Supercritical carbon dioxide (scCO2) is an interesting reaction medium for 
homogenous catalysis due to its inertness to most catalytic reactions, whilst in some cases it 
has also been employed as a reactant. Supercritical fluid is one of the best ecologically 
friendly alternatives to conventional solvents and it attracted the attention of chemists due to 
its abundance in nature, its non-toxicity, non-flammability, non-corrosive nature, it is also 
inexpensive, readily available and it could be easily removed from the reaction mixture.
44
 
Normally, in a standard temperature and pressure (STP) it behaves as a gas, while at pressure 
of (Pc) 72.9 bar at (Tc) 31.0 ºC, the gas converted into a fluid called supercritical fluid (Fig. 
14).
44
  
 
 
Fig. 14. Schematic phase diagram of carbon dioxide fluid (T: triple point, C: critical point). Picture 
taken from.
45
 
 
Noyori and co-workers
46
 showed that transition metal complexes of trialkylphosphine 
derivatives were highly soluble in scCO2 with an excellent catalytic activity for the 
homogenous hydrogenation of CO2 in the supercritical state. The catalysts RuH2{P(C6H5)3}4, 
RuH2{P(CH3)3}4, RuCl2{P(CH3)3}4, RuCl(O2CCH3){P(CH3)3}4, trans-RuCl2(dmpe)2, trans-
RuHCl(dmpe)2 {dmpe = (CH3)2P(CH2)2P(CH3)2} and Ru3(CO)12 have been studied for 
hydrogenation of scCO2 to formic acid, alkyl formate and formamides. Among these 
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catalysts, the more active catalyst precursors are shown in Fig. 15, and the catalyst 
[RuCl2{P(CH3)3}]4 showed excellent catalytic activities (eq 12-14). 
 
 
Fig. 15. Catalytically active transition metal trialkylphosphine complexes.
46
 
 
 
The Ru(II)phosphine catalyst [RuCl2{P(CH3)3}4] promoted the hydrogenation of 
scCO2 to formic acid (eq. 12) in the presence of triethylamine under a supercritical mixture 
{80 atm of H2 and 130 atm CO2} at 50 ºC with a turn over number (TON) up to 7,200.
46-47
 
With methanol as additive in the presence of triethylamine at 80 ºC, the same catalyst 
converted formic acid  into methyl formate (eq. 13) by dehydration (80 atm of H2 and 130 
atm of CO2) and with a TON up to 3,500.
46
 While replacing the base from triethylamine to 
dimethylamine, the catalyst efficiently produced dimethylformamide (DMF) with a very high 
turnover number 370,000 {under 80 atm of H2 and 130 atm of CO2} at 100 ºC in supercritical 
fluid (eq. 14).
45,48
 
One of the major obstacles in green catalysis is the poor solubility of metal complexes 
in scCO2 and this problem has been circumvented by the addition of fluorinated alcohols to 
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the reaction mixture.
45,49
 Introducing fluorinated counter-anions such as tetrakis-{3,5-
bis(trifluoromethyl)phenyl}borate (BARF) or trifluoromethanesulfonate (CF3SO3) with 
cationic catalyst
44
 or ligand modifications using “fluorous ponytails” (perfluroalkyl-
substituted) in transition metal catalyst,
50
 has improved the solubility of metal complexes in 
scCO2 as well as increased the catalytic activity. 
Noyori and co-workers
49
 showed the hydrogenation of α,β-unsaturated carboxylic 
acid in scCO2 medium in the presence of optically active catalyst [Ru(OOCCH3)2{(S)-H8-
binap}] {binap = 2,2’-bis(diphenylphosphino)-1,1’-binaphthyl} (Fig. 16). For example, 
hydrogenation of tiglic acid to (S)-2-methylbutanoic acid in the presence of catalyst in scCO2 
(33 atm H2 and 175 atm CO2) afforded 99 % conversion with 81 % ee at 50 ºC. While 
introducing the fluorinated additive like pentadecafluoro-1-octanol {CF3(CF2)6CH2OH} 
significantly increased the catalyst solubility in scCO2 with enantioselectivities up to 89 % 
even under a very low (5 atm) H2 pressure (eq. 15).  
 
 
Fig. 16. Molecular structure of catalyst [Ru(OOCCH3)2{(S)-H8-binap}]. 
 
Burk and Tumas
44
 employed the highly lipophilic fluorinated counter-anion [B{3,5-
(CF3)2C6H3}4]
- 
{tetrakis-(3,5-bis(trifluoromethyl)phenyl)borate (BARF)} with cationic 
 Chapter 2: Catalytically active dinuclear ruthenium complexes 
 
 
24 
 
rhodium catalysts in order to improve the solubility in scCO2 (Fig. 17). This strategy was 
successfully used for asymmetric catalytic hydrogenation. 
 
 
Fig. 17. Cationic rhodium catalyst employed with fluorinated counter-anion.
44
 
 
Later, Leitner and co-workers
50
 showed an alternative approach to improve the 
solubility of transition metal complexes in supercritical fluid by introducing “fluoro-
ponytails” at the periphery of bis-arylphosphanes ligands (Fig. 18). The CO2-philic or 
fluorophilic long perfluroalkyl-substituted chain {m-(CH2)2(CF2)nCF3} directly attached to a 
bidentate chelating arylphosphane of transition metal complexes remarkably increased the 
solubility in scCO2 without changing their catalytic properties. 
 
 
 
 
 
 
 
 
Fig. 18. Transition metal complexes attached with “Fluoro-ponytails”.50 
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 The complex RuCl2(dppe)2 {dppe = (C6H5)2P(CH2)2P(C6H5)2} is an active catalyst 
showing very high turnover number (up to 740,000) for dimethylformamide (DMF) 
productions (H2 = 84 atm, CO2 = 128 atm, T = 99 ºC, additive = dimethylamine). Though, 
catalyst RuCl2(dppe)2 is not soluble in scCO2; the dimethylammonium dimethylcarbamate 
formation from additive (dimethylamine) in scCO2 in the reaction medium influenced the 
catalyst solubility.
51
 Berven et al.
51b
 have improved the catalyst (RuCl2(dppe)2) solubility by 
attaching fluoro-ponytail of (CF2)5CF3 to dppe. The incorporation of eight perfluoroalkyl 
“ponytails” {(CF2)5CF3} enhanced the solubility of the metal complex in scCO2 when 
compared to the insoluble parent compound. They suggested that, the highly CO2-philic 
complex of ruthenium RuCl2(dfppe)2 {dfppe = {CF3(CF2)5(p-C6H4)}2P(CH2)2P{(p-C6H4)-
(CF2)5CF3}2 could be a potential catalyst in supercritical fluids (Fig. 19) for DMF 
productions.
51b
 
 
 
Fig. 19. Ruthenium chloro complex attached with di-phosphine ligand of “Fluoro-ponytail”.51b 
 
 
Sakakura and co-workers
52
 reported the hydrosilation of polyfluoroolefin in the 
presence of the catalyst RuCl2{P(C6H4-p-CF3)3}3, which resulted in high yield (74 %) with 
high selectivity (98 %) in scCO2 under 300 atm of CO2, at 90 ºC for 24 h (catalyst/substrate 
ratio 1:200) (eq. 16). The high conversion and selectivity were achieved because of the 
remarkable solubility of the catalyst in scCO2. 
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2.2. Sawhorse-type complexes containing μ2-η
2 
carboxylato ligands derived from 
saturated fatty acids and fluorinated fatty acids 
 Since the discovery of sawhorse-type diruthenium complexes, a considerable number 
of complexes with carboxylato bridges have been synthesized and they have been studied for 
different catalytic applications. Recent review gave a detailed view of the chemistry of 
sawhorse-type ruthenium complexes.
7
 Herein, we report the synthesis and characterization of 
several new Ru2(CO)4 sawhorse-type complexes containing carboxylato ligands derived from 
saturated fatty acids such as butyric, heptanoic, nonanoic, decanoic, dodecanoic, tridecanoic, 
tetradecanoic, heptadecanoic and octadecanoic acids as well as fluorinated fatty acids such as 
perfluorobutyric and perfluorododecanoic acids with a variety of axial ligands (pyridine, 
triphenylphosphine or 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane). Sawhorse-type 
diruthenium tetracarbonyl complexes derived from perfluoroalkyl ponytails (fluorinated fatty 
acids) showed good solubility in scCO2, which have motivated us to test them as catalysts for 
the hydrogenation of styrene under scCO2 condition. 
 
2.2.1. Synthesis of sawhorse-type diruthenium tetracarbonyl complexes 
Dodecacarbonyltriruthenium reacts with the appropriate carboxylic acid [heptanoic, 
CH3(CH2)5COOH; nonanoic, CH3(CH2)7COOH; decanoic, CH3(CH2)8COOH; tridecanoic, 
CH3(CH2)11COOH; tetradecanoic, CH3(CH2)12COOH; heptadecanoic, CH3(CH2)15COOH; 
octadecanoic, CH3(CH2)16COOH; perflurorobutyric, CF3(CF2)2COOH; and 
perfluorododecanoic, CF3(CF2)10COOH; in thf at reflux under high pressure to yield a 
solution containing the thf intermediates Ru2(CO)4(μ2-η
2
-O2C(CH2)5CH3)2(thf)2, 
Ru2(CO)4(μ2-η
2
-O2C(CH2)7CH3)2(thf)2, Ru2(CO)4(μ2-η
2
-O2C(CH2)8CH3)2(thf)2, Ru2(CO)4(μ2-
η2-O2C(CH2)11CH3)2(thf)2, Ru2(CO)4-(μ2-η
2
-O2C(CH2)12CH3)2(thf)2, Ru2(CO)4(μ2-η
2
-
O2C(CH2)15CH3)2(thf)2, Ru2(CO)4(μ2-η
2
-O2C(CH2)16CH3)2(thf)2, Ru2(CO)4(μ2-η
2
-
O2C(CF2)2CF3)2(thf)2 and Ru2(CO)4(μ2-η
2
-O2C(CF2)10CF3)2(thf)2,  respectively. These labile 
dinuclear thf intermediates further react with two-electron donor ligands (L), such as 
pyridine (NC5H5) (a), triphenylphosphine (PPh3) (b) or 1,3,5-triaza-7-
phosphatricyclo[3.3.1.1]decane (PTA) (c) to generate the stable dinuclear complexes 
Ru2(CO)4(μ2-η
2
-O2C(CH2)5CH3)2(L)2 (1a, L = C5H5N; 1b, L = PPh3), Ru2(CO)4(μ2-η
2
-
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O2C(CH2)7CH3)2(L)2 (2a, L = C5H5N; 2b, L = PPh3), Ru2(CO)4(μ2-η
2
-O2C(CH2)8CH3)2(L)2 
(3a, L = C5H5N; 3b, L = PPh3), Ru2(CO)4(μ2-η
2
-O2C(CH2)11CH3)2(L)2 (4a, L = C5H5N; 
4b, L = PPh3), Ru2(CO)4(μ2-η
2
-O2C(CH2)12CH3)2(L)2 (5a, L = C5H5N; 5b, L = PPh3), 
Ru2(CO)4(μ2-η
2
-O2C(CH2)15CH3)2(L)2 (6a, L = C5H5N; 6b, L = PPh3), Ru2(CO)4(μ2-η
2
-
O2C(CH2)16CH3)2(L)2 (7a, L = C5H5N; 7b, L = PPh3), Ru2(CO)4(μ2-η
2
-O2C(CF2)2CF3)2(L)2 
(8a, L = C5H5N; 8b, L = PPh3; 8c, L = PTA) and Ru2(CO)4(μ2-η
2
-O2C(CF2)10CF3)2(L)2 
(9a, L = C5H5N; 9b, L = PPh3; 9c, L = PTA), in reasonable yields (see Scheme 1). 
Within the saturated fatty acids series 1-7, the complex containing axial pyridine and 
triphenylphosphine ligands were isolated in good yield (Scheme 1). 
 
 
 
L n = 5 n = 7 n = 8 n = 11 n = 12 n = 15 n = 16 n = 2 n = 10 
C5H5N 1a 2a 3a 4a 5a 6a 7a 8a 9a 
PPh3 1b 2b 3b 4b 5b 6b 7b 8b 9b 
PTA - - - - - - - 8c 9c 
 
Scheme 1. Synthesis of the dinuclear complexes Ru2(CO)4(μ2-η
2
-O2C(CX2)nCX3)2(L)2; X = H, F (1-9). 
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Fig. 20. Molecular structure of the dinuclear complexes Ru2(CO)4(μ2-η
2
-O2C(CH2)2CH3)2(PPh3)2 
(10); Ru2(CO)4(μ2-η
2
-O2C(CH2)10CH3)2(PPh3)2 (11). 
 
The same synthetic method was followed to prepare the complexes Ru2(CO)4(µ2-η
2
-
O2C(CH2)2CH3)2(PPh3)2 (10); Ru2(CO)4(µ2-η
2
-O2C(CH2)10CH3)2(PPh3)2 (11). The catalytic 
activity of complexes 8 and 9 were compared with the parent complexes 10 and 11 (Fig. 20) 
as well as with the starting precursor Ru3(CO)12. The catalytic activity
 
of these complexes 
will be discussed at the end of this chapter. 
The sawhorse-type dinuclear tetracarbonyl complexes are air-stable yellow crystalline 
powders and have been completely characterized by infrared (IR), NMR and mass 
spectrometry as well as by their micro-analytical data. All compounds exhibit the 
characteristic pattern of the Ru2(CO)4 sawhorse unit in the ν(CO) region of the IR spectra, 
which consist of three bands (very-strong; medium; very-strong) between 2100 and 1900 cm
-
1
, and the strong and broad band for symmetric and asymmetric ν(OCO) vibrations of the 
bridging carboxylato groups around 1560 cm
-1
.
7
 In the fluorinated derivatives 8 and 9, this 
asymmetric ν(OCO) vibration band is observed at 1660 cm
-1
. The PPh3 derivatives 1b-9b, 10 
and 11 showed a sharp singlet at ≈ 15 ppm in their 31P NMR spectra (CDCl3, 23 °C), while 
PTA derivatives 8c and 9c shown a signal at ≈ -54 ppm, both in accordance with coordination 
of PTA and PPh3 in the axial positions of sawhorse-type diruthenium tetracarbonyl 
complexes.
12a,b,53
 In 1-11, all 
1
H NMR spectra (CDCl3, 23 °C) showed the expected 
resonances for the axial ligands. For example, in complexes 1a-9a the protons of the pyridyl 
ligands appeared at  = 7.5, 7.9 and 8.7 ppm in a 2:1:2 integration ratio, while for the PTA 
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derivative 8c and 9c two multiplets of equal integrations at 4.3 and 4.6 ppm were observed. 
In complexes 1b-9b, 10 and 11 the axial PPh3 ligands showed two multiplets in the aromatic 
region. In the 
19
F NMR spectra (CDCl3, 23 °C) of complexes 8, three distinct signals were 
observed and easily assigned, while for complexes 9 several additional signals corresponding 
to median CF2 groups appeared between -120 and -125 ppm.  
 
2.2.2. Single-crystal X-ray structures of sawhorse-type diruthenium tetracarbonyl 
complexes derived from saturated fatty acid 
The single-crystals of 1b, 2a, 3a, 4a and 5a were obtained by slow diffusion of 
pentane into a dichloromethane solution of the corresponding complex. The single-crystal 
structure analysis of 1b showed a Ru2(CO)4 sawhorse backbone with the two PPh3 ligands in 
the axial positions and the carboxylato bridges in the equatorial positions, as expected (Fig. 
21). The Ru-Ru distance [2.7239(5) Å] is in the range of a ruthenium-ruthenium single bond, 
as it was also observed in analogous complexes containing triphenylphosphine axial 
ligands.
12a,12d,54
 The P-Ru-Ru-P torsion angle is 40.4(2)°, which is comparable to those 
observed in Ru2(CO)4{O2CCH2O-C6H2Cl2-COC(CH2)C2H5}2(PPh3)2
12a
 and Ru2(CO)4-
(O2CC5H4FeC5H5)2(PPh3)2.
54
 
 
 
Fig. 21. ORTEP drawing of 1b with ellipsoids at the 35 % probability level. 
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Fig. 22. ORTEP drawings of 2a, 3a, 4a and 5a with ellipsoids at the 35 % probability level. 
2a 
4a 
3a 
5a 
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Table 1. Selected bond lengths (Å) and angles (º) for 1b, 2a, 3a, 4a and 5a. 
 1b 2a 3a 4a 5a 
Distances (Å)      
Ru-Ru 2.7239(5) 2.6804(8) 2.6817(5) 2.6793(14) 2.6829(5) 
Ru-PPPh3 2.4566(11)     
Ru-PPPh3 2.4296(11)     
Ru-Npyridine  2.223(6) 2.224(3) 2.246(9) 2.215(4) 
Ru-Npyridine  2.211(6) 2.209(3) 2.206(9) 2.216(4) 
Ru-Ocarboxylato 2.123(3) 2.128(6) 2.148(3) 2.122(8) 2.150(3) 
Ru-Ocarboxylato 2.114(3) 2.120(5) 2.115(3) 2.123(8) 2.118(3) 
Ru-Ocarboxylato 2.138(3) 2.131(6) 2.126(3) 2.136(8) 2.125(4) 
Ru-Ocarboxylato 2.114(3) 2.124(6) 2.127(3) 2.132(8) 2.121(4) 
Angles (º)      
Ocarboxylato      
O-Ru-O 85.06(14) 83.3(2) 82.81(12) 81.4(4) 82.82(15) 
O-Ru-O 84.32(12) 83.7(2) 83.22(12) 82.3(3) 83.47(16) 
Ccarbonyl      
C-Ru-C 90.2(2) 88.5(4) 88.3(2) 86.7(6) 88.3(2) 
C-Ru-C 88.4(2) 89.4(4) 89.3(2) 88.4(5) 89.4(2) 
Torsion angles (°)      
L-Ru-Ru-L 40.4(2) -6.5(11) 10.2(5) -6.1(16) 9.0(6) 
 
Similarly, the single-crystal structure analyses of 2a, 3a, 4a and 5a exhibit the 
Ru2(CO)4 sawhorse backbone with the two pyridyl ligands in the axial positions and the 
carboxylato bridges in the equatorial positions (Fig. 22). Selected geometrical parameters are 
given in Table 1. The Ru-Ru distances [2a: 2.6804(8) Å, 3a: 2.6817(5) Å, 4a: 2.6793(14) Å, 
5a: 2.6829(5) Å] are as well in the range of a ruthenium-ruthenium single bond but they are 
considerably shorter than the one observed in the triphenylphosphine derivative 1b (Table 1). 
This difference in the metal-metal distance can be associated to an increase in electron 
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density between the metal atoms as a result of the lack of back-bonding to the pyridyl 
ligands.  
In the crystal packing of 2a, closed parallel π-π stacking interactions is observed 
between pyridyl groups of two adjacent dinuclear complexes (Fig. 23). The centroid-centroid 
separation is 3.73 Å and agreed well with the theoretical value calculated from this π stacking 
mode.
55
 
 
Fig. 23. Parallel -stacking interaction observed in the crystalline packing of 2a. 
 
Similarly, in the crystal packing of 3a, 4a and 5a parallel π stacking interactions are 
observed between neighboring pyridyl moieties of adjacent sawhorse complexes, however, 
the centroid-centroid separations are slightly shorter in these crystals (3a: 3.64 Å, 4a: 3.63 Å, 
5a: 3.64 Å). The presence of longer alkyl chains in 3a, 4a and 5a induces a different packing 
arrangement as compared to 2a. Indeed, to maximize van der Waals and electrostatic 
interactions between alkyl chains, and to optimize packing density, the two alkyl chains of 
the sawhorse-type complex adopt a parallel arrangement. Moreover, these parallel pair of 
alkyl chains interacts with neighboring parallel pair of alkyl chains from symmetry related 
molecules to generate layers of alkyl chains. As an example, the head-to-tail arrangement of 
parallel alkyl chains observed in 5a is presented in Fig. 24. The width of these layers is 
approximately 14.0 Å in 3a [Ru-Ru separation], while in 4a it reaches 17.6 Å and in 5a it is 
greater than 25.0 Å. 
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Fig. 24. Main interactions involved in the crystalline packing of 5a, -stacking interactions between 
adjacent pyridyl groups and van der Waals interactions between parallel alkyl chains. 
 
2.2.3. Comparing X-ray structures of saturate fatty acid with non-fatty acid derivative 
(8a and 10) 
Crystals of 8a and 10 were obtained by slow diffusion of pentane into a 
dichloromethane solution of the corresponding complex. The single-crystal structure 
analyses of 8a and 10 showed the Ru2(CO)4 sawhorse backbone with the two pyridine (8a) 
or triphenylphosphine (10) ligands in the axial positions and the carboxylato bridges in the 
equatorial positions (Fig. 25). The Ru-Ru distances [8a: 2.694(1) Å, 10:  2.7477(5) Å] are  
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Fig. 25. ORTEP representation of complexes 8a and 10 showing ellipsoids at the 35 % probability 
level with hydrogen atoms omitted for clarity (symmetry code: i = -x, y, ½-z). 
 
Table 2. Selected bond lengths (Å) and angles (°) 
8a  10 
Ru1-Ru1
i 2.694(1) Ru1-Ru1i 2.7477(5) 
Ru1-N1 2.218(4) Ru1-P1 2.4524(8) 
Ru1-O1 2.151(4) Ru1-O1 2.130(2) 
Ru1-O2 2.149(4) Ru1-O2 2.124(2) 
O1-C1-O2
i 129.2(5) O1-C1-O2i 125.3(3) 
N1-Ru1-Ru1
i 165.79(13) P1-Ru1-Ru1i 163.97(2) 
O1-Ru1-O2 83.52(18) O1-Ru1-O2 87.66(10) 
 
in the range of a ruthenium-ruthenium single bond, as it was also observed in analogous 
complexes.
12a,53a
 The OCO bond angles of the carboxylato bridges [8a: 129.2(5)°, 10: 
125.3(3)°] differ only slightly from those observed in other  Ru2(CO)4(μ2-η
2
-O2CR)2L2 
complexes.
12a
 In 10, the Ru-P distance is 2.4524(8) Å, consistent with the Ru-P distances 
observed in analogous complexes.
12a,53a
 The remaining structural parameters appear to be 
normal for this type of complexes.
7
 Selected bond lengths and angles for 8a and 10b are 
listed in Table 2. 
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2.3. Catalytic evaluation of sawhorse-type diruthenium tetracarbonyl complexes 
Quantitative yields of such new complexes containing in particular carboxylato 
ligands derived from saturated fluorinated fatty acids motivated us to evaluate their catalytic 
properties under supercritical conditions of carbon dioxide. Indeed, ligand modifications with 
perfluoroalkyl ponytails are known to exhibit a great CO2-philic character, and thus they have 
been used to increase the solubility of homogeneous catalysts in scCO2.
56
 In this preliminary 
catalytic study, selected sawhorse-type diruthenium complexes with short (8b and 8c) and 
long (9b) fluorinated alkyl chains were considered as catalyst for the hydrogenation of 
styrene in scCO2 conditions (eq. 17), and their activities were also compared with those 
obtained with non-fluorinated analogues 10, 11 and Ru3(CO)12. 
 
 
 
Catalytic data are summarized in Table 3. It appears that the sawhorse-type 
diruthenium complexes are very poor catalysts for the hydrogenation of styrene. The 
conversions of styrene into ethyl benzene are always below 15 % regardless of the length of 
the fluorinated alkyl chains and the nature of the axial ligands (PPh3 axial ligands seem to be 
the most suitable). In addition, the yield in ethyl benzene is not exalted by the supercritical 
conditions of carbon dioxide (entries 2 and 4). The incorporation of fluorinated alkyl chains 
showed a modest improvement. In previous studies, the addition of a co-solvent, such as 
methanol, has been reported to be helpful for increasing the catalytic activity of transition 
metal catalysts under scCO2 conditions.
57
 Herein, for the same complex (8b), we only 
observe a weak positive effect with the presence of methanol (entries 2 and 3). In fact, the 
best conversion was obtained using Ru3(CO)12 as catalyst (entry 9). Enhancement in the 
conversion was observed when the reaction was carried out in the presence of H2 (entries 10 
and 11). However, the degradation of the catalyst was also observed, leading to a final black 
precipitate suspected to be ruthenium nanoparticles.
58
 Thus, the low activity recorded with 
these sawhorse-type diruthenium tetracarbonyl complexes can be rationalized by the stability 
and preservation of the starting ruthenium species in the scCO2 reaction medium. 
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Table 3. Hydrogenation of styrene under supercritical carbon dioxide conditions to 
ethylbezene. 
Entry Catalyst Medium Conversion(%) 
1 10 H2
a
/CO2
b
 7 
2 8b H2
a
/CO2
b
 6 
3 8b H2
a
/CO2
b
/CH3OH
c
 10 
4 8b H2
a
 12 
5 8c H2
a
/CO2
b
 4 
6 11 H2
a
/CO2
b
/CH3OH
c
 3 
7 9b H2
a
/CO2
b
/CH3OH
c
 6 
8 9b H2
a
 6 
9 Ru3(CO)12 H2
a
/CO2
b
 22 
10 Ru3(CO)12 H2
a
 71 
11 recovery of entry 10 H2
a
 95 
Reaction conditions: Amount of catalyst = 0.02 mmol, substrate/catalyst = 500/1, T = 65 °C, 
reaction time = 16 h.
 a
 PH2 = 10 bar. 
b
 Ptotal = 120 bar. 
c 
1 mL. 
 
In conclusion, we have synthesized and characterized a series of sawhorse-type 
complexes containing carboxylates derived from fluorinated and non-fluorinated fatty acids. 
The single-crystal structure analyses of 2a, 3a, 4a and 5a revealed that for n  8, the packing 
of the non-fluorinated alkyl chains and the π-π interactions between pyridyl groups 
dominated, while for n  7, only the arrangement of the axial pyridyl ligands played a 
significant role in the crystalline packing of these sawhorse-type complexes. Complexes 8, 9, 
10 and 11 were evaluated as catalyst for the hydrogenation of styrene under scCO2. All these 
catalysts gave a very poor conversion. 
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3. Supramolecular properties of dinuclear ruthenium complexes 
3.1. Molecular Tweezers 
The term molecular tweezer has been introduced by Whitlock
59
 and was popularized 
by Zimmerman.
60
 Molecular tweezers are synthetic macrocyclic receptors with an 
interactive site able to bind with a substrate. These interactive sites are often obtained 
by coupling two functional groups to a rigid or a semi-rigid spacer (Fig. 26). The 
interactions between the functional groups of the receptor and the substrate can be of 
different natures, hydrogen bonds, metal-coordinations, hydrophobic forces, solvophobic 
effects, π-π stacking or van der Waals interactions.61 
 
 
 
 
Fig. 26. Cartoon representation of molecular tweezer (picture taken from
61b
) and the first molecular 
tweezer described by the Whitlock group.
59
 
 
These kinds of substrate-receptor recognition processes play important roles in 
biology, for example for energy transduction in organisms, to control metabolic processes 
via participation in various enzymatic reactions, in DNA polymerizations, for transportation 
of neutral and ionic species through membranes and also in the transformation of genetic 
information during cell metabolism.
62
 To better understand and to mimic some of these 
fundamental recognition processes operating in living organisms, chemists have designed 
artificial molecular tweezers. 
spacer 
substrate 
substrate- 
receptor 
interaction 
interactive site 
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3.2. Organic, inorganic and organometallic molecular tweezer 
Pyrene is the smallest peri-fused polycyclic aromatic hydrocarbon and it is obtained 
during the combustion of organic compounds.
63
 The pyrene molecule is highly 
symmetrical and despite having 16 π electrons and not following the Hückel’s (4n + 2) rule, 
pyrene is aromatic.
64
 These features provide to pyrene some interesting electronic 
properties,
65
 which can be exploited for the preparation of chemosensors. The large planar 
π-conjugated surface of pyrene generates a high fluorescence quantum yield and pyrene 
shows a strong excimer emission with itself or with pyrene analogues. The face-to-face 
arrangement of pyrenes bound with a spacer associated with an intramolecular excimer 
formation has been widely utilized to detect the presence and absence of guest molecules. 
The preparation of pyrenyl-containing chemosensors has been mainly designed around 
organic spacers.
66
 Two pyrene units have been covalently bonded to 1,5-bis(2-
aminophenoxy)-3-oxopentane to generate a tweezer for metal ions (Fig. 27; A).
67
 A bis-
pyrenyl derivative (Fig. 27; B), which possesses the ability to form π-π stacking interactions 
and hydrogen bonds, has been synthesized by Colquhoun and Zhu.
68
 Biomolecules, such as 
sugar
69
 or bile acid
7 0
 (Fig. 27; C) have also been used as scaffolds to form bis-pyrenyl 
tweezers. Similarly, two pyrenyl units have been coupled to cyclodextrin
71
 and 
calix[4]arene
72
 to generate supramolecular tweezers. These examples, among others, 
illustrate the diversity and popularity of organic spacers in the design of pyrenyl-based 
tweezers. 
 
 
Fig. 27. Examples of organic bis-pyrenyl tweezers A, B and C. 
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Despite being scarce, example of pyrenyl-based tweezers obtained from coordination 
chemistry can be found in the literature. Inorganic tweezers such as Cu- and Rh-based 
tweezers (Fig. 28 ; D) able to trap chloride in their cavities have been prepared by Mirkin.
73
 
A NCN-pincer type palladium aqua complex with an appended pyrenyl group (Fig. 28; E) 
has been designed by van Koten.
74
 This organometallic complex interacts with picric 
acid in solution and catalyzes aldol condensation. In the presence of pyrophosphate, two 
mono-pyrenyl zinc cations have been assembled (Fig. 28; F) to generate a molecular 
tweezer.
75
 In water, this di-zinc pyrophosphate complex showed high fluorescence due to 
the formation of an excimer. Similar excimeric emission was obtained by coordinating two 
(diphenylphosphino)pyrene ligands to silver.
76
 These examples are, to the best of our 
knowledge, the only examples in which metals were used to assemble pyrenyl-based 
tweezers, despite the versatility of coordination chemistry.  
 
 
Fig. 28. Examples of inorganic and organometallic pyrenyl appended molecular tweezers D, E and F. 
 
Similarly, porphyrins were also used to design molecular tweezers because of their 
planar aromatic nature. The large aromatic surface provided by the tetrapyrrol core allows π-
stacking interactions with guest molecules,
77
 while inserting zinc in the porphyrin core gives 
an additional coordination site for additional bonding.
78
 In fact, the Zn(II) center is easily five 
coordinated and interact strongly with N-donor ligands. Strategies to connect two porphyrin 
units involve either organic chemistry,
79
 definitely the most common strategy, or 
coordination chemistry. Among inorganic connectors, Reed and Boyd have used dichloro-
palladium metal center and two mono-pyridyl porphyrin derivatives to generate a molecular 
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tweezer (Fig. 29, G), which shows excellent affinity for C60 and C70.
80
 Similarly, Shinkai 
reported on-off switchable tweezers for C60 using palladium-dppp metal center (dppp = 1,3-
bis(diphenylphosphino)propane) and two mono-pyridyl-functionalized zinc metallo-
porphyrin derivatives (Fig. 29, H).
81
 Despite these examples and the versatility of metal 
centers to build two and three dimensional assemblies,
82
 coordination chemistry has scarcely 
been used to assemble two porphyrin panels to generate molecular tweezers.
83
 
 
 
Fig. 29. Examples of porphyrin appended inorganic molecular tweezers G and H. 
 
Since the discovery of sawhorse-type diruthenium tetracarbonyl complexes,
8
 a 
tremendous number of such complexes with carboxylato bridges have been synthesized and 
studied (more information can be read in general introduction) for different applications.
7
 
However, to the best of our knowledge, sawhorse units have never been used to build 
molecular tweezers. Herein we report the synthesis of sawhorse-type diruthenium 
tetracarbonyl molecular tweezers containing pyrenyl or porphyrinyl group in the equatorial 
position of the sawhorse backbone and evaluate their ability to act as molecular tweezers with 
guest molecules such as fullerene (C60), pyridine (pyr), 4,4’-bipyridine (bpy), 1,2-bis(4-
pyridyl)ethylene (bpe), and photoactive guests, like 5,10-bis(4-pyridyl)-15,20-di-phenyl-
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21H,23H-porphyrin (5,10-dpp), and 5,15-bis(4-pyridyl)-10,20-diphenyl-21H,23H-porphyrin 
(5,15-dpp) (Fig. 38). 
 
3.3. Sawhorse-type molecular tweezers derived from pyrenyl-carboxylic acids 
Ru3(CO)12 reacts with an excess of the pyrenyl-carboxylic acid derivatives, 1-
pyrenecarboxylic acid (C16H9COOH), 1-pyreneacetic acid (C16H9CH2COOH) and 1-
pyrenebutyric acid {C16H9(CH2)3COOH}, under high pressure conditions to yield a solution 
containing the thf intermediates Ru2(CO)4(μ2-η
2
-OOCC16H9)2(thf)2, Ru2(CO)4(μ2-η
2
-
OOCCH2C16H9)2(thf)2 and Ru(CO){μ2-η
2
-OOC(CH2)3C16H9}(thf)2, respectively. These labile 
thf intermediates further react with two-electron donor ligands (L), such as pyridine 
(NC5H5) (a) and triphenylphosphine (PPh3) (b), to generate in reasonable yields the stable 
dinuclear tetracarbonyl complexes Ru2(CO)4(μ2-η
2
-OOCC16H9)2(L)2 (12a, L = C5H5N; 12b, 
L = PPh3), Ru2(CO)4(μ2-η
2
-OOCCH2C16H9)2(L)2 (13a, L = C5H5N; 13b, L = PPh3) and 
Ru(CO){μ2-η
2
-OOC(CH2)3C16H9}(L)2 (14a, L = C5H5N; 14b, L = PPh3) (Fig. 30). 
 
Fig. 30. Structures of the sawhorse-type diruthenium tetracarbonyl complexes 12, 13  and 14 (a, L 
= NC5H5; b, L = PPh3). 
 
All complexes are yellow crystalline powders, stable in air, and they have been 
fully characterized by IR, NMR, UV-Vis, mass spectrometry and by elemental analysis. 
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In the infrared spectra, the complexes show the characteristic three band pattern (very 
strong - medium - very strong) at around 1945, 1970 and 2020 cm
-1
, together with a 
strong and broad band for the symmetric and asymmetric ν(OCO) vibrations of the two 
bridging carboxylato groups around 1570 cm
-1
. For 12b, 13b and 14b, the 
31
P{
1
H} NMR 
spectra show a sharp singlet at δ ≈ 15 ppm which correspond to the PPh3 axial ligands. In 
the 
1
H NMR spectra, complexes 13a and 13b show a singlet at δ = 3.68 and 4.17 ppm 
respectively, associated with the CH2 of the pyrenyl-carboxylato ligands, while for 
complexes 14a and 14b two triplets and one quintet are observed between 1.68 and 3.19 
ppm. These signals correspond to the aliphatic protons of the butyl chains in 14. 
The electronic absorption spectra of the sawhorse-type diruthenium tetracarbonyl 
complexes 12‒14 and of the free pyrenyl-carboxylic acids (A1 = 1-pyrenecarboxylic acid, 
A2 = 1-pyreneacetic acid, A3 = 1-pyrenebutyric acid) show bands from 278 to 383 nm 
(Fig. 31). The complexes 12b, 13b and 14b show an additional absorption at 383 nm which 
is due to the presence of the axial PPh3 ligands. Notably, the absorption bands of the 
uncoordinated pyrenyl-carboxylic acids and those of the complexes 12‒14 remain 
unchanged, suggesting the absence of sizeable ground-state inter-pyrene electronic 
interactions. 
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Fig. 31. The UV-Vis spectra of complexes 12‒14, 1-pyrenecarboxylic acid (A1), 1-pyreneacetic acid 
(A2) and 1-pyrenebutyric acid (A3) at 10
-5 
M concentration in CH2Cl2 at room temperature. 
 
The molecular structures of 12b, 13b and 14b have been determined by single-
crystal X-ray structure analysis (Fig. 32 - Fig. 34). Selected bond lengths and angles are 
reported in Table 4. All complexes show a typical diruthenium backbone with the pyrenyl-
carboxylato ligands being in the equatorial positions and bridging the two ruthenium atoms, 
while the triphenylphosphine ligands occupy the axial coordination sites. As often 
encountered in such complexes, the Ru-Ru distances [2.7098(9) Å (12b); 2.7036(3) Å (13b); 
2.7502(5) Å (14b)] remain in the range of a metal-metal single bond,
7
 and the P-Ru-Ru-P 
axes deviate significantly from linearity, the Ru-Ru-P angles being comprised between 162° 
and 167°. Overall, the geometrical parameters observed in 12b, 13b and 14b are comparable 
to those found in analogous diruthenium tetracarbonyl complexes with triphenylphosphine 
axial ligands.
12a
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Fig. 32. ORTEP drawing of complex 12b with ellipsoids at the 35 % probability level. 
 
 
Fig. 33. ORTEP drawing of complex 13b with ellipsoids at the 35 % probability level. 
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Fig. 34. ORTEP drawing of complex 14b with ellipsoids at the 35 % probability level (symmetry code 
i = -x, y, ½-z). 
 
Interestingly, in the crystal packing of 14b, the complex crystallizes with two 
molecules of toluene. These toluene molecules fill the voids left between the pyrenyl-
butyric moieties, and they interact weakly with either the pyrenyl groups through π-π 
stacking interactions or with the phenyl groups of the PPh3 ligands. In 13b, strong 
intermolecular pyrenyl-pyrenyl interactions are observed between neighboring sawhorse 
complexes (Fig. 35). The distance between the two symmetry related pyrenyl-planes is 
only 3.49 Å, the typical distance for a slipped-parallel π- stacking interaction.55 
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Table 4. Selected bond lengths (Å) and angles (º) for 12b, 13b and 14b 
 
 12b 13b 14b 
Distances (Å)    
Ru-Ru 2.7098(9) 2.7036(3) 2.7502(5)
a
 
Ru1-P1 2.452(2) 2.4350(7) 2.4674(7) 
Ru2-P2 2.452(2) 2.4512(7)  
Ru1-O1 2.111(6) 2.132(2) 2.123(2) 
Ru1-O3 2.161(5) 2.136(2) 2.126(2) 
Ru2-O2 2.167(6) 2.137(2)  
Ru2-O4 2.110(5) 2.136(2)  
Angles (°)    
Ru-Ru-P1 167.45(6) 164.01(2) 164.09(2) 
Ru-Ru-P1 161.92(5) 165.99(2)  
O1-Ru-O3 82.6(2) 84.58(7) 85.90(7) 
O2-Ru-O4 85.8(2) 83.80(7)  
O1-C-O2 125.1(8) 125.8(2) 125.6(2) 
O3-C-O4 125.2(6) 126.0(2)  
CCO-Ru1-CCO 89.2(4) 89.6(4) 86.2(1) 
CCO-Ru2-CCO 89.7(4) 87.2(1)  
a 
symmetry code -x, y, ½-z 
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Fig. 35. Intermolecular pyrenyl-pyrenyl interactions observed in the crystal packing of 13b. 
 
After confirming the molecular structures of complexes 12‒14, the ability for 
these complexes to act as molecular tweezers in solution was studied. Fullerene (C60) was 
selected as a guest to evaluate the hosting potential of the bis-pyrenyl derivatives. Planar 
aromatic moieties are known to interact with C60 through π-π stacking interactions.
84
 Upon 
addition of increasing amounts of C60 (up to 4 equiv.) to a solution of complexes 12, 13 and 
14 (12b: 3.3 x 10
-6
 M in toluene; 13b: 2.3 x 10
-6 
M in toluene, 14a: 5.4 x 10
-6
 M in 
toluene, 14b: 6.5 x 10
-6
 M in cyclohexane), no changes were observed in the UV-Vis 
spectra. Fluorescence measurements also suggest no interaction between 14 and C60, 
showing no spectral changes during the titration experiments (toluene, 4.5 x 10
-6
 M 
concentrations, up to 5 equiv. of C60, λexc = 345 nm). Finally, upon addition of increasing 
amounts of complex 14b to a toluene-d8 solution of C60, no chemical shift was observed for 
the 
13
C NMR signal of C60. Therefore, to rationalize this lack of host-guest interaction 
between the complexes and C60, molecular modeling was performed. 
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Fig. 36. Chem3D model showing a fullerene molecule between the two pyrenyl groups of 14. 
 
The Chem3D software was used to place a fullerene molecule in the cavity of the 
bis-pyrenyl complexes 12‒14. In 12, the rigidity and limited flexibility of the two pyrenyl 
groups did not allow t he  fullerene to interact significantly with pyrene, while with 13, 
fullerene fits better but the π-stacking interaction is not optimal. On the other hand, with 
complex 14, the flexibility provided by the butyl chains seems to offer an appropriate 
cavity between the pyrenyl groups to interact with fullerene (Fig. 36). Yet, no meaningful 
interaction was observed in solution between 14 and fullerene (C60). 
 
3.4. Porphyrin derived sawhorse-type molecular tweezers 
In a similar fashion, π-conjugated aromatic porphyrin moieties were also used for the 
synthesis of sawhorse-type diruthenium tetracarbonyl tweezers. Their binding ability with 
different guest molecules in solution was evaluated by using optical spectroscopic methods. 
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Herein, we report the synthesis and the binding affinity of the sawhorse-type dinuclear 
ruthenium complex [Ru2(CO)4(O2CC44H29N4)2(PPh3)2] (15), which was previously evaluated 
as photosensitizer for cancer cells,
12b
 and the new tetranuclear ruthenium complex, 
[{Ru2(CO)4(PPh3)2}2(O2CC44H28N4CO2)2] (16), which is composed of two sawhorse units 
connected by di-carboxylic porphyrin bridges. In addition, the corresponding zinc(II)-
porphyrin derivatives [Ru2(CO)4(O2CC44H27N4Zn)2(PPh3)2] (17) and 
[{Ru2(CO)4(PPh3)2}2(O2CC44H26N4ZnCO2)2] (18) have been prepared (Fig. 37).  
 
 
Fig. 37. Molecular structures of sawhorse-type diruthenium tetracarbonyl tweezers 
incorporating porphyrin moieties. 
 
All complexes possess two porphyrin moieties perfectly positioned to potentially act 
as molecular tweezers for guest molecules. The efficacy for molecular recognition of these 
organometallic tweezers have been studied with fullerene (C60), pyridine (pyr), 4,4’-
bipyridine (bipy), 1,2-bis(4-pyridyl)ethylene (bpe), and photoactive guests such as 5,10-di-(4-
pyridyl)-15,20-diphenyl-21H,23H-porphyrin (5,10-dpp) and 5,15-di-(4-pyridyl)-10,20-
diphenyl-21H,23H-porphyrin (5,15-dpp) using optical spectroscopic methods (Fig. 38). 
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Fig. 38. Molecular structure of the guest molecules 
 
3.4.1. Synthesis of molecular tweezers 
The thermal reaction of Ru3(CO)12 with excesses of 5-(4-carboxyphenyl)-10,15-20-
triphenyl-21H,23H-porphyrin (HO2CC44H29N4), the corresponding zinc(II)-porphyrin 
complex (HO2CC44H27N4Zn), 5,10-di(4-carboxyphenyl)-15,20-diphenyl-21H,23H-porphyrin 
(HO2CC44H28N4CO2H) or the corresponding zinc(II)-porphyrin (HO2CC44H26N4ZnCO2H) in 
refluxing thf yields a solution containing the thf complexes [Ru2(CO)4(O2CC44H29N4)2(thf)2], 
[Ru2(CO)4(O2CC44H27N4Zn)2(thf)2], [{Ru2(CO)4(thf)2}2(O2CC44H28N4CO2)2] or [{Ru2(CO)4-
(thf)2}2(O2CC44H26N4ZnCO2)2], respectively. These labile thf intermediates react easily with 
triphenylphosphine to afford, after precipitation and column chromatography, the neutral 
complexes [Ru2(CO)4(O2CC44H29N4)2(PPh3)2] (15), [{Ru2(CO)4(PPh3)2}2-
(O2CC44H28N4CO2)2] (16), [Ru2(CO)4(O2CC44H27N4Zn)2(PPh3)2] (17) and [{Ru2(CO)4-
(PPh3)2}2(O2CC44H26N4ZnCO2)2] (18) in moderate yields. These four bis-porphyrin 
molecular tweezers built from sawhorse diruthenium units are depicted in (Fig. 37). 
All compounds are air-stable, dark-purple solids, which are sparingly soluble in polar 
organic solvents and they were characterized by IR (KBr pellet), NMR, UV-Vis and 
fluorescence spectroscopic techniques as well as by combustion analysis. In the ν(CO) region 
of the infrared spectrum (2100-1900 cm
-1
), the characteristic three-band pattern of the 
Ru2(CO)4 sawhorse moiety, which is observed in all complexes of this type.
7
 Moreover, due 
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to the presence of the porphyrin groups, a strong absorption centered at 1587 cm
-1
 that 
corresponding to ν(NCN) is observed, and a medium absorption at 3054 cm
-1 
is associated
 
to the 
C-H stretching vibration.
85
 
The 
1
H NMR spectra of 15-18 in CDCl3 at room temperature display a similar signal 
pattern for the protons of the coordinated porphyrin(carboxyphenyl) derivatives as well as for 
the triphenylphosphine axial ligands. In 15 and 16 an additional signal attributed to the N-H 
protons is observed at δ = -2.8 ppm, while in all complexes multiplets at δ = 7.43, 7.77, 7.82 
and 8.22 ppm are found in the aromatic region, which corresponding to the protons of the 
phenyl rings of both the porphyrin and the triphenylphosphine ligands. Moreover, in the 
31
P{
1
H} NMR spectra, a sharp singlet at ≈ 17 ppm corresponding to the PPh3 axial ligands is 
observed. All NMR data were consistent with the proposed structures. 
 
 
Fig. 39. DOSY NMR spectra of 15 (black line) and 16 (red line) in CDCl3 at room temperature. 
 
Unable to grow crystals suitable for X-ray structure analysis, the size and shape of the 
complexes were estimated using diffusion-ordered NMR spectroscopy (DOSY) and 
molecular modeling. The radii of the complexes were derived from the diffusion coefficients 
(D) by using the Stokes-Einstein equation.
86
 The radii of complexes 15 and 17 are equivalent 
at 9.7 Å, whereas the radii of complexes 16 and 18 are slightly longer at 10.5 Å. These values 
determined from DOSY experiments (Fig. 39) are in agreement with the structural data 
obtained from molecular modeling (Fig. 40), for which the volume of the dinuclear complex 
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15 is only slightly smaller than the volume of the tetranuclear derivative 16. In addition, it is 
worth mentioning that these models show median porphyrin-porphyrin cavity sizes of ca. 16 
Å for all complexes. 
 
 
Fig. 40. Molecular modeling of complexes 15 (top) and 16 (bottom) 
 
The absorption spectra of bis-porphyrin complexes 15-18 and of the reference 
sawhorse complex containing no porphyrin units, [Ru2(CO)4(O2CC8H17)2(PPh3)2] (3b),
53a
 are 
shown in Fig. 41. The limited solubility of 15 in CCl4 forced us to use cyclohexane for this 
compound. All four bis-porphyrin derivatives absorb throughout the visible region, showing 
the characteristic Soret and Q bands; the absorption features of 16 are slightly red-shifted 
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compared to 15, as a consequence of the different solvents. The reference sawhorse-type 
complex 3b shows a weak absorption maximum at 382 nm, which scarcely contributes to the 
spectra of multi-chromophoric systems 15-18. Notably, the molar extinction coefficients of 
all complexes match those of similar bis-porphyrin systems, suggesting the absence of 
sizeable ground state inter-porphyrin electronic interactions.
87
 
 
 
Fig. 41. The electronic absorption spectra of 15 in cyclohexane (black line), 16−18 and 3b in CCl4 
(black dashed, grey, grey dashed and black dotted lines, respectively). 
 
The fluorescence spectra of 15 and 16 are almost identical in shape and position to the 
non-coordinated porphyrin ligands (not shown), and the similar singlet lifetime (τ) values (9.3 
and 8.1 ns respectively) indicate negligible intramolecular porphyrin interactions in the 
excited state. The same is observed for the Zn-porphyrin derivatives (τ = 2.3 ns and 2.2 ns for 
17 and 18 respectively), and this confirms that the presence of diruthenium sawhorse moieties 
does not perturb the electronic properties of the porphyrin moieties. Also, the luminescence 
of the reference complex 3b is rather weak and it cannot significantly contribute to the 
emission spectra of bis-porphyrin complexes 15-18. 
By taking advantage of the strong affinity of porphyrin units for fullerene (C60) in 
apolar solvents,
77h,84a,87b,88
 the bis-porphyrin hosts 15 and 16 were titrated with increasing 
amounts of C60 in cyclohexane and CCl4, respectively. The process was monitored by UV- 
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Vis absorption spectroscopy. The spectra of the titrated solutions containing 15 or 16 
and C60 (5 equiv.) are shown in Fig. 42 and Fig. 43. Unlike other bis-porphyrin host 
platforms,
87b,88
 no significant changes are observed in the absorption features of 15 and 16 
indicating the absence of sizeable interaction between the two components. The large cavity 
size (Fig. 40) and the rigid bis-porphyrin framework of 15 and 16 could be the reasons for the 
lack of formation of supramolecular adducts. In fact, molecular modeling suggests that 
allowing porphyrins to move freely around C60 would facilitate the supramolecular 
complexation (Fig. 44). Hence, the experimental results suggest that the porphyrin units 
anchored to the sawhorse backbone in 15 and 16 apparently cannot provide the structural 
conditions for the formation of stable adducts with C60. 
 
 
Fig. 42. Change in the absorption spectra of 15 (2.3 × 10
-6
 M) upon addition of increasing amounts 
of C60 (up to 5 equiv.) in cyclohexane. Inset: The corresponding changes in the Q bands spectral 
region. All the observed spectral variations are solely attributable to the added fullerene 
chromophore. 
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Fig. 43. Change in the absorption spectra of 16 (5.8 × 10
-7
 M) upon addition of increasing amounts 
of C60 (up to 5 equiv.) in CCl4. Inset: The corresponding changes in the Q bands spectral region. All 
the observed spectral variations are solely attributable to the added fullerene chromophore. 
 
 
 
Fig. 44. Molecular modeling of C6015 (top) and C6016 (bottom) adducts. 
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Zinc-porphyrin hosts are expected to have a structural rigidity similar to their free-
base analogues, with no tendency to give adducts with C60. Therefore, 17 and 18 were titrated 
with molecules bearing two pyridine units,
87a,89
 namely 4,4’-bipyridine (bpy), 1,2-bis(4-
pyridyl)ethylene (bpe), 5,10-di-(4-pyridyl)-15,20-diphenyl-21,23H-porphyrin (5,10-dpp) and 
5,15-di-(4-pyridyl)-10,20-diphenyl-21,23H-porphyrin (5,15-dpp) (Fig. 38), which can afford 
a bridging bidentate coordination to the Zn(II) ions of the bis-porphyrin tweezers 17 and 18. 
It has to be emphasized that external coordination of Zn-porphyrin by the pyridine (pyr), bpy 
and bpe moieties are in principle possible, but monodentate coordination exhibits a much 
lower association constant (ca. 10
4
 M
-1
)
87a
 compared to bidentate (ca. 10
7
 M
-1
)
90
 
complexation. To discern the two different coordination modes, titrations of 17 and 18 were 
first carried out with pristine pyridine (Fig. 45). The absorption spectral changes of the host 
molecules upon addition of increasing amounts of pyridine (up to 8000 equiv.) in CCl4; a 
significant red shift in the Soret (∆λ = 10 nm) and Q bands (∆λ = 15 nm) of the bis-porphyrin 
hosts were observed. Similar results can be found in the literature with Zn-porphyrin 
systems.
87a,89a
 Therefore, the observed absorption changes are attributed to the pyridine 
coordination to the Zn-porphyrin moieties of 17 and 18. The related association constants 
were derived from Benesi-Hildebrand equations
91
 and, as expected, are in the order of 10
3
 M
-
1
 (Table 5). The fitted absorption spectral points are shown in Fig. 46. 
 
Table 5. Association constants of 17 and 18 with different pyridyl containing guests in CCl4 
at room temperature.  
Compound Association constant Ka [M
-1
]  
 pyr Bpy bpe 5,10-dpp
[a] 
17 6.4 x 10
3 
9.9 x 10
4 
8.8 x 10
4 
4.5 x 10
4 
18 6.7 x 10
3 
1.5 x 10
5 
3.5 x 10
5 
4.0 x 10
7 
[a] Titrations carried out in toluene 
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Fig. 45. Change in the absorption spectra of 17 {9.9×10
-7
 M, (a)} and 18 {9.9 × 10
-7
 M, (b)} upon 
addition of increasing amounts of pyridine (up to 8000 eq.) in CCl4. Insets: The corresponding 
changes in the Q bands spectral region. 
 
 
 
Fig. 46. The Benesi-Hildebrand linear fitting of absorption data points collected from the titration 
curves of 17 (at 421 nm) and 18 (at 422 nm) against increasing amounts of pyridine in CCl4. 
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Taking these values as benchmark for monodentate coordination, 17 and 18 were then 
titrated with bpy and bpe in CCl4. The absorption spectra of the Zn-porphyrin derivatives 
upon continuous addition of aliquot amounts of bpy (up to 10 equiv.) display a moderate 
intensity decrease of the Soret and Q bands together with a slight red-shift (Fig. 47). On the 
other hand, the titration with bpe, which exhibits longer interpyridyl distance, leads to sharp 
changes in the absorption spectra of the hosts (Fig. 48). Particularly in the case of 18, an 
optimized fitting of the interpyridyl distance of bpe with the size of the cavity the between 
Zn-porphyrin moieties could enable a strong interaction. Fluorescence measurements support 
this hypothesis, because the emission features of the Zn-porphyrin are significantly red-
shifted in bpe18 (bpe-in-18), corroborating the occurrence of a stronger host-guest 
complexation,
87a,89b
 whereas bpe17 shows fluorescence attributable to the free porphyrin 
units (Fig. 49). 
 
 
Fig. 47. Change in the absorption spectra of 17 {1.0 × 10
-6
 M, (a)} and 18 {1.0 × 10
-6
 M, (b)} upon 
addition of increasing amounts of bpy (up to 10 equiv.) in CCl4. Insets: The corresponding changes in 
the Q bands spectral region. 
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Fig. 48. Changes in the absorption spectra of 17 {1.0 × 10-6 M, (a)} and 18 {1.0 × 10-6 M, (b)} upon 
addition of increasing amounts of bpe (up to 5 equiv.) in CCl4. Insets: The corresponding changes in 
the Q bands spectral region. 
 
 
Fig. 49. Fluorescence spectra of 1.0 × 10
-6
 M solutions of 17 (black dashed line) and 18 (grey dashed 
line), and supramolecular adducts bpe17 (17 = 1.0 × 10-6 M, [bpe] = 5.0 × 10-6 M, black line) and 
bpe18 (18 = 1.0 × 10-6 M, [bpe] = 5.0 × 10-6 M, grey line), excited at 545 nm in CCl4. The emission 
of 17 and 18 are normalized at the corresponding maxima of the supramolecular complexes. The 
arrows in the spectrum of 17 indicate a feature attributable to the emission from free porphyrin units. 
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The weak interaction between 17 and bpe is attributed to the comparatively larger bis-
porphyrin cavity size (vide supra). The host-guest binding efficiency was determined 
quantitatively by plotting the absorption changes of the Soret band of 17 and 18 against the 
concentration of guest moieties. The resulting curves were fitted with a nonlinear equation 
(Fig. 50),
87a,92
 and the corresponding association constant values are collected in Table 5. The 
stronger affinity of 17 and 18 to bpy and bpe guest molecules compared (one and two orders 
of magnitude, respectively) to pyridine suggests bidentate complexation of bpe and bpy 
within the cavity. On the other hand, analogous bis-porphyrin based host systems
87a,89b,c
 
display a 2-3 times higher association constants compared to the present case, indicating a 
non-optimal match between the host cavity of 17 and 18 and the length of these bis-pyridyl 
guests.  
 
 
Fig. 50. Non-linear fitting of the absorption data points collected from the titration curves of 17 (at 
421 nm) and 18 (at 422 nm) against increasing amounts of bpe (up to 5 equiv.) in CCl4. 
 
Subsequently, we have investigated the interaction of 17 and 18 with 5,10-dpp and 
5,15-dpp, which are strong chromophoric guests having a free base porphyrin core and two 
coordinating pyridine units; toluene was used as solvent for solubility reasons. The 
absorption changes during the titration of 17 and 18 with 5,10-dpp and 5,15-dpp are 
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monitored by “differential” measurements, i.e. the absorption contribution of the added guest 
being subtracted from that of the host.
87a
 The differential absorption spectral traces of 17 
upon adding increasing amounts of 5,10-dpp in toluene are shown in Fig. 51a. Similar to the 
cases described above, the addition of 10 equiv. of 5,10-dpp to 17 results in a continuous 
bathochromic shift of the Soret and Q bands. Surprisingly, the absorption changes in the 
differential spectra of 18 reach a plateau after the addition of less than 2 equiv. of 5,10-dpp 
(Fig. 51b). It is worth emphasizing that the concentrations of 17 and 18 are of the order of 10
-
7
 M, and additionally both the host and the guest show excellent solubility in toluene. 
Therefore, the formation of aggregates can be ruled out, and the changes observed in the 
titration curves are solely the consequence of host-guest complexation. The association 
constants are calculated in a similar way as mentioned above and the values are in the order 
of 10
4
 M
-1
 and 10
7
 M
-1 
for 5,10-dpp17 and 5,10-dpp18, respectively (Table 4). The 
significantly higher binding constant value of 5,10-dpp18 reflects the higher affinity of 18 
for 5,10-dpp and can be attributed to two factors: (i) the inter-pyridyl distance in 5,10-dpp 
summed with the length of two coordination bonds Npyridyl-Zn (2.2 Å each) perfectly matches 
the cavity size of 18; (ii) the pyridine units in 5,10-dpp show an appropriate orientation to 
coordinate with the Zn-porphyrin units in 18, where a coordination angle of approximately 
45° from the porphyrin molecular plane is required to facilitate coordination. In other words, 
5,10-dpp can approach 18 with an optimal angle, thus, the combined spatial and structural 
effects favor a strong host-guest interaction, which is corroborated by molecular modeling 
(Fig. 52). 
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Fig. 51. Differential absorption spectral traces of 17 (2.4 × 10
-7
 M, (a)) and 18 (5.8×10
-7
 M, (b)) 
upon addition of increasing amounts of 5,10-dpp (up to 10 and 4 equiv. respectively) in toluene. Inset 
(i): The corresponding changes in the Q bands spectral region; inset (ii): The fitted data points 
collected at 424 and 425 nm from 17 and 18, respectively. 
 
 
 
Fig. 52. Molecular modeling of the 5,10-dpp18 adduct (5,10-dpp represented as space-filling 
model). 
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Fig. 53. Differential absorption spectral traces of 17 (5.1 × 10
-7
 M, (a)) upon addition of increasing 
amounts of 5,15-dpp (up to 3.5 equiv.) in toluene. 
 
Similarly, 17 and 18 were titrated in toluene with 5,15-dpp, the bidentate guest with 
the longest interpyridyl distance (ca. 16 Å)
87a
 among those investigated here. Because of the 
linear arrangement of the two pyridine units, 5,15-dpp clearly prefers axial coordination with 
Zn-porphyrin moieties in 17 and 18. Fig. 53 and Fig. 54 show the differential spectral traces 
of hosts 17 and 18 upon addition of increasing amounts of 5,15-dpp. The absorption changes 
observed therein are significantly weaker than those observed with 5,10-dpp. In the case of 
17, some changes are observed, which is likely due to the increased inter-pyridine distance of 
5,15-dpp (ca. 16 Å) compared to 5,10-dpp (ca. 11 Å).
87a
 However, in 18, structural and 
spatial mismatching between the host and the guest resulted in negligible interactions. As a 
result of the minimal changes in the absorption spectra of the hosts, the binding affinity 
constants could not be appraised quantitatively. 
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Fig. 54. Differential absorption spectral traces of 18 (5.2 × 10
-7
 M, (b)) upon addition of increasing 
amounts of 5,15-dpp (up to 3.5 equiv.) in toluene. 
 
In conclusion, we have synthesized and photophysically characterized a series of 
sawhorse-type diruthenium tetracarbonyl tweezers derived from either pyrenyl or porphyrin 
carboxylic bridging units. The molecular modeling of 14, 15 and 16 suggests that the pyrenyl 
and porphyrin moieties are adequately positioned to allow these complexes to act as 
molecular tweezers with fullerene. However, these systems have showed no interaction with 
fullerene in solution, despite possessing appropriate structural features, as predicted by 
modeling for compounds 14, 15 and 16. On the other hand, with the Zn(II)-porphyrin 
derivatives, 17 and 18 interaction with bis-pyridyl ligands were observed. In particular, a 
relatively high association constant between 5,10-di-(4-pyridyl)-15,20-diphenyl-21,23H-
porphyrin and 18 was found, thus indicating size specific tweezing properties, and overall 
showing a new application for an old class of compounds, the sawhorse-type diruthenium 
tetracarbonyl complexes. 
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4. Biologically application of dinuclear (Ru, Rh and Ir) complexes 
4.1. Transition metal complexes in cancer treatment  
Cancer results from the uncontrolled growth of cells; unless the growth is controlled 
the disease could be lethal. According to a recent survey, cancer is the second leading cause 
of death in developed countries and third leading cause of death in developing countries.
93
 
One in four deaths in the USA and one in eight deaths worldwide are due to cancer. Cancer 
can be treated by surgery, radiotherapy and/or chemotherapy. Among the treatment methods, 
chemotherapy has been widely accepted and used all around the world.
94
 
Though organic molecules have been used as an active ingredient in most of the 
anticancer drugs, the development of metal based therapeutic agents for cancer treatments is 
gaining momentum in recent years.
95
 The square planar cisplatin or cis-
dichlorodiamineplatinum(II) (Fig. 55) was the first metal based drug approved for clinical 
use.
96
 Cisplatin is being used as an effective drug to treat human malignancies such as lung, 
head-and-neck, ovarian, bladder and testicular cancers by itself or in combination with other 
drugs.
97
 Although cisplatin is an effective drug for cancer treatment, it also has limitations. 
Particularly, the non-selective cytotoxicity towards healthy cells, which leads to undesirable 
side-effects and intrudes into drug resistance mechanisms.
98
 Thus, it is necessary and 
challenging to develop alternate drugs based on platinum with superior activity and minimal 
side effects compared to cisplatin. Over the last three decades there were more than 4000 
platinum derived compounds investigated for chemotherapy. Among them only ten reached 
clinical trials. The food and drug administration (FDA) has approved only carboplatin and 
oxaliplatin for clinical use (Fig. 55).
96a,99
 Even though some of the problems encountered 
with cisplatin were diminished by carboplatin and oxaliplatin, they still showed high level of 
non-selective cytotoxicity which hampered their extensive use as an anticancer drugs.
100
 
Many organometallic compounds of titanium,
101
 ruthenium,
102
 rhodium,
103
 
palladium,
104
 copper
105
 and gold
106
 have been studied for cancer treatment because of their 
cytotoxicities on cancer cells. Among these metal derivatives ruthenium has been considered 
as an interesting alternative to the platinum counterparts. Most of the ruthenium anticancer 
drugs directly attack and kill primary tumors while others prevent the tumor growth from 
spreading to rest of the healthy tissues.  
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Fig. 55. Structures of platinum based cancer drugs. 
 
Ruthenium, with the atomic number of 44, is located just below iron (Fe) in the 
periodic table. Among its numerous oxidation states, Ru(II) and Ru(III) have been shown to 
be effective in anticancer treatments. Most Ru(II) (S = 
1
/2) and Ru(III) (S = 0) complexes 
have low-spin and the first-order water exchange rate constants (k), for aquated Ru(II) is 
about one order of magnitude faster than that of Pt(II), suggesting that complexes of Ru(II) 
suit better to react with biological system. The high exchange rate of aquated Ru(II) is an 
added advantage towards the elimination of metal ruthenium from biological systems. 
Consequently, the accumulation effect of platinum drug in the biological system could be 
overcome by ruthenium drugs. Also, it has been shown that due to the redox behavior of 
ruthenium inside the biological system, Ru(III) is being reduced to Ru(II) and subsequently 
eliminated, which could give a better explanation for the elimination of Ru(III) drugs, 
suggesting that Ru(II) is the active species.
107
 
Imidazolium trans-[imidazoledimethylsulfoxide-tetrachlororuthenate(III)] (NAMI-A) 
(Fig. 56) and indazolium-trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) (Fig. 
56) are the two ruthenium(III) complexes that have successfully completed phase-I clinical 
trial.
102
 Preclinical studies show that NAMI-A has a remarkable effect against the formation 
of cancer metastases in a variety of tumor models, but appears to be poorly active against 
primary tumors.
108
 NAMI-A weakly binds with DNA which is in contrast to cisplatin, 
suggesting that its mode of action is different from that of other platinum(II) compounds.
109
 
On the other hand, KP1019 was found to be more stable and has a high anti-tumor activity. 
More interestingly, KP1019 showed higher anti-tumor activity towards primary cisplatin-
resistant colorectal tumors but it did not show any anti-metastatic activities.
110
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Fig. 56. Structure of NAMI-A and KP1019 
 
In contrast to NAMI-A and KP1019, arene-ruthenium complexes are more cytotoxic 
in their ruthenium (II) oxidation state. Dyson’s RAPTA-C {[(η6-p-MeC6H4Pr
i
)Ru(PTA)Cl2]; 
PTA = 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane} (Fig. 57)
96a,98,111
 as well as Sadler’s 
derivative {[(C6H5Ph)Ru(en)Cl][PF6]} (RM175, en = ethane-1,2-diamine) (Fig. 57)
112
 are the 
two promising drugs having anticancer activities in vitro and in vivo.
113
 Though RAPTA-C 
exhibits very low activity in vitro, it is very active in vivo (with lung metastases in CBA 
mice); RAPTA-C is also an anti-metastatic agent like NAMI-A.
114
 
 
 
Fig. 57. Structure of anticancer ruthenium complexes RAPTA-C and RM175
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Unlike the mononuclear complexes, dinuclear or multinuclear ruthenium complexes 
have recently been reported for their anticancer activities:
114-115
 Hartinger et al. synthesized 
the dinuclear arene ruthenium complexes of pyridinone derivatives (η6-p-MeC6H4Pr
i
)Ru-
(O,O-C6H5O2N(CH2)nNC6H5O2-O,O)Ru(η
6
-p-MeC6H4Pr
i
) (n = 3, 6 and 12) (Fig. 58). In vitro 
studies of the complex (η6-p-MeC6H4Pr
i
)Ru(O,O-C6H5O2N(CH2)12NC6H5O2-O,O)Ru(η
6
-p-
MeC6H4Pr
i
) showed very high cytotoxic effect against ovarian (A2780; IC50 = 1.5 µM) and 
colon (SW480; IC50 = 0.29 µM) cancer cell lines.
116
 Sadler et al. studied the photodynamic 
therapy effects of this type [{(arene)RuCl}2(N,N:N,N-dpp)}]
2+
 of dinuclear arene ruthenium 
complexes {arene = C6H6, C6Me6, C9H10, p-MeC6H4Pr
i
; dpp = 2,3-bis(2-pyridyl)pyrazine}. 
The indane derivative [{(η6-C9H10)RuCl}2(N,N:N,N-dpp)]
2+ 
(Fig. 58) gives dinuclear reactive 
species upon UV irradiation in the presence of water in the dark and this dinuclear active 
species strongly interact with DNA to give diruthenium DNA adducts.
117
 Notably, these types 
of dinuclear arene-ruthenium complexes have interesting advantages of photo-induced cell 
death and fluorescence image traceability of localizations inside biological systems.
114,117
 
 
 
Fig. 58. Structure of [(η6-p-MeC6H4Pr
i
)Ru(O,O-C6H5O2N(CH2)nNC6H5O2-O,O)Ru(η
6
-p-MeC6H4Pr
i
)] 
(Left) and [{(C9H10)RuCl}2(N,N:N,N-dpp)]
2+ 
(Right). 
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Among the dinuclear complexes, thiolato bridged arene ruthenium complexes are well 
known for their biological applications.
38a,118
 Giannini et al.
118
 reported a series of water 
soluble and air-stable arene ruthenium cationic complexes of the type [(η6-arene)2Ru2(SR)3]
+
 
(Fig. 59) which were tested for anticancer activity. From the in vitro studies it was shown that 
the thiolato bridged arene ruthenium complex [(η6-p-MeC6H4Pr
i
)2Ru2(µ-SC6H4-p-Bu
t
)3]
+
 
(Fig. 59) displayed a very high cytotoxicity (IC50 value of 0.03 µM on both A2780 and 
A2780cisR cancer cell lines) even at very low concentration. 
 
 
Fig. 59. Highly cytotoxic thiolato bridged arene ruthenium complexes. 
 
 
Fig. 60. Structures of [(η5-C5Me5)2Rh2(µ-SCH2Ph)3]
+
 (left) and [(η5-C5Me5)2Ir2(µ-SCH2Ph)3]
+ 
(right). 
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The chemistry of cyclopentadienyl rhodium(III) and iridium(III) is similar to that of 
the arene ruthenium(II) analogues.
119
 Like arene ruthenium derivatives, cyclopentadienyl 
rhodium or iridium derivatives react with thiolato ligands to give thiolato-bridged 
cyclopentadienyl rhodium or iridium complexes under similar reaction conditions. Recently, 
we have shown that dinuclear thiolato-bridged pentamethylcyclopentadienyl rhodium and 
iridium complexes possess surprising cytotoxicities. These rhodium(III) and iridium(III) 
metal complexes had very high cytotoxicity, which were similar to arene ruthenium(II) 
complexes. For example, the complex [(η5-C5Me5)2Rh2(µ-SCH2Ph)3] (Fig. 60) showed IC50 
values of 0.14 µM on A2780 and 0.09 µM on A2780cisR cancer cell lines. The complex [(η5-
C5Me5)2Ir2(µ-SCH2Ph)3] (Fig. 60) showed IC50 values of 0.09 µM on A2780 and 0.06 µM on 
A2780cisR cancer cell lines.
119
  
 
4.2. Cytotoxic chalcogenolato-bridged dinuclear half-sandwich complexes 
4.2.1. Introduction 
In biology, selenium is essential to life and it plays an important role in redox 
enzymatic processes.
120
 At low concentrations, selenium stimulates cell growth and exhibits 
anticancer properties, while at higher concentrations it can induce cell death.
121
 In addition, 
studies have shown that in combination with cisplatin, the most successful metal-based 
drug,
122
 selenium reduces the nephrotoxicity associated with cisplatin treatment.
123
 On the 
other hand, the biological relevance of tellurium remains uncertain, but the potential of using 
tellurium derivatives as therapeutic agents has been already recognized.
124
 
Recently, we have shown that the thiolato-bridged dinuclear arene ruthenium 
complexes of the type [(η6-p-MeC6H4Pr
i
)2Ru2(μ-SR)3]
+
,
38a,43,118,125
 as well as the rhodium and 
iridium pentamethylcyclopentadienyl analogues [(η5-C5Me5)2M2(μ-SR)3]
+
 (M = Rh, Ir),
119
 
possess excellent cytotoxicity on the ovarian cancer cell lines A2780 and A2780cisR. The 
most active compounds show cytotoxicity against both cell lines in the sub-micromolar range 
with IC50 values below 0.1 μM. The high antiproliferative effect was tentatively ascribed to 
the presence of the thiolato-bridging groups and the catalytic activity of the 
complexes.
38a,43,118-119,125
 These dinuclear arene ruthenium complexes are among the most 
active arene ruthenium complexes evaluated so far in vitro.
38a,43,118,125
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Therefore, due to the high activity of the dinuclear thiolato-bridged half-sandwich 
complexes and the biological relevance of selenium and tellurium, we have prepared a series 
of selenolato and tellurolato p-cymene ruthenium derivatives [(η6-p-MeC6H4Pr
i
)2Ru2(μ-
EC6H5)3]
+
 (E = S, 19; E = Se, 20; E = Te, 21), as well as the pentamethylcyclopentadienyl 
(C5Me5) rhodium and iridium analogues [(η
5
-C5Me5)2M2(μ-EC6H5)3]
+ 
(M = Rh, E = S, 22; E 
= Se, 23; E = Te, 24; M = Ir, E = S, 25; E = Se, 26; E = Te, 27). In addition, a series of mixed 
thiolato-selenolato and thiolato-tellurolato bridged complexes have also been synthesized, 
[(η6-p-MeC6H4Pr
i
)2Ru2(μ-EC6H5)(μ-SCH2C6H4-p-Bu
t
)2]
+
 (E = Se, 28; E = Te, 29) and [(η5-
C5Me5)2M2(μ-EC6H5)(μ-SCH2C6H5)2]
+
 (M = Rh, E = Se, 30; E = Te, 31; M = Ir, E = Se, 32; 
E = Te, 33). The cytotoxicity of all complexes was evaluated on human ovarian cancer cells, 
and comparison with the parent thiolato-derivatives is discussed. 
 
4.2.2. Synthesis of chalcogenolato-bridged dinuclear half-sandwich complexes  
Despite numerous papers dealing with thiolato-bridged dinuclear arene ruthenium 
complexes,
42a,126
 the only investigation of a dinuclear selenolato complex, [(η6-p-
MeC6H4Pr
i
)2Ru2(μ-SeC6H5)3]PF6, was reported 15 years ago by Mashima.
127
 Low yield (19 
%) and difficulties with reproducibility of the method prompted us to prepare the desired 
cationic complex under new conditions (Scheme 2). Our synthetic strategy is based on the 
synthesis of the thiolato-bridged analogues
38a,43,118,125
 and affords [(η6-p-MeC6H4Pr
i
)2Ru2(μ-
SeC6H5)3]Cl in 66 % yield after column chromatography. The rhodium and iridium analogues 
are obtained in comparable yields following the same strategy (Scheme 2). The known 
thiolato-bridged p-cymene ruthenium complex, [(η6-p-MeC6H4Pr
i
)2Ru2(μ-SC6H5)3]
+
, was 
also synthesized for comparison.
40,43
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Scheme 2. Synthesis of thiolato- and selenolato-bridged complexes 19, 20, 22, 23, 25 and 26 
 
The tellurolato derivatives 21, 24 and 27 are prepared following an established 
procedure.
127
 They are synthesized in ethanol from the reaction of (η6-p-MeC6H4Pr
i
)2Ru2(µ-
Cl)2Cl2 or (η
5
-C5Me5)2M2(µ-Cl)2Cl2 (M = Rh, Ir) with sodium tellurophenolate (Scheme 3): 
Sodium tellurophenolate being prepared in situ by treating diphenyl ditelluride with sodium 
borohydride. These complexes are all isolated as their hexafluorophosphate salts, which are 
obtained upon addition of 1 eq. of KPF6 to the crude ethanolic solution, just before 
purification of the corresponding salts by column chromatography. The analytical data of the 
salt, [(η6-p-MeC6H4Pr
i
)2Ru2(μ-TeC6H5)3]PF6, are in agreement with those reported by 
Mashima.
127
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Scheme 3. Synthesis of tellurolato-bridged complexes 21, 24 and 27. 
 
As previously reported for analogous p-cymene ruthenium complexes,
42,126
 all 
1
H 
NMR spectra show diastereotopic protons for the dinuclear complexes 19-21, two doublets 
and a multiplet for the isopropyl group, a singlet for the methyl, four doublets for the 
aromatic protons of the p-cymene and two broad multiplets for the protons of the chalcogen-
phenyl groups. The ESI mass spectrum in positive mode gives the expected cationic parent 
peak of [(η6-p-MeC6H4Pr
i
)2Ru2(μ-EC6H5)3]
+
 at m/z = 799.1, 939.1 and 1084.3, respectively. 
The 
1
H NMR spectra of the pentamethylcyclopentadienyl derivatives are much simpler, 
showing only an intense singlet between 1.3 and 1.8 ppm for the C5Me5 groups and 
multiplets in the aromatic region for the bridging chalcogen-phenyl groups. The ESI MS 
spectra show as well the cationic peaks corresponding to the intact complexes 22-27. 
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The neutral dichloro dithiolato complexes (η6-p-MeC6H4Pr
i
)2Ru2Cl2(μ-SCH2C6H4-p-
Bu
t
)2 
38a
 and (η5-C5Me5)2M2Cl2(μ-SCH2C6H5)2 
41,119
 react with benzeneselenol and sodium 
tellurophenolate in ethanol to give the mixed dithiolato-selenolato and dithiolato-tellurolato 
cationic dinuclear complexes [(η6-p-MeC6H4Pr
i
)2Ru2(μ-EC6H5)(μ-SCH2C6H4-p-Bu
t
)2]
+
 (E = 
Se, 28; E = Te, 29) and [(η5-C5Me5)2M2(μ-EC6H5)(μ-SCH2C6H5)2]
+
 (M = Rh, E = Se, 30; E = 
Te, 31; M = Ir, E = Se, 32; E = Te, 33) (Scheme 4 and Scheme 5). 
 
 
Scheme 4. Synthesis of the mixed dithiolato-selenoato-bridged complexes 28, 30 and 32. 
 
The dithiolato-selenolato derivatives (28, 30, 32) are synthesized in ethanol at reflux 
from the neutral dichloro dithiolato intermediates and benzeneselenol (Scheme 4), while the 
dithiolato-tellurolato analogues are obtained at room temperature by adding sodium 
tellurophenolate to the same neutral intermediates (Scheme 5). The selenolato derivatives are 
obtained as chloride salts, while the tellurolato complexes (29, 31, 33) are isolated as 
hexafluorophosphate salts, after addition of KPF6 to the reaction mixture. 
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Scheme 5. Synthesis of the mixed dithiolato-tellurolato-bridged complexes 29, 31 and 33. 
 
These mixed dithiolato-selenolato and dithiolato-tellurolato complexes are extremely 
stable under the harsh conditions of electro-spray ionization mass spectrometry, showing 
peaks corresponding to the intact cations; [M - Cl]
+
 for complexes 28, 30 and 32 and [M - 
PF6]
+
 for complexes 29, 31 and 33 (see Experimental section). These peaks are 
unambiguously assigned on the basis of their respective isotope patterns. 
 
4.2.3. Biological studies of chalcogenolato-bridged dinuclear half-sandwich complexes  
In order to evaluate the biological potential of these chalcogenolato-bridged dinuclear 
half-sandwich complexes in vitro, cell biology and biophysical experiments have been 
carried out. Effect of these complexes on normal (CRL-2115, CRL-2120) and human 
cancer (A549, B16F10 and MCF-7) cell lines was studied using MTT assays (MTT = 3-(4,5-
dimethyl-2-thiazoyl)-2,5-diphenyltetrazolium bromide) and cell count assays. Among the 
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organometallic complexes evaluated in the present study, the most active derivatives were 
selected and further analysed using flow cytometry, confocal microscopy and DNA cleavage 
experiments. In order to better understand their unique intracellular activity, interaction with 
DNA for the selected candidates was also studied.  
 
4.2.3.1. MTT assays 
MTT assay is a simple, accurate and reliable test to estimate the activity of living 
cells before and after addition of a biological agent.
128 
Therefore, this assay was used with 
complexes 19-33 on normal (CRL-2115 and CRL-2120 fibroblasts) and human cancer 
(A549 lung, B16F10 melanoma and MCF-7 breast cancers) cell lines. The assay was 
performed at different concentrations of complexes (10 nM, 50 nM, 100 nM, 300 nM, 500 
nM, 1 µM and 2 µM) and the absorbance obtained at 570 nm was plotted against the 
concentration of the complex to determine the half maximal inhibitory concentration (IC50 
value). The IC50 values of the complexes and the Tm (Tm = melting temperature) values 
obtained in the presence of CT-DNA (calf thymus DNA) are presented in Table 6, together 
with the corresponding standard deviations. Among the normal and cancer cell lines studied, 
the cytotoxic effect is higher in the B16F10 cell line and among all complexes, compounds 
19, 22 and 25 appear to be the most active derivatives. Indeed, the IC50 of 19 on the B16F10 
cell line is approximately 300 nM, closely followed by complexes 22 (≈ 315 nM) and 25 
(≈ 320 nM). Complexes 19, 22 and 25 are those with thiolato bridges, thus suggesting that 
the nature of the metal plays only a minor role, while the nature of the chalcogenolato 
bridges is somehow important. These trends are clearly seen on the B16F10 cell line. 
Accordingly, complex 19 shows the strongest affinity with CT-DNA with a Tm of ≈ 
75 º C, which is closely followed by complexes 22 (≈ 70 º C) and 25 (≈ 69 º C). 
Overall, all complexes interact with CT-DNA, showing Tm values higher than 62 ºC. In 
addition, the complexes show some selectivity towards the cancerous cell lines, being less 
active by half on the CRL-2115 and CRL-2120 normal fibroblast cells. 
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Table 6. Cytotoxicity of complexes 19-33 after 24 h exposure to various cell lines and Tm 
values of the complexes with CT-DNA. 
 
4.2.3.2. Cell viability assays 
Cell viability assays were performed to corroborate the results obtained from the 
MTT assays, to find the extent of cytotoxicity induced in these cell lines and to study the 
selectivity of the complexes between normal and cancerous cells. Both normal and 
cancer cells were treated with the compounds at a 300 nM concentration. After 24 h of 
incubation, the number of viable cells was counted in normal as well as in cancer cells using 
complex IC50 (nM)     Tm
 
(
o
C) 
 CRL-2115 CRL-2120 MCF-7 B16F10 A549  
19 935 ±4 1078 ± 5 543 ± 5 306 ± 3 424 ± 4 75 
20 965 ± 6 1082 ± 7 574 ± 6 352 ± 5 440 ± 5 66 
21 950 ± 5 1074 ± 6 562 ± 4 346 ± 4 432 ± 3 68 
22 965 ± 3 1172 ± 4 567 ±6 314 ± 2 437 ± 5 70 
23 987 ± 7 1354 ± 6 553 ± 4 357 ± 5 457 ± 4 64 
24 976 ± 6 1287 ± 7 561 ± 5 332 ± 4 442 ± 5 66 
25 1024 ± 5 1136 ± 4 582 ± 6 319 ± 5 442 ± 6 69 
26 1037 ± 7 1232 ± 6 597 ± 7 358 ± 6 472 ± 5 64 
27 1025 ± 8 1187 ± 8 587 ± 4 341 ± 5 456 ± 4 67 
28 967 ± 7 1087 ± 7 592 ± 5 342 ± 4 445 ± 7 68 
29 953 ± 5 1079 ± 8 583 ± 6 331 ± 5 432 ± 5 65 
30 986 ± 7 1089 ± 7 557 ± 4 345 ± 6 446 ± 4 62 
31 972 ± 5 1076 ± 8 543 ±7 328 ± 5 439 ± 7 64 
32 1028 ± 7 1254 ± 7 568 ± 6 354 ± 7 453 ± 5 63 
33 1017 ± 8 1215 ± 6 552 ± 5 346 ± 5 446 ± 6 66 
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a hemocytometer. From these results, it is clear that among the complexes studied, 
complexes 19, 22 and 25 exhibit a higher cytotoxicity in cancer cells as compared to 
normal cells. The elevated cytotoxicity in cancer cells can be due to a higher uptake of the 
cationic complexes into cancer cells.
129 
Among the cell lines tested, the melanoma 
B16F10 cells are the most affected by the presence of the complexes. Bar graphs 
indicating the number of viable cells in normal as well as in cancer cells after treatment 
with complexes 19, 22 and 25 are shown in Fig. 61. The bar graphs which are statistically 
significant with p values ≤ 0.05 are marked with an asterisk (*). 
 
 
Fig. 61. Cell viability assays with normal and cancer cells after 24 h of treatment with complexes 19, 
22 and 25 at 300 nM concentrations. 
 
4.2.3.3. Flow cytometry experiments  
The results obtained from cell viability and MTT assays indicate that among 
the complexes studied, complexes 19, 22 and 25 exhibited the highest cytotoxicity in 
these cancer cell lines. Therefore, to better understand the role of these complexes in 
cells and to find a plausible cause for the higher cytotoxicity and efficacy of complexes 
19, 22 and 25 in cells, cell cycle assays and apoptotic assays were performed using flow 
cytometry in the presence and absence of the complexes at their respective IC50 values. 
These tests suggest that complexes 19, 22 and 25 inhibit the cell cycle at the G2 stage (Fig. 
62). It has been previously reported that G2 arrest can enhance cytotoxicity and induce 
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apoptosis in cells.
130 
Among the complexes studied, the G2 phase inhibition is maximum in 
the B16F10 cells with complex 19 (24.82 %) followed by complex 22 (23.05 %) and 
complex 25 (21.37 %), while the untreated B16F10 cells show a G2 phase inhibition of 
only 14.71 % (Table 7). Similarly, inhibition of cell cycle at sub-G1 phase with complexes 
19 (6.79 %), 22 (5.59 %) and 25 (4.80 %) also occurs in the same order as compared to 
untreated cells (4.58 %). These results confirm that all the complexes induce 
cytotoxicity followed by apoptosis induction in the cancer cell lines through G2 phase 
inhibition. G2 phase inhibition prevents the cells to proceed further to the mitotic phase. 
The details of the cell cycle assays are presented in Fig. 62. 
 
Table 7. Distribution of cells in various phases of the cell cycle in untreated (control) and 
treated B16F10 cells with complexes 19, 22 and 25. 
complex sub-G1 
(%) 
G0/G1 
(%) 
S 
(%) 
G2/M 
(%) 
control 4.58 57.40 9.80 14.71 
19 6.79 44.79 9.60 24.82 
22 5.59 46.17 9.09 23.05 
25 4.80 52.20 8.47 21.37 
 
Table 8. Percentage of alive, early apoptotic, late apoptotic and necrotic cells in untreated 
(control) and treated B16F10 cells with complexes 19, 22 and 25. 
complex alive 
cells 
(%) 
(%) 
 
(%) 
early 
apoptotic 
(%) 
 
late 
apoptotic 
(%) 
 
(%) 
necrotic 
cells 
(%) 
total 
apoptotic cells 
(%) 
 
unstained control 99.66 0.02 0.01 0.05 low 
stained control 69.54 0.02 0.10 29.33 low 
19 9.16 55.82 33.15 0.78 88.97 
22 20.18 68.79 10.03 0.31 78.82 
25 29.30 54.50 15.31 0.41 69.81 
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Fig. 62. Untreated (control) and treated B16F10 cells with complexes 19, 22 and 25, the cells 
were stained with propedium iodide (PI). The cellular DNA content frequency histogram and scatter 
plots are shown. 
 
From apoptotic assays it is clear that complex 19 possesses a higher potential to 
induce apoptosis (88.97 %) in B16F10 cells than complexes 22 (78.82 %) and 25 (69.81 
%) (Table 8). From the results, it is evident that 19 is effective in inducing higher 
proportion of apoptotic cells: more late apoptotic cells (Annexin-V+/PI+) than early 
apoptotic cells Annexin-V+/PI-) in B16F10 cells. Whereas on treatment with complex 22 a 
higher percentage of early apoptotic cells are observed (Annexin-V+/PI-) over treated cells 
with complexes 19 and 25. On the other hand, when the B16F10 cells are treated with 
complexes 19 and 25, more late apoptotic cells (Annexin-V+/PI+) are observed as 
compared to complex 22, emphasizing the higher potential of complex 19 in inducing both 
early and late apoptosis in human cancer cells. The results obtained with apoptotic assays 
support the findings of the MTT and cell viability assays. The percentages of cell 
population which are in viable, necrotic, early or late apoptotic phase and in various stages 
of the cell cycle are shown in Table 8. The results obtained in the apoptotic assays with 
stained and unstained controls as well as in cells treated with complexes 19, 22 and 25 are 
presented in Fig. 63. 
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Fig. 63. Untreated and treated B16F10 cells with complexes 19, 22 and 25. The cells were 
stained with Annexin-V and propedium iodide and analysed for various types of cells like: viable 
(lower left), early apoptotic (lower right), late apoptotic (upper right) and necrotic cells (upper left). 
 
4.2.3.4. Confocal studies 
In order to corroborate the results obtained by flow cytometry and to understand 
the interaction of the complexes with cellular DNA in cells, the B16F10 melanoma cells 
were treated with complexes 19, 22 and 25 for 48 hours and the state of DNA in cells after 
treatment was examined by staining of the DNA with 300 nM DAPI (4',6-diamidino-2-
phenylindole). On careful examination under a microscope of the cellular DNA of both, 
treated and untreated B16F10 cells, it appears that complex 19 creates maximum DNA 
fragmentations, followed by 22 and 25, respectively. We can speculate that the higher 
cytotoxicity observed with 19 is due to its greater DNA fragmentation activity. The 
results indicate that complexes 19, 22 and 25 are capable of crossing the cell membrane 
barrier and to interact with the cellular DNA. The data obtained from the confocal 
studies are shown in Fig. 64. It is evident from Fig. 64 that several B16F10 cells have lost 
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their usual shape and have wrinkled upon treatment with complex 19. The number of cells 
with altered shapes is comparatively less with complexes 22 and 25. The presence of 
wrinkled and shrunken cells indicates that the cells are entering into the apoptosis phase.
131
 
These results also indicate that complex 19 has higher potential to fragment cellular DNA 
and to induce apoptosis, which overall supports the results obtained by MTT cell viability 
and flow cytometry assays. 
 
 
Fig. 64. Confocal microscopic pictures of B16F10 cells stained with 300 nM  DAPI. B16F10 cells 
were treated with 300 nM of complexes 19, 22 and 25 for 24 h. Untreated cells are considered as 
control. 
 
4.2.3.5. DNA cleavage experiments 
Confocal experiments clearly suggest that DNA in cell is getting fragmented on 
treatment with complexes 19, 22 and 25. It also confirms that complex 19 yields 
maximum DNA cleavage at its IC50 concentration (i.e at around 300 nM) which is 
closely followed by 22 and 25. To verify these results, DNA cleavage experiments were 
carried out by incubating B16F10 cells with each complex and the results confirm that all 
compounds enter the cells by crossing the cell membrane barrier and are able to interact 
with DNA. B16F10 cells were treated with 300 nM of complexes 19, 22 and 25. DNA 
cleavage assay also indicates that fragmentation of DNA is prominently observed in cells 
treated with complex 19 followed by complexes 22 and 25. The picture of the agarose gel 
after electrophoresis is shown in Fig. 65. 
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Fig. 65. Agarose gel showing the fragmentation of DNA in B16F10 cells after treatment with 
complexes 19, 22 and 25 for 48 h. Lane 1, B16F10 cells without any treatment. lanes 2, 3 and 4, 
B16F10 cells after treatment with 300 nM concentration of complexes 19, 22 and 25, 
respectively. 
 
4.2.3.6. DNA binding studies 
The previous experiments such as flow cytometry, confocal and DNA cleavage 
assays suggest that complexes 19, 22 and 25 are efficient in inducing apoptosis in various 
cancer cells. It is understood that the interaction with DNA is playing a major role for the 
development of various biological activities in cells. Interaction of these complexes with 
CT-DNA under in vitro conditions can therefore provide insight to better understand the role 
of these complexes in inducing apoptosis. 
CT-DNA interactions with the selected complexes were studied by spectroscopic 
methods, circular dichroism (CD) and UV-Vis spectroscopy. CD spectra of CT-DNA were 
recorded with complexes 19, 22 and 25. The CD spectrum of CT-DNA alone exhibit a 
positive band at 275 nm and a negative band at around 245 nm, which is a characteristic CD 
signature of the right handed B form of DNA.
132
 Among the studied complexes, 19 exhibits 
hyperchromicity of the positive CD band at 275 nm, indicating its potential to stabilize 
DNA upon interaction. On the other hand, with complexes 22 and 25, the intensity of the 
CD bands at 275 nm exhibits a hypochromic effect indicating its role in unwinding CT-
DNA. The CD spectra obtained on interaction with complexes 19, 22 and 25 with CT-
DNA at higher stoichiometry (1:1) are shown in Fig. 66. 
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Fig. 66. CD spectra obtained when complexes 19, 22 and 25 interact with CT-DNA. The 
spectra were labeled accordingly and the corresponding sample names are shown as an inset in the 
Figure. CD spectra were recorded twice and averaged to limit experimental errors. 
 
The UV-Vis spectrum of complex 19 shows an absorption peak at 230 nm. On 
addition of CT-DNA, the soret band at 230 nm exhibits hypochromicity (about 10-15 %) 
and shifts to 263 nm (about 33 nm bathochromic shift). Hypochromicity of the soret band 
occurs due to interaction between the electronic states of the cationic complex and those 
of the DNA bases,
133
 whereas a bathochromic shift is associated with the decrease in 
the energy gap between the highest occupied molecular orbital (HOMO) and the lowest 
unoccupied molecular orbital (LUMO).
134
 In general, hypochromicity and bathochromic 
shifts indicate that molecules bind to the DNA-helix by intercalative mode through π-
staking interactions of the aromatic chromophore of the complex between DNA bases.
135
 
An isobestic point is also observed around 240 nm and it is not a single sharp point 
suggesting that the interaction between complex 19 and CT-DNA takes place in multiple 
steps and at a given time more than one species exist at equilibrium (Fig. 67A). The UV-
Vis spectra of complexes 22 and 25 show two absorption bands at 230 nm -263 nm, 
and 230 nm - 325 nm, respectively. On addition of CT-DNA, the soret bands exhibit 
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hypochromicity. The extent of hypochromicity of the soret band is an indication of strength 
of ligand intercalation to DNA.
136
 From Fig. 67B and 67C, it is also clear that the soret 
band of 25 at 230 nm shows higher hypochromicity as compared to complex 22. This 
suggests that complex 25 has a better interaction with DNA and unwinds the double helical 
structure more effectively than 22.
137
 The UV-Vis absorption spectra of CT-DNA obtained 
in the presence of complexes 19, 22 and 25 are shown in Fig. 67(A, B, C). 
 
 
 
 
 
 
 
 
Fig. 67. UV-Vis spectra obtained on titrating CT-DNA with complexes 19 (A), 22 (B) and 25 (C). 
UV-Vis spectra were recorded twice and averaged to limit experimental errors. 
 
In conclusion, fifteen chalcogenolato-bridged diruthenium, dirhodium and diiridium 
complexes have been prepared and characterized. The biological activity of the 
complexes has been evaluated in vitro on normal (CRL-2115, CRL-2120) and human 
cancer (A549, B16F10, MCF-7) cell lines. All complexes are highly cytotoxic showing 
activity in the sub-micromolar range with even some selectivity for cancer cells over normal 
fibroblast cells. Interestingly, the nature of the chalcogenolato bridges seems to have an 
impact on the activity: The complexes with the thiolato bridges being slightly more 
cytotoxic than the selenolato and tellurolato analogues. Additionally, the nature of the metal 
centers appears to have a modest impact on the activity: The ruthenium derivatives being 
more active by a few nM on all cell lines tested. The best candidates were further studied 
by flow cytometry, showing that the complexes can induce early and late apoptosis in 
B16F10 cells. In addition, all complexes show strong interaction with DNA, a potential 
target for these complexes.  
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4.3. Sawhorse-type diruthenium tetracarbonyl complexes containing biologically 
relevant acids 
Carbon monoxide and nitric oxide have now been recognized as two essential 
signaling agents in the body.
138
 Despite the CO ability to bind to hemoglobin and inhibit the 
respiratory cycle, evidence has been found that CO possesses valuable anti-inflammatory, 
vasodilatory and anti-apoptotic therapeutic effects.
139
 In that respect, complexes able to 
release CO in biological media have been studied by Mann and his co-workers. For example, 
the ruthenium complexes {Ru(µ-Cl)Cl(CO)3}2 (tricarbonyldichlororuthenium(II) dimer) and 
Ru(CO)3Cl(glycinate) {tricarbonylchloro(glycinato)ruthenium(II)} (Fig. 68), two known CO-
releasing molecules (CORMs), have shown anti-microbial activity on several types of 
bacteria,
140
 as well as interesting in vivo activity in human.
141
 
 
 
Fig. 68. Examples of CO-releasing ruthenium complexes
139
 
 
In these CO-releasing complexes, the choice of exploiting ruthenium centers was not 
accidental. Ruthenium complexes are showing great promises as chemotherapeutic agents,
114-
115,142
 and the ability of ruthenium to mimic iron in biological environments gives to 
ruthenium complexes several interesting properties in designing metal-based drugs.
114-115,142
 
In addition, the chemistry of ruthenium carbonyl complexes is well developed and known for 
many years.
143
 Among ruthenium carbonyl complexes, sawhorse-type diruthenium 
tetracarbonyl complexes are well known for their interesting biological applications.
7,144
 
Recently, we have shown that porphyrin-derived diruthenium tetracarbonyl complexes 
possess interesting phototoxicity towards female reproductive cancer cells
12b,145
 while 
sawhorse-type diruthenium complexes derived from biological active acids such as aspirin, 
ibuprofen, ethacrynic acid and chlorambucil were not cytotoxic due to their low solubility in 
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water
12a,54
 (Fig. 69). Consequently, a new series of sawhorse-type diruthenium tetracarbonyl 
complexes incorporating other biologically relevant carboxylic acids has been synthesized. 
Three commercially available carboxylic acids were selected for their therapeutic properties 
(Fig. 69): Probenecid (uricosuric drug);
146
 indomethacin and sulindac, two anti-inflammatory 
agents.
146b,147
 All Ru2(CO)4(μ2-η
2
-OOCR)2L2 complexes were fully characterized with L 
being pyridine (NC5H5), triphenylphosphine (PPh3) or 5-(4-pyridyl)-10,15,20-
triphenylporphyrin (C43H29N5). 
 
 
Fig. 69. Biologically active carboxylic acids incorporated within sawhorse-type diruthenium 
tetracarbonyl complexes. 
 
4.3.1. Synthesis of sawhorse-type diruthenium tetracarbonyl complexes 
Dodecacarbonyltriruthenium reacts with an excess of the biologically relevant 
carboxylic acids, probenecid (C13H19NO4S), indomethacin (C19H16ClNO4), and sulindac 
(C20H17FO3S) in refluxing tetrahydrofuran (thf) to yield a solution containing the thf 
intermediates Ru2(CO)4(μ2-η
2
-O2CC12H18NO2S)2(thf)2, Ru2(CO)4(μ2-η
2
-O2CC18H15ClNO2)-
(thf)2 and Ru2(CO)4(μ2-η
2
-O2CC19H16FOS)(thf)2, respectively. These labile dinuclear thf 
intermediates further react with two electron donor ligands (L), such as pyridine (NC5H5) (a), 
triphenylphosphine (PPh3) (b) or 5-(4-pyridyl)-10,15,20-triphenylporphyrin (C43H29N5) (c), 
to generate in moderate yields the stable dinuclear complexes Ru2(CO)4(μ2-η
2
-
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O2CC12H18NO2S)2L2 (L = NC5H5, 34a; PPh3, 34b; C43H29N5, 34c), Ru2(CO)4(μ2-η
2
-
O2CC18H15ClNO2)L2 (L = NC5H5, 35a; PPh3, 35b; C43H29N5, 35c), and Ru2(CO)4(μ2-η
2
-
O2CC19H16FOS)L2 (L = PPh3, 36b) (Fig 70). Within the sulindac series, only the complex 
containing axial triphenylphosphine ligands was isolated in sufficient yield. 
 
 
Fig 70. Sawhorse-type diruthenium tetracarbonyl complexes 34−36 containing biologically relevant 
acids, probenecid (34), indomethacin (35) and sulindac (36). 
 
All complexes are air stable, and compounds 34a, 34b, 35a, 35b, 36b are yellow 
crystalline powders, while 34c and 35c are purple in color due to the presence of the 
porphyrin ligands. All complexes have been characterized by IR, NMR, MS, UV-Vis 
spectroscopy (34c and 35c) as well as by elemental analysis. In the infrared spectra, the 
Ru2(CO)4 sawhorse unit exhibits the characteristic three-band pattern for the ν(CO) absorption 
at 1950, 1975 and 2020 cm
-1
.
7
 In addition, the two carboxylato bridges show absorption for 
the ν(OCO) stretching frequencies around 1550 cm
-1
, whilst for complexes 34c and 35c, a 
strong absorption centered at 1580 cm
-1
 corresponding to ν(NCN), along with a strong 
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absorption at 1224 cm
-1
 for N-H deformation and a medium absorption at 3055 cm
-1
 
attributed to the ν(CH) of the porphyrinic axial ligands can be observed. The UV-visible 
spectra of complexes 34c and 35c display an intense Soret band around 418 nm, and four Q 
bands between 515 and 645 nm (Table 9). As previously observed with analogous sawhorse-
type complexes with porphyrinic ligands,
12b,145
 the absorption bands of the uncoordinated 
porphyrinic ligand and those observed after coordination to the diruthenium backbone remain 
identical, suggesting no perturbation of the porphyrin π-orbitals upon coordination. 
 
Table 9. The electronic absorption spectra of complexes 34c, 35c and the porphyrinic ligand 
(c) (10
-6 
M concentration) in CH2Cl2 at room temperature. 
Compound Soret band Q band IV Q band III Q band II Q band I 
34c 418 515 551 590 646 
35c 418 515 551 590 645 
c 415 514 548 589 645 
 
The NMR spectrum of all complexes was carried out in CDCl3 at room temperature. 
All spectra show the signals corresponding to the bridging and axial ligands. For example, the 
1
H NMR spectra of 34c and 35c display similar pattern for the protons of the coordinated 5-
(4-pyridyl)-10,15,20-triphenylporphyrin units. The N-H protons are observed at δ = -2.7 ppm, 
while two multiplets at 7.8 and 8.2 ppm are found in the aromatic region corresponding to the 
protons of the phenyl rings of the porphyrin ligands, whereas the pyrrolic protons are found 
between 8.9 and 9.0 ppm. The 
13
C{
1
H} NMR spectrum of this type of complexes shows 
signals for the terminal carbonyl groups (CO) and the carboxylato bridges (μ2-η
2
-O2CR) at 
205 and 176 ppm, respectively. In addition, for complexes 34b, 35b and 36b, in the 
31
P{
1
H} 
NMR spectra, a sharp singlet is observed at ≈ 15 ppm which corresponds to the PPh3 axial 
ligands. Overall, these data are consistent with the proposed structures. 
The molecular structure of 34a was further confirmed by single-crystal structure 
analysis. Crystals were obtained by the slow diffusion of benzene in a CDCl3 solution of 34a, 
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thus giving rise to a crystalline benzene solvate adduct (34a · 0.5 C6H6). As expected, the 
molecular structure shows a normal diruthenium tetracarbonyl core being completed with two 
pyridine axial ligands and two carboxylato-probenecid ligands in the equatorial positions 
(Fig. 71). At 2.6701(7) Å, the Ru-Ru distance is in the range of a single metal-metal bond, 
while the N-Ru-Ru-N torsion angle is almost linear at 2.8(7)º. These data are comparable to 
those observed in analogous C5H5N-Ru-Ru-NC5H5 sawhorse-type diruthenium tetracarbonyl 
complexes.
53a
 Similarly, the alike OCO bond angles of the carboxylato bridges in 34a, both 
being 125.4(5)°, differ only slightly from those observed in other Ru2(CO)4(μ2-η
2
-OOCR)2L2 
complexes (Table 10).
53a
 
 
Table 10. Selected bond lengths (Å) and angles (°) 
34a · 0.5 C6H6 
Selected bond lengths (Å) and angles (°) 
Ru1-Ru2 2.6701(7) Ru2-O6 2.123(4) 
Ru1-N3 2.213(5) O1-C1-O2 125.4(5) 
Ru2-N4 2.216(5) O5-C14-O6 125.4(5) 
Ru1-O1 2.120(4) O1-Ru1-O5 83.15(16) 
Ru1-O5 2.126(4) O2-Ru2-O6 83.55(16) 
Ru2-O2 2.143(4) N1-Ru1-Ru2-N2 2.8(7) 
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Fig. 71. ORTEP drawing of 34a · 0.5 C6H6 at 35 % probability level ellipsoids (hydrogen atoms and 
C6H6 solvent molecule omitted for clarity).  
 
Fig. 72. Crystal packing of 34a · 0.5 C6H6 showing the empty voids of 185 Å
3
 along the a axis. 
Chapter 4: Biological application of dinuclear (Ru, Rh and Ir) complexes 
 
 
 
96 
 
The unit cell of 34a contains a molecule of benzene, which is located between the two 
probenecid units of 34a, thus filling some of the voids observed in the crystals. These 
benzene molecules form weak slipped-parallel and T-shaped π-stacking interactions with the 
neighboring phenyl ring of the probenecid moieties. However, more voids remain in the 
crystal packing, which seem to be empty despite being of approximately 185 Å
3
: No 
significant residual densities being observed in that empty space. Empty channels are 
observed along the a axis and represent almost 7 % of the total volume within the unit cell 
(Fig. 72). 
The effects of the organometallic complexes 34-36 were investigated in vitro on 
human ovarian cancer cells (A2780). The complexes were first dissolved in dimethyl 
sulfoxide (DMSO) and then diluted in complete medium (RPMI 1640 medium) to the desired 
concentration, the DMSO concentration remaining below 5 % v/v. In all cases, after cell 
exposure at 37 ºC to increasing concentration of complexes, precipitation of the complexes in 
the culture medium occurred and accordingly no cytotoxicity was observed. 
In conclusion, we have synthesized and characterized seven new sawhorse-type 
diruthenium tetracarbonyl complexes with pyridine, triphenylphosphine, 5-(4-pyridyl)-
10,15,20-triphenylporphyrin as axial ligands and containing biologically relevant acids as 
carboxylato bridging ligands. However, the limited solubility of these complexes in aqueous 
medium resulted in no cytotoxicity for these systems against human cancer cells. 
 
4.4. Anticancer activities of sawhorse-type diruthenium tetracarbonyl complexes 
derived from fluorinated fatty acids 
On the other hand, sawhorse-type diruthenium tetracarbonyl complexes 8a, 8b and 8c  
derived from fluorinated fatty acids showed moderate cytotoxicity on human cancer cell 
lines. The synthesis of sawhorse-type complexes derived from fluorinated fatty acid 8 and 9 
were detailed in chapter 2. Cytotoxicity of complexes 8a, 8b and 8c were evaluated with 
HeLa cervix, A549 pulmonary, Me300 melanoma and A2780 ovarian cancer cell lines. 
Unfortunately, the poor solubility of fluorinated complexes 9a, 9b and 9c did not allow their 
assessment. Cells were exposed for 72 h to increasing concentrations of compounds 8a-8c, 
and their survival was determined using the MTT assay. In all cell lines, the complexes show 
similar cytotoxicity with an IC50 ranging from 60 to 200 μM depending on the cell line tested 
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(Table 11). These results suggest that the nature of the axial ligands plays only a minor role 
on the overall cytotoxicity. Interestingly, among the cell lines tested, it appears that the 
Me300 melanoma cells were the most sensitive cells to all complexes. This point is important 
since melanoma tumours are aggressive and resistant to common chemotherapeutic 
treatments.
148
 
 
Table 11. Cytotoxicity of complexes 8a-8c after 72 h exposure of human cancer cells. 
IC50 [μM] 
cell lines 8a 8b 8c 
HeLa 199 ± 9 179 ± 1 178 ± 2 
A549 190 ± 9 184 ± 5 190 ± 2 
Me300 73 ± 1 61 ± 8 63 ± 1 
A2780 124 ± 1 111 ± 1 129 ± 1 
 
In conclusion, the in vitro studies showed that, the complexes Ru2(CO)4(μ2-η
2
-
O2CC3F7)2(L)2 (8a-8c) exhibit moderate cytotoxicity with cancer cell lines such as HeLa, 
A549, Me300 and A2780. Observed cytotoxicity on Me300 melanoma cells is encouraging 
for further investigations. 
 
4.5. Photoactive sawhorse-type diruthenium tetracarbonyl complexes 
Photodynamic therapy (PDT) is a treatment which can be used to cure cancer and 
other diseases.
149
 During PDT treatment, a photosensitizing agent (photosensitizer) is 
activated by light of specific wavelength. This results in the production of reactive oxygen 
species (ROS) such as singlet oxygen (
1
O2) and oxygen radicals. These oxygen species 
oxidize cell components leading to cell death either by apoptosis or necrosis.
150
 The light 
needed to activate the photosensitizer is often a drawback of PDT as most photosensitizer’s 
efficacy is limited by the penetration of light across biological tissues, which are in the order 
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of several mm for wavelengths shorter than 640 nm. For this reason, PDT is mostly used to 
treat retinal, skin, mucosal or endothelial lesions.
151
 To overcome this limitation, it is 
necessary to use photosensitizers that can be excited by light at longer wavelengths, as the 
optimal window for light tissue penetration in PDT is between 650-850 nm.
152
 
Most of the photosensitizers used in PDT are porphyrin-like compounds. Initially 
proposed by Figge et al.
153
 different classes of porphyrins are now available. 
Hematoporphyrin and its derivatives were the first porphyrin-like compounds clinically used 
in PDT.
154
 Isolated from blood, hematoporphyrin is a mixture of compounds which was 
commercialized as Photofrin
®
, also called porfimer sodium (Fig 73). This mixture is effective 
but patients remain subject to skin photosensitization several weeks after treatment.
155
 
Furthermore, the short excitation wavelength (630 nm) is another limitation of the treatment. 
Preparation of chlorin, the reduced form of porphyrin, can potentially overcome this 
wavelength limitation. Foscan
®
, meta-tetrahydroxyphenylchlorin (Fig 73), which strongly 
absorbs light at 652 nm has been approved and commercialized. However, the phototoxicity 
of the product is highly variable in human cancer and its long-term skin photosensitization is 
also problematic,
155-156
 thus limiting its application in the clinic. Nowadays, photosensitizers 
are tethered to biomolecules
157
 in view to enhance their cellular uptake, solubility, selectivity, 
and ultimately to increase PDT efficiency. However, the ideal photosensitizer has still to be 
found.
158
 
 
Fig 73.  Structures of photofrin and foscan. 
In chemotherapy, metal-based drugs are widely used since the introduction of 
cisplatin on the market in the 1970s.
159
 In analogy to the functionalization of photosensitizers 
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with biomolecules to increase efficiency or overcome limitations, cisplatin has been coupled 
to several functional groups.
160
 Among these combinations, Brunner and his co-workers have 
coordinated {Pt(NH3)2}
2+
 units to porphyrin ligands.
161
 Several platinum-porphyrin 
derivatives were synthesized and some of them were evaluated in vitro.
162
 For example, the 
diammine {7,12-bis[1-(poly(ethylenglycol)-750-monomethylether-1-yl)ethyl]-3,8,13,17-
tetra-methylporphyrin-2,18-dipropionato}platinum(II) complex (Fig 74, left) has shown low 
selectivity and high toxicity in both healthy and cancer cells, thus hampering its biological 
potential. Therefore, replacing platinum by a less toxic metal, such as ruthenium,
114-115,142c,163
 
is offering interesting perspectives for the development of chemotherapeutics. A few years 
ago, we,
164
 Swavey,
165
 and soon after Alessio
166
 have described ruthenium-porphyrin systems 
potentially able to combine PDT and chemotherapy. Among those, the sawhorse-type 
diruthenium tetracarbonyl porphyrin system, [Ru2(CO)4(μ2-η
2
-OOCCH3)2(L)2] (L = 5-(4-
pyridyl)-10,15,20-triphenyl-21,23H-porphyrin) (Fig 74, right), has demonstrated an 
interesting selectivity for female reproductive cancer cells.
12b
 These results encouraged us to 
study further this family of ruthenium-porphyrin complexes. 
 
 
Fig 74. Structures of metal-based porphyrin derivatives 
 
Herein, we describe the synthesis, characterization and in vitro activity in the dark and 
after light irradiation of a new series of sawhorse-type diruthenium tetracarbonyl complexes 
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incorporating carboxyphenyl porphyrin moieties and pyridine axial ligands, the 
photosensitizers being anchored to the diruthenium backbone by the carboxylato binding sites 
of the sawhorse diruthenium unit. 
 
4.5.1. Synthesis of photoactive sawhorse-type diruthenium tetracarbonyl complexes 
The thermal reaction of Ru3(CO)12 with an excess of the mono-carboxylic porphyrin 
derivatives 5-(4-carboxyphenyl)-10,15,20-triphenyl-21,23H-porphyrin (HO2CC44H29N4) and 
the corresponding zinc(II) metallo-porphyrin (HO2CC44H27N4Zn), the di-carboxylic 
porphyrin derivatives 5,10-di(4-carboxyphenyl)-15,20-diphenyl-21,23H-porphyrin 
(HO2CC44H28N4CO2H) and the corresponding zinc(II) metallo-porphyrin 
(HO2CC44H26N4ZnCO2H) in refluxing tetrahydrofuran (thf) yields a solution containing the 
thf complexes [Ru2(CO)4(μ2-η
2
-O2CC44H29N4)2(thf)2], [Ru2(CO)4(μ2-η
2
-O2CC44H27N4Zn)2-
(thf)2], [{Ru2(CO)4(thf)2}2(μ2-η
2
-O2CC44H28N4CO2-η
2
-µ2)2], and [{Ru2(CO)4(thf)2}2(μ2-η
2
-
O2CC44H26N4ZnCO2-η
2
-µ2)2], respectively. These labile thf intermediates react easily with 
pyridine to afford, after precipitation and/or column chromatography the neutral complexes 
[Ru2(CO)4(μ2-η
2
-OOCC44H29N4)2(NC5H5)2] (37), [Ru2(CO)4(μ2-η
2
-O2CC44H27N4Zn)2-
(NC5H5)2] (38), [{Ru2(CO)4(NC5H5)2}2(μ2-η
2
-O2CC44H28N4CO2-η
2
-µ2)2] (39) and 
[{Ru2(CO)4(NC5H5)2}2(μ2-η
2
-O2CC44H26N4ZnCO2-η
2
-µ2)2] (40) in moderate yields (Fig. 75). 
The air-stable dark purple solids 37−40 are sparingly soluble in polar organic 
solvents, and they have been characterized by IR, MS, NMR, UV-Vis and by micro-
analytical data. In the infrared spectra, complexes 37−40 exhibit the characteristic three-band 
pattern of the Ru2(CO)4 sawhorse moiety at 1950, 1975 and 2020 cm
-1
, which is observed in 
all complexes of this type.
7
 In addition, due to the presence of the porphyrin groups, a strong 
absorption centered at 1587 cm
-1
 associated to ν(NCN) and a medium absorption at 3054 cm
-1
 
corresponding to the C-H stretching vibration are observed. The 
1
H NMR spectra of 37−40 at 
room temperature show a similar signal pattern for the protons of the coordinated 
carboxyphenyl porphyrin moieties and for the axial pyridine ligands. All complexes exhibit 
in the aromatic region multiplets at 7.6, 7.8, 8.0 and 8.2 ppm, corresponding to the phenyl 
protons of both the porphyrin and pyridine ligands, while the pyrrolic protons are observed at 
8.8 and 8.9 ppm. Complexes 37 and 40 display an additional signal at δ = -2.8 ppm for the N-
H protons of the porphyrin core. 
Chapter 4: Biological application of dinuclear (Ru, Rh and Ir) complexes 
 
 
 
101 
 
 
 
Fig. 75. Molecular structure of complexes 37−40. 
 
The electronic absorption spectra of the sawhorse-type diruthenium tetracarbonyl 
complexes 37−40 and the non-coordinated carboxyphenyl porphyrin derivatives 
(HO2CC44H29N4, HO2CC44H27N4Zn, HO2CC44H28N4CO2H and HO2CC44H26N4ZnCO2H) 
display the typical Soret band at 420 nm, and the Q bands between 500 and 700 nm. The 
metal-free porphyrin derivatives possess four Q bands, while all Zn(II) metallo-porphyrin 
compounds show no Q bands I and IV in their absorption spectra. The absorption bands of 
the uncoordinated carboxyphenyl porphyrin unit and those of complexes 37−40 remain 
unchanged after complexation, suggesting no perturbation of the porphyrin π-orbitals upon 
coordination (Table 12).  
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Table 12. UV-Vis maximum absorption wavelength (nm) of complexes 37−40, 15 and 17 
and the porphyrinic ligands in CH2Cl2 at 10
-6
 M concentration. 
Compound Soret band Q band IV Q band III Q band II Q band I 
37 414 515 550 590 647 
38 418 - 550 592 - 
39 415 515 548 589 645 
40 423 - 551 591 - 
15 418 515 549 590 647 
17 418 - 550 592 - 
HO2CC44H29N4 415 515 549 590 646 
HO2CC44H27N4Zn 420 - 551 592 - 
HO2CC44H28N4CO2H 418 515 549 589 645 
HO2CC44H26N4ZnCO2H 423 - 552 593 - 
 
The organometallic porphyrin complexes were investigated in vitro as potential drug 
candidates for cancer therapy by evaluating the growth inhibition of human A549 lung 
cancer, HeLa cervix cancer, A2780 ovarian cancer and Me300 melanoma cells. For 
comparison, the known triphenylphosphine derivative, [Ru2(CO)4(OOCC44H27N4Zn)2(PPh3)2] 
(17),
167
 was also evaluated. And for discussion, the previously tested metal-free porphyrin 
derivative with triphenylphosphine axial ligands, [Ru2(CO)4(OOCC44H29N4)2(PPh3)2] (15),
12b
 
was used. The molecular structures of these two analogues of complexes 15 and 17 are 
presented in Fig. 37 (chapter 3). 
Cells were exposed for 72 h to increasing concentrations of compounds 37-40 and 17, 
their survival was determined using the MTT assay in the absence of laser exposure (dark 
toxicity). In all cell lines, complex 38 presented the highest cytotoxicity with an IC50 ranging 
from 22 to 52 µM depending on the cell line tested, while complex 37, its metal-free related 
compound, induced the lowest cytotoxicity. Therefore, the presence of the Zn(II) ion in the 
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porphyrin tetrapyrrolic ring increased significantly the cytotoxicity. In comparison, the other 
Zn(II) metallo-derivatives 40 and 17 are moderately cytotoxic in the dark. Among the cell 
lines tested, it appears that the Me300 melanoma cells were the most sensitive cells to all 
complexes (Table 13). This point is important since melanoma tumors are aggressive and 
resistant to common chemotherapeutic treatments,
148a,b,168
 whilst easily accessible by PDT 
protocols. 
 
Table 13. Cytotoxicity in the dark of complexes 37−40 and 17 after 72 h exposure of human 
cancer cells. 
IC50 [μM] 
cell lines 37 38 39 40 17 
HeLa 191 ± 9 42 ± 2 193 ± 7 196 ± 4 155 ± 22 
A549 173 ± 3 52 ± 7 118 ± 6 137 ± 12 131 ± 5 
Me300 58 ± 13 22 ± 3 49 ± 2 37 ± 12 41 ± 6 
A2780 174 ± 15 32 ± 3 198 ± 11 191 ± 8 76 ± 14 
 
The phototoxicities of the different complexes were also evaluated using a red laser 
irradiating at 652 nm. The cells were exposed for 24 h to 5 μM concentration of the 
complexes, since all complexes were not cytotoxic in the dark at this concentration and 
exposure time. Then, cell cultures were irradiated with an irradiance of 30 mW/cm
2
 and light 
doses ranging between 2 and 20 J/cm
2
. Cell toxicity was determined using the MTT assay 24 
h after the completion of the irradiation. Untreated cells were not photosensitive in the 
absence of complexes. Cells exposed to the complexes under identical conditions but not 
irradiated were used as controls for phototoxicity. The viability of the HeLa cervix and 
A2780 ovarian cells exposed to complexes 37−40, 17 and light-irradiated at increasing doses 
is shown in Fig. 76. Complex 37 induced good phototoxicity in both cancer cells with 
corresponding LD50 values (light dose necessary to inhibit 50 % cell survival) of 4.5 and 7.5  
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Fig. 76. PDT effect in HeLa cervix and A2780 ovarian cancer cells, 5 μM concentration of 
37−40, 17 and irradiation at 652 nm (irradiance = 30 mW/cm2; Ctrl = cells exposed to the 
complexes under identical conditions but not irradiated).  
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J/cm
2
, respectively. Good phototoxicity was also observed on HeLa cervix and A2780ovarian 
cells when exposed to the triphenylphosphine derivative 15,
12b
 thus suggesting that the nature 
of the axial ligands is not crucial. Complex 39 was slightly phototoxic with LD50 values 
higher than 20 J/cm
2
, while complexes 38, 40 and 17, the Zn(II) metallo-porphyrin 
derivatives, were not phototoxic in our experimental conditions. Thus, these results revealed 
that only zinc-free porphyrin-ruthenium complexes present good phototoxic activity. This is 
in agreement with the spectroscopic data which indicate that for the Zn(II) metallo-porphyrin 
compounds the Q band I is not observed around 650 nm (Table 13), thus explaining the 
absence of PDT effect for complexes 38, 40 and 17. 
In conclusion, a series of sawhorse-type diruthenium tetracarbonyl complexes 
appended with two porphyrin units positioned at 90° from each other has been synthesized 
and characterized. The presence of Zn(II) ions within the porphyrin cores increases the 
cytotoxicity and reduced the photocytotoxicity. On the other hand, the non-metallated 
porphyrin derivatives are poorly cytotoxic, and interestingly in the case of [Ru2(CO)4(µ2-η
2
-
O2CC44H29N4)2(NC5H5)2] (37), highly phototoxic. 
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5. General conclusion 
The present work deals with the synthesis and characterization of dinuclear Ru(II), 
Rh(III) and Ir(III) complexes. These dinuclear complexes have been studied for their 
catalytic, supramolecular and biological applications. In the first part, we have shown the 
synthesis and characterization of a series of sawhorse-type complexes derived from saturated 
(fluorinated and non-fluorinated) fatty acids. The single-crystal X-ray structure analyses of 
2a, 3a, 4a and 5a revealed that for n  8, the packing of the non-fluorinated alkyl chains and 
the π-π interactions between pyridyl groups dominated, while for n  7, only the arrangement 
of the axial pyridyl ligands played a significant role in the crystalline packing of these 
sawhorse-type complexes. Complexes 8, 9, 10 and 11 were evaluated as catalyst for the 
hydrogenation of styrene under scCO2. All the catalysts gave a very poor conversion. 
In the second part, we have synthesized and photophysically characterized a series of 
sawhorse-type molecular tweezers derived from either pyrenyl or porphyrin carboxylic 
bridging units. The molecular modeling of 14, 15 and 16 suggests that the pyrenyl and 
porphyrin moieties are adequately positioned to allow these complexes to act as molecular 
tweezers with fullerene. However, these systems have showed no interaction with fullerene in 
solution, despite possessing appropriate structural features, as predicted by modeling for 
compounds 14, 15 and 16. On the other hand, with the Zn(II)-porphyrin derivatives, 17 and 
18, interaction with bis-pyridyl ligands were observed. In particular, a relatively high 
association constant between 5,10-di-(4-pyridyl)-15,20-diphenyl-21,23H-porphyrin and 18 
was found, thus indicating size specific tweezing properties, and overall showing a new 
application for an old class of compounds, the sawhorse-type diruthenium tetracarbonyl 
complexes.   
In the final part, we have investigated the anti-cancer ability of different dinuclear 
(Ru, Rh and Ir) complexes. Fifteen chalcogenolato-bridged diruthenium, dirhodium and 
diiridium complexes (19-33) have been synthesized and the biological activity of these 
complexes has been studied in vitro on normal (CRL-2115, CRL-2120) and human cancer 
(A549, B16F10 and MCF-7) cell lines. All complexes are highly cytotoxic even in the sub-
micromolar range. Interestingly, the nature of the chalcogenolato bridges seems to have an 
impact on the activity: The complexes with the thiolato bridges (19, 22 and 25) being slightly 
more cytotoxic than the selenolato and tellurolato analogues. In addition, all complexes show 
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strong interaction with DNA, a potential target for these complexes. Overall, these results 
confirm that the thiolato-bridged dinuclear half-sandwich complexes are very promising 
anticancer agents and deserve more biological studies. 
Similarly, a series of sawhorse-type diruthenium tetracarbonyl complexes (8, 17, 34-
36, and 37-40) have been synthesized and evaluated for biological studies. The complexes 
34-36 were synthesized from biological active acids such as probenecid, indomethacin and 
sulindac. However, the limited solubility of the complexes 34-36 in aqueous medium resulted 
in no cytotoxicity against human cancer cells. On the other hand, complexes of sawhorse-
type diruthenium complexes derived from fluorinated carboxylic acid Ru2(CO)4(μ2-η
2
-
O2C(CF2)2CF3)2(L)2 (8a, L = C5H5N; 8b, L = PPh3; 8c, L = PTA) showed moderated 
cytotoxicity on HeLA, A549, Me300 and A2780.  
In a similar fashion, photoactive sawhorse-type diruthenium tetracarbonyl complexes 
were synthesized from porphyrin carboxylic units 17 and 37-40. These complexes were 
evaluated in vitro as anticancer drugs on HeLA, A549, Me300 and A2780 cancer cells. The 
presence of Zn(II) ions within the porphyrin cores [Ru2(CO)4(O2CC44H27N4Zn)2(NC5H5)2] 
(38) increases the cytotoxicity and reduced the photocytotoxicity. While, the non-metallated 
porphyrin derivative [Ru2(CO)4(O2CC44H29N4)2(NC5H5)2] (37) were poorly cytotoxic and 
interestingly phototoxic. Complex 37 possesses an excellent ratio of cytotoxicity versus 
phototoxicity, and optimization of the system is currently under investigation in our 
laboratory. Replacement of the porphyrin units with chlorins or phthalocyanines is envisaged 
with the goal to induce a bathochromic shift of the absorption bands and consequently to 
potentially further increase the gap between cytotoxicity versus phototoxicity. 
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6. Experimental section 
6.1. General Remarks 
Unless otherwise stated, all manipulations were carried out under nitrogen atmosphere 
by conventional Schlenk techniques. Organic solvents were degassed and saturated with 
nitrogen prior to use, except ethanol. 5-(4-Carboxyphenyl)-10,15,20-triphenyl-21,23H-
porphyrin, 5-(4-carboxyphenyl)-10,15,20-triphenylporphyrin-Zn, 5,10-di(4-carboxyphenyl)-
15,20-diphenyl-21,23H-porphyrin, 5,10-di(4-carboxyphenyl)-15,20-diphenylporphyrin-Zn, 5-
(4-Pyridyl)-10,15,20-triphenyl-21,23H-porphyrin, 5,10-di-(4-pyridyl)-15,20-diphenyl-
21,23H-porphyrin and 5,15-di-(4-pyridyl)-10,20-diphenyl-21,23H-porphyrin were purchased 
from TriPorTech GmbH, fullerene was purchased from SES RESEARCH (Houston, Texas). 
1-Pyrenecarboxylic acid, 1-pyreneacetic acid, 1-pyrenebutyric acid, pyridine, 4,4’-bipyridine, 
1,2-bis(4-pyridyl)ethylene, 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane and triphenyl-
phosphine were commercially available from Sigma-Aldrich and used as received. The 
starting materials Ru3(CO)12,
3
 (η6-p-MeC6H4Pr
i
)2Ru2(µ-Cl)2Cl2,
33
 (η5-C5Me5)2Rh2(µ-
Cl)2Cl2,
36-37
 (η5-C5Me5)2Ir2(µ-Cl)2Cl2,
36-37
 (η6-p-MeC6H4Pr
i
)2Ru2Cl2(μ-SCH2C6H4-p-Bu
t
)2
38a
, 
(η5-C5Me5)2Rh2Cl2(μ-SCH2C6H5)2 
119
 and (η5-C5Me5)2Ir2Cl2(μ-SCH2C6H5)2
41
 were prepared 
according to published methods. Column chromatography was performed using silica gel 60 
(63-200, 60 Å, Brunschwig). 
6.1.1. Infrared spectroscopy 
IR spectra were recorded on a Perkin-Elmer 1720x FT-IR spectrometer (4000 - 400 
cm
-1
). Samples were analysed in solution (CaF2 plates) or as solids (KBr pellet). 
6.1.2. Mass spectroscopy 
Mass spectra were performed by the analytical service faculty of university of 
Neuchâtel or the University of Fribourg. 
6.1.3. NMR spectroscopy 
The 
1
H, 
13
C, 
19
F, 
31
P, 2D and DOSY NMR spectra were recorded on a Bruker 400 
MHz spectrometer and operated with Mestre-C and Mnova. All the deuterated solvents were 
purchased from Cambridge Isotope Laboratories, Inc. the chemical shifts δ are given in ppm 
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and coupling constants J are given in Hz spectra were calibrated to the residual signal of the 
non-deuterated solvent. For all DOSY experiments, the temperature was regulated at 298 K, 
the airflow was increased to 670 Lmin
-1
, and the NMR tube was spun. The diffusion NMR 
experiments were performed using a standard pulsed-gradient stimulated echo (LED-
PFGSTE) sequence, using bipolar gradient.
169
 DOSY spectra were generated by using the 
TopSpin 2.0 software package (Bruker). Experimental parameters were Δ = 50.0 ms 
(diffusion delay), τDOSY = 1.0 ms (gradient recovery delay), and Te = 5.0 ms (eddy current 
recovery delay). For each data set, 4096 complex points were collected, and the gradient 
dimension was sampled using 16 experiments in which the gradient strength was 
exponentially incremented from 1.0 to 50.8 Gcm
-1
. The gradient duration δ/2 was adjusted to 
observe a near complete signal loss at 50.8 Gcm
-1
. Typically, the δ/2 delay was chosen in the 
1.2-2.0 ms range. A 1.0 s recycle delay was used between scans for data shown. For each data 
set, the spectral axis was processed with an exponential function (3-5 Hz line broadening), 
and Fourier transform was applied in order to obtain 4096 real points. The DOSY 
reconstruction was realized with 256 points in the diffusion dimension. The number of scans 
ranged from 8 to 64 and was adapted to each sample. The experimental time ranged from 4 to 
30 min. 
6.1.4. UV-Vis and fluorescence spectroscopy 
For porphyrin complexes (14-18), the spectroscopic investigations were carried out in 
cyclohexane, carbon tetrachloride and toluene (Carlo Erba spectroscopic grade) in 
fluorimetric cuvettes with an optical path of 1 cm. Absorption spectra were recorded with a 
Perkin-Elmer λ950 spectrophotometer. Steady-state photoluminescence spectra were 
measured in right angle mode with an Edinburgh FLS920 spectrometer (continuous 450 W 
Xe lamp), equipped with a Peltier-cooled Hamamatsu R928 photomultiplier tube (185-850 
nm) at room temperature. The excitation and emission monochromators slit widths were 
manually adjusted to have a peak resolution of ± 3 nm for the emission measurements. 
Fluorescence lifetimes were measured with an IBH 5000F time-correlated single-photon 
counting device, by using pulsed NanoLED excitation sources at 331, 373, 465 and 560 nm. 
Analysis of the luminescence decay profiles against time was accomplished with the Decay 
Analysis Software DAS6 provided by the manufacturer. For pyrene complexes (12-14), UV-
Vis absorption spectra were recorded on an Uvikon 930 spectrophotometer using precision 
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quartz cells (1 cm). Fluorescence titrations were performed on a Varian Cary Eclipse 
spectrophotometer using Sarstedt acrylic cuvettes (10 x 10 x 45 mm).  
6.1.5. Elemental analyses 
Elemental analyses were performed by the Mikroelementarisches Laboratorium, 
ETH Zürich (Switzerland) or the laboratory of pharmaceutical chemistry, university of 
Geneva (Switzerland). 
 
6.2. Catalytic experiments (complexes 8-11)  
General procedure for hydrogenation of styrene in supercritical carbon dioxide: The 
reaction was carried out in a 125 mL stainless steel reactor equipped with a magnetic stirrer. 
The reactor was purged with argon prior to the introduction of adequate amounts of Ru-
catalyst and styrene (amount of catalyst = 0.02 mmol, substrate/catalyst ratio = 1/500) via a 
cannula transfer. When methanol was used as co-solvent, catalysts were prior dissolved in 1 
mL of degassed methanol. After introduction of H2 (10 bar), CO2 was admitted, leading to a 
total reaction pressure of 120 bar. The reaction temperature was controlled by an internal 
thermocouple. After a reaction time of 16 h the reactor was cooled down to 0 °C, the pressure 
was gently released and the liquid phase was transferred to a Schlenk tube. Trap-to-trap 
distillation under vacuum at ambient temperature allowed separation of volatile compounds 
that were quantitatively analysed by GC (Thermo Scientific FOCUS GC, TR-Wax 30 m 
capillary column, FID detector). 
Safety Warning: Experiments involving pressurized gases can be hazardous and must only 
be conducted with suitable equipment and following appropriate safety conditions.
170
 
 
6.3. Biological studies (complexes 19-33) 
6.3.1. MTT assay  
In order to find the half maximal inhibitory concentration (IC50) of each potential 
complex with normal human cell lines (CRL-2115, CRL-2120) and human cancer cell lines 
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(MCF-7, B16F10 and A549) were cultured according to the supplier’s recommendations. To 
study the cytotoxicity of the ligands, after 80 % confluence, cells were trypsinized with 0.1 % 
trypsin-EDTA and harvested by centrifugation at 500 x g. Serial dilutions of cells were made 
from 1 x 10
6  
to 1 x 10
3 
cells per ml. The cells were seeded in triplicate in a 96 well plate. The 
suspended cells were treated for 24 h with 10 nM, 50 nM, 100 nM, 300 nM, 500 nM, 1 µM 
and 2 µM of each complex. Normal as well as cancer cells to which no ligand added, served 
as control. After incubation, MTT (100 µl, 5 mg/ml) solution was added to each well and the 
cell viability was determined by measuring the ability of cells to transform MTT to a purple 
coloured formazan dye. The absorbance of samples at 570 nm was measured using a UV-Vis 
spectrophotometer. Percentage of viable cells was calculated using the formula given below. 
Where the OD570 (sample) corresponds to absorbance obtained from the wells treated with 
ligands and the OD570 (control) represents the absorbance from the wells in which no ligand 
was added. 
 
 
 
The melting experiments were carried out using UV-Vis spectrophotometer (Lambda 
35, ABI, USA) with a water bath attached to control the temperature. CT-DNA and each 
complex concentration were maintained at 25 µM in the cuvette. The variation of the CT-
DNA absorbance at 260 nm was recorded plotted verses the temperature. 
6.3.2. Cell viability assays 
Normal and cancer cell lines were seeded at 20000-40000 cells/cm
2
 with 0.2 ml/cm
2
 
media and incubated for 48 h at 37 ºC, 6 % CO2, 95 % relative humidity. All cells were 
treated with complexes at 300 nM concentrations. After 24 h of incubation, cells were 
washed with 300 μl PBS or 0.02 % EDTA, trypsinized, followed by harvesting at 37 ºC. A 
200 μl cell suspension was transferred into a 1.5 ml micro-centrifuge tube. To the cell 
suspension, 300 μl PBS followed by 500 μl of 0.4 % trypan blue solutions were added. To get 
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a homogenized solution, the micro-centrifuge tube was gently tapped for 5 min, 20 μl of cell 
suspension was loaded into a chamber of the hemocytometer for measurements. 
6.3.3. Flow cytometry and confocal microscopy studies 
Since MTT and cell culture assays yielded encouraging results with B16F10 cells, 
hence they were considered for confocal and flow cytometry experiments. Cell cycle assay 
was performed by following the protocol reported by Angelis et al..
171
 After 70 % 
confluence, the cells were treated with 300 nM concentration of each complexes, for 3 h (1 x 
10
6
) cells were washed with 2x binding buffer and re-suspended in 100 μl binding buffer and 
Annexin-V-FITC from Abcam (USA) (1.0 μg). The cells were then incubated at room 
temperature for 10 min, followed by the addition of 400 μl of binding buffer containing 1 μl 
of propidium iodide (PI) from Sigma-Aldrich. Stained cells were analysed using FACS 
Calibur Flow Cytometer from B.D. Biosceinces (USA). Annexin-V-FITC and PI labeled cells 
were excited using a 488 nm solid-state laser and fluorescence emission intensity of FITC 
and PI was captured using 530/30 and 585/42 band pass filters, respectively. 
For confocal microscopic studies, B16F10 cells were rinsed with 1X PBS and 
incubated with 2.5 % formaldehyde in PBS for 10 min at room temperature, followed by 
permeabilization with 0.5 % Triton X-100 for 5 min. The fixed cells were incubated with 10 
% FCS in PBS for 1 h at room temperature. The culture plate was then washed with 1X PBS 
and placed in mounting medium (Vectashield), containing anti-fade reagent with 300 nM 
DAPI and incubated for 1-5 min. The cells were rinsed with PBS several times and observed 
using a fluorescent microscope. 
6.3.4. DNA fragmentation assays 
B16F10 cells were seeded (1 x 10
6
) in six-well plates. After 24 h of incubation, cells 
were treated with 300 nM of complexes 19, 22 and 25 (at half maximal inhibitory 
concentration). After 24 h of treatment, cells were collected and centrifuged at 2500 rpm for 
5 min at 4 ºC. Pellet was collected and washed with phosphate buffered saline (PBS). Then 
100 μl of lysis buffer was added and centrifuged at 3000 rpm for 5 min at 4 ºC and the 
supernatant was collected. To the mixture, 10 μl of 10 % SDS and 10 μl of (50 mg/ml) 
RNaseA were added and incubated for 2 h at 56 ºC. After incubation, Proteinase K (25 
mg/ml) was added and the cells were incubated at 37 ºC for an additional 2 h. Further 65 μl 
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of 10 M ammonium acetate and 500 μl of ice cold ethanol was added and mixed well. Then 
these samples were incubated at 80 ºC for 1 h. The incubated samples were centrifuged at 
12000 rpm for 20 min at 4 ºC, washed with 80 % ethanol and air dried for 10 min at room 
temperature. The pellets were dissolved in 50 μl of TE buffer and electrophoresis was carried 
out using 2 % agarose gel in a TE buffer. 
6.3.5. DNA-complex interaction studies 
UV-Visible titrations were performed using a Lambda 35 spectrophotometer (ABI, 
USA). The stock solutions of CT-DNA (obtained from Sigma-Aldrich, USA) and of the 
complexes were prepared in the BPES buffer. Equal aliquots of CT-DNA (50 μM) solution 
were added to 25 μM solution of the complex in a quartz cuvette. Absorbance spectra were 
collected from 200 nm to 400 nm after each addition of CT-DNA into the 19, 22 and 25 
solutions of the complexes. Titration was performed until the absorption bands of the 
complex remained intact. Each titration was repeated twice to minimize errors. 
CD analyses were performed using a JASCO 815 CD Spectrometer (Jasco, Tokyo, 
Japan) equipped with a 1 cm path length quartz cuvette. All CD measurements and titrations 
were performed at 25 ºC in 100 mM KBPES buffer (pH 7.0) with spectra collected over a 
wavelength range of 200-400 nm. The CT-DNA concentration was maintained at 50 μM and 
titrated by adding fixed aliquots of the complexes 1, 4 and 7 (100 μM stock solutions) to the 
CT-DNA solution. CD spectra were collected at stoichiometry values (DNA: complex) 1:0, 
1:1 and 1:2 for each complex. 
6.3.6. Statistical analyses 
The results obtained from cell viability and MTT assays were subjected to a 
statistical analysis. The SPSS statistic software (Version 18.0, Chicago, IL) was used for all 
statistical analyses. The statistical parameters like mean value and standard deviation were 
calculated using descriptive statistics. Data were considered significant with p value ≤ 0.05. 
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6.4. Biological studies (complexes 8, 17, 37-40) 
6.4.1. Cell culture 
 Lung A549 and cervix (HeLa) cancer cells were obtained from the American Tissue 
Type Culture Collection (Manassas, VA, USA). A2780 ovarian cancer cells were obtained 
from the ECACC (Salisbury, UK). Human Me300 melanoma cells were kindly provided by 
D. Rimoldi, Ludwig Institute of Cancer Research, Lausanne. A549 and HeLa cervix cells 
were routinely grown in Dulbecco’s modified Eagle’s medium containing 4.5 g/L glucose, 
while A2780 and Me300 cells were grown in RPMI 1640 medium. All were supplemented 
with 10 % heat-inactivated fetal calf serum and with antibiotics (all from Gibco, Basel, 
Switzerland). The organometallic complexes were dissolved in dimethyl sulfoxide and then 
diluted in complete medium to the required concentration. The dimethyl sulfoxide 
concentration did not exceed 1 % v/v and this concentration did not show any effects on cells. 
6.4.2. Determination of cytotoxicity 
Cells in 96-well plates (Costar) were exposed at 37 °C to increasing concentrations of 
complexes in complete culture medium for 72 h. Cell survival was measured using the MTT 
test. MTT (Merck) was added at 250 µg/ml and incubation was continued for 2 h, as 
previously described.
12b
 Then the cell culture supernatants were removed, the cell layer was 
dissolved in isopropanol/0.04 N HCl, and the absorbance at 540 nm was measured in a 96-
well multiwell-plate reader (iEMS Reader MF, Labsystems, Bioconcept, Switzerland) and 
compared with the values of control cells incubated without complexes. Experiments were 
conducted in triplicate wells and repeated three times. 
6.4.3. Determination of phototoxicity  
Cells were grown in 96-well cell culture plates (Costar) until 20 % confluence. The 
culture medium was replaced with complete medium containing ruthenium complexes 17, 
37-40 at 5 μM concentration (1 mM stock solution in DMSO), and the cells were exposed to 
the complexes for 24 h. Thereafter, Culture medium was replaced by fresh medium free of 
photosensitizer and the cells were irradiated at 652 nm using a diode laser (Ceralas PDT 652, 
Bonn, Germany) coupled to a frontal diffuser (Type FD1, Medlight SA, Ecublens, 
Switzerland), at an irradiance of 30 mW/cm
2
 and light doses ranging from 2 to 20 J/cm
2
 as 
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previously described.
12b
 Experiments were conducted in triplicate. Analysis of cell viability 
using the MTT assay as described above was performed 24 h after irradiation and the 
obtained values were compared with the values of control cells irradiated without the 
complexes. 
 
6.5. Sawhorse-type complexes containing μ2-η2 carboxylato ligands derived from 
saturated fatty acids and fluorinated fatty acid (Chapter-2) 
6.5.1. General method for the preparation of complexes 1-7, 10 and 11 
A solution of Ru3(CO)12 (100 mg, 0.16 mmol) and the appropriate carboxylic acid 
(0.47 mmol) in dry tetrahydrofuran (25 ml) was heated at 120 °C in a pressure Schlenk tube 
for 22 hours. Then the appropriate axial ligand L (0.47 mmol) was added (L = pyridine 1a-
7a, L = triphenylphosphine 1b-7b, 10 and 11). The solution was stirred at room temperature 
for 3 hours, evaporated and the product isolated from the residue by crystallization from a 
tetrahydrofuran/hexane or dichloromethane/pentane mixture. In order to improve the purity, 
the raw product was subjected to thin-layer chromatography on silica gel using 
dichloromethane/pentane as eluents and obtained as yellow products. 
Ru2(CO)4{μ2-η
2
-O2C(CH2)5CH3}2(C5H5N)2 (1a) 
Yield: 50 mg (44 %). 
1
H NMR (400 MHz, CDCl3): δ = 0.85 (t, 6 H, 
3
J = 6.8 Hz, CH3), 1.22-
1.24 (m, 12 H, CH2), 1.48-1.53 (m, 4 H, CH2), 2.27 (t, 4 H, 
3
J = 7.3 Hz, CH2COO), 7.44-7.48 
(m, 4 H, C5H5N), 7.81-7.85 (tt, 2 H, C5H5N, 
3
J = 7.6 Hz, 
4
J = 1.6 Hz), 8.73-8.75 (m, 4 H, 
C5H5N). IR (KBr): ν(OCO) 1568 s, ν(CO) 1945 vs, 1966 m, 2021 vs cm
-1
. ESI-MS: m/z = 704.3 
[M - CO]
+
. Anal. Calc. for C28H36N2O8Ru2: C 46.02, H 4.97. Found C 45.95, H 4.87 %. 
Ru2(CO)4{μ2-η
2
-O2C(CH2)5CH3}2(PPh3)2 (1b) 
Yield: 161 mg (94 %). 
1
H NMR (400 MHz, CDCl3): δ = 0.84 (t, 6 H, 
3
J = 7.2 Hz, CH3), 0.91-
1.40 (m, 16 H, CH2), 1.94 (t, 4 H, 
3
J = 7.3 Hz, CH2COO), 7.39-7.55 (m, 30 H, CHph). 
31
P{
1
H} NMR (161 MHz, (CDCl3): δ = 14.21 ppm. IR (KBr): ν(OCO) 1565 s ν(CO) 1951 vs, 
1977 m, 2024 vs cm
-1
. ESI-MS: m/z = 1015.72 [M - 3CO]
+
. Anal. Calc. for C54H56O8P2Ru2: 
C 59.12, H 5.14. Found C 59.02, H 4.97 %. 
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Ru2(CO)4{μ2-η
2
-O2C(CH2)7CH3}2(C5H5N)2 (2a) 
Yield: 80 mg (65 %). 
1
H NMR (400 MHz, CDCl3): δ = 0.87 (t, 6 H, 
3
J = 6.9 Hz, CH3), 1.22-
1.28 (m, 20 H, CH2), 1.48-1.53 (m, 4 H, CH2), 2.27 (t, 4 H, 
3
J = 7.3 Hz, CH2COO), 7.40-7.43 
(m, 4 H, C5H5N), 7.81-7.85 (tt, 2 H, 
3
J = 7.6 Hz,
 4
J = 1.6 Hz, C5H5N), 8.73-8.75 (m, 4 H, 
C5H5N). IR (KBr): ν(OCO) 1567 s, ν(CO) 1945 vs, 1968 m, 2021 vs cm
-1
. ESI-MS: m/z = 758.76 
[M-CO+H]
+
. Anal. Calc. for C32H44N2O8Ru2: C 48.89, H 5.64, N 3.56.  Found C 48.76, H 
5.60, N 3.50 %. 
Ru2(CO)4{μ2-η
2
-O2C(CH2)7CH3}2(PPh3)2 (2b) 
Yield: 50 mg (27 %). 
1
H NMR (400 MHz, CDCl3): δ = 0.87 (t, 6 H, 
3
J = 7.1 Hz, CH3), 0.90-
1.44 (m, 24 H, CH2), 1.94 (t, 4 H, CH2COO,
 3
J = 7.3 Hz), 7.39-7.55 (m, 30 H, CHph). 
31
P{
1
H} 
NMR (161 MHz, CDCl3): δ = 14.22 ppm. IR (KBr): ν(OCO) 1559 s, ν(CO) 1942 vs, 1974 m, 
2019 vs, cm
-1
. ESI-MS: m/z = 1070.23 [M-3CO]
+
. Anal. Calc. for C58H64O8P2Ru2: C 60.55, H 
5.66. Found C 60.41, H 5.59 %. 
Ru2(CO)4{μ2-η
2
-O2C(CH2)8CH3}2(C5H5N)2 (3a) 
Yield: 80 mg (32 %). 
1
H NMR (400 MHz, CDCl3): δ = 0.88 (t, 6 H, CH3, 
3
J = 6.9 Hz), 1.22-
1.28 (m, 22 H, CH2), 1.50-1.53 (m, 6 H, CH2), 2.27 (t, 4 H, CH2COO,
3
J = 7.1Hz), 7.40-7.43 
(m, 4 H, C5H5N), 7.81-7.85 (m, 2 H, C5H5N), 8.73-8.75 (m, 4 H, C5H5N). IR (KBr): ν(OCO) 
1568 s, 1945 vs, 1966 m, ν(CO) 2021 vs cm
-1
. ESI-MS: m/z = 759.10 [M - 2CO]
+
. Anal. Calc. 
for C34H48N2O8Ru2: C 50.11, H 5.94, N 3.44. Found C 49.12, H 5.82, N 3.29 %. 
Ru2(CO)4{μ2-η
2
-O2C(CH2)8CH3}2(PPh3)2 (3b) 
Yield: 127 mg (69 %). 
1
H NMR (400 MHz, CDCl3): δ = 0.88 (t, 6 H, CH3, 
3
J = 7 Hz), 1.09-
1.18 (m, 16 H, CH2), 1.23-1.35 (m, 12 H, CH2),  1.97 (t, 4 H, CH2COO,
 3
J = 7.2 Hz), 7.26-
7.55 (m, 30 H, CHph). 
31
P{
1
H} NMR (161 MHz, (CDCl3): δ = 14.01 ppm. IR (KBr): ν(OCO) 
1557 s, ν(CO) 1942 m, 1976 m, 2018 vs cm
-1
. ESI-MS: m/z = 1182.25 [M + H]
+
. Anal. Calc. 
for C60H68O8P2Ru2: C 61.01, H 5.80. Found C 61.00, H 5.83 %. 
Ru2(CO)4{μ2-η
2
-O2C(CH2)11CH3}2(C5H5N)2 (4a) 
Yield: 85 mg (55 %). 
1
H NMR (400 MHz, CDCl3): δ = 0.88 (t, 6 H, 
3
J = 7.2 Hz, CH3), 1.22-
1.25 (m, 36 H, CH2), 1.51-1.53 (m, 4 H, CH2), 2.26 (t, 4 H,
 3
J = 7.1Hz, CH2COO), 7.40-7.43 
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(m, 4 H, C5H5N), 7.81-7.85 (m, 2 H, C5H5N), 8.73-8.75 (m, 4 H, C5H5N). IR (KBr): ν(OCO) 
1569 s, ν(CO) 1945 m, 1968 m, 2022 vs cm
-1
. ESI-MS: m/z = 843.19 [M - 2CO]
+
. Anal. Calc. 
for C40H60N2O8Ru2: C 53.44, H 6.72, N 3.11. Found C 53.17, H 6.53, N 2.99 %. 
Ru2(CO)4{μ2-η
2
-O2C(CH2)11CH3}2(PPh3)2 (4b) 
Yield: 85 mg (42 %). 
1
H NMR (400 MHz, CDCl3): δ = 0.90 (t, 6 H,
 3
J = 6.8 Hz, CH3), 1.01-
1.15 (m, 16 H, CH2), 1.20-1.34 (m, 24 H, CH2), 1.94 (t, 4 H, 
3
J = 7.2 Hz, CH2COO), 7.26-
7.58 (m, 30 H, CHph). 
31 
P{
1
H} NMR: (161 MHz, (CDCl3): δ = 14.23 ppm. IR (KBr): ν(OCO) 
1558 s, ν(CO) 1943 m, 1974 m, 2021 vs cm
-1
. ESI-MS: m/z = 1266.35 [M + H]
 +
. Anal. Calc. 
for C66H80O8P2Ru2: C 62.64, H 6.37. Found C 62.68, H 6.45 %. 
Ru2(CO)4{μ2-η
2
-O2C(CH2)12CH3}2(C5H5N)2 (5a) 
Yield: 50 mg (34 %). 
1
H NMR (400 MHz, CDCl3): δ = 0.88 (t, 6 H, CH3,
 3
J = 6.8 Hz), 1.22-
1.32 (m, 40 H, CH2), 1.48-1.53 (m, 4 H, CH2), 2.28 (t, 4 H, CH2COO,
 3
J = 7.2 Hz), 7.40-7.43 
(m, 4 H, C5H5N), 7.80-7.84 (m, 2 H, C5H5N), 8.73-8.75 (m, 4 H, C5H5N). IR (KBr): ν(OCO) 
1568 s, ν(CO) 1944 m, 1969 m, 2022 vs cm
-1
. ESI-MS: m/z = 872.22 [M - 2CO]
+
. Anal. Calc. 
for C42H64N2O8Ru2: C 54.41, H 6.99, N 3.02. Found C 54.03, H 6.92, N 2.91 %. 
Ru2(CO)4{μ2-η
2
-O2C(CH2)12CH3}2(PPh3)2 (5b) 
Yield: 60 mg (30 %). 
1
H NMR (400 MHz, CDCl3): δ = 0.88 (t, 6 H, 
3
J = 6.8 Hz, CH3), 1.22-
1.65 (m, 44 H, CH2), 1.91 (t, 4 H, 
3
J = 7.2 Hz, CH2COO), 7.35-7.52 (m, 30 H, CHph). 
31
P{
1
H} NMR (161 MHz, (CDCl3): δ =14.21 ppm. IR (KBr): ν(OCO) 1559 s, ν(CO) 1952 vs, 
1981 m, 2031 vs cm
-1
. ESI-MS: m/z = 1266.40 [M - CO]
+
. Anal. Calc. for C68H84O8P2Ru2: C 
63.14, H 6.55. Found C 63.16, H 6.53 %. 
Ru2(CO)4{μ2-η
2
-O2C(CH2)15CH3}2(C5H5N)2 (6a) 
Yield: 50 mg (43 %). 
1
H NMR (400 MHz, CDCl3): δ = 0.88 (t, 6 H, 
3
J = 6.8 Hz, CH3), 1.22-
1.29 (m, 52 H, CH2), 1.48-1.53 (m, 4 H, CH2),  2.26 (t, 4 H, 
3
J = 7.2 Hz, CH2COO), 7.40-
7.43 (ddd, 4 H, 
3
J = 7.6 Hz, 
3
J = 4.9 Hz, 
4
J = 1.4 Hz, C5H5N), 7.80-7.84 (tt, 2 H, 
3
J = 7.6Hz,
 
4
J = 1.6 Hz, C5H5N), 8.73-8.75 (m, 4 H, C5H5N). IR (KBr): ν(OCO) 1567 s, ν(CO) 1946 vs, 1969 
m, 2022 vs cm
-1
. ESI-MS: m/z = 955.33 [M - 2CO]
+
. Anal. Calc. for C48H76N2O8Ru2: C 
57.01, H 7.58, N 2.77. Found C 57.03, H 7.58, N 2.72 %. 
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Ru2(CO)4{μ2-η
2
-O2C(CH2)15CH3}2(PPh3)2 (6b) 
Yield: 170 mg (78 %). 
1
H NMR (400 MHz, CDCl3): δ = 0.86 (t, 6 H,
 3
J = 6.76 Hz, CH3), 
0.90-1.11 (m, 16 H, CH2), 1.20-1.32 (m, 40 H, CH2), 1.92 (t, 4 H, CH2COO,
 3
J = 7.26 Hz), 
7.35-7.57 (m, 30 H, CHph). 
31
P{
1
H} NMR (161 MHz, (CDCl3): δ =14.21 ppm. IR (KBr): 
ν(OCO) 1567 s, ν(CO) 1952 vs, 1978 m, 2022 vs cm
-1
. ESI-MS: m/z = 1347.93 [M - CO]
+
. Anal. 
Calc. for C74H96O8P2Ru2: C 64.52, H 7.02. Found C 64.59, H 7.13 %. 
Ru2(CO)4{μ2-η
2
-O2C(CH2)16CH3}2(C5H5N)2 (7a) 
Yield: 50 mg (30 %). 
1
H NMR (400 MHz, CDCl3): δ = 0.88 (t, 6 H, CH3 ,
3
J = 6.8 Hz), 1.22-
1.26 (m, 56 H, CH2), 1.47-1.49 (m, 4 H, CH2), 2.26 (t, 4 H, CH2COO, 
3
J = 7.2 Hz), 7.43-7.40 
(m, 4 H, C5H5N), 7.80-7.84 (m, 2 H, C5H5N), 8.73-8.75 (m, 4 H, C5H5N). IR (KBr): ν(OCO) 
1568 s, ν(CO) 1945 vs, 1969 m, 2022 vs cm
-1
. ESI-MS: m/z = 1012.6 [M - CO]
+
. Anal. Calc. 
for C50H80N2O8Ru2: C 57.78, H 7.76, N 2.70. Found C 57.89, H 7.82, N 2.58 %. 
Ru2(CO)4{μ2-η
2
-O2C(CH2)16CH3}2(PPh3)2 (7b) 
Yield: 113 mg (34 %). 
1
H NMR (400 MHz, CDCl3): δ = 0.88 (t, 6 H, CH3, 
3
J = 6.8 Hz), 0.90-
1.13 (m, 16 H, CH2), 1.20-1.32 (m, 44 H, CH2), 1.92 (t, 4 H, CH2COO, 
3
J = 7.3 Hz),  7.37-
7.52 (t, 18 H, CHph), 7.54-7.56 (m, 12 H, CHph). 
31
P{
1
H} NMR (161 MHz, CDCl3): δ = 14.21 
ppm. IR (KBr): ν(OCO) 1567 s, ν(CO) 1950 vs, 1982 m, 2033 vs cm
-1
. ESI-MS: m/z = 1348.88 
[M-2CO]
+
. Anal. Calc. for C76H100O8P2Ru2: C 65.00, H 7.27. Found C 64.94, H 7.17 %. 
6.5.2. General method for the preparation of complexes 8-9. (Chapters 2 and 4) 
A solution of Ru3(CO)12 and three equivalent of the appropriate fluorinated fatty acids 
in dry tetrahydrofuran (20 mL), was heated at 110 ˚C in a pressure Schlenk tube for 15 h. 
Then, addition of three equivalent of the axial ligand [(L = NC5H5); (L = PTA); (L = PPh3)] 
under stirring at room temperature for 2 h, afforded the final products. The complexes were 
isolated from the residue by precipitation from dichloromethane/pentane. In order to improve 
the purity, the crude products were subjected to chromatography on silica gel using a 
dichloromethane/pentane mixture as eluent (for 8c and 9c a dichloromethane/ethanol mixture 
was used), and the solid obtained was dried under vacuum. 
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Ru2(CO)4(μ2-η
2
-O2C(CF2)2CF3)2(NC5H5)2 (8a) 
Yield: 200 mg (71 %). 
1
H NMR (400 MHz, CDCl3): δ = 7.46-7.50 (m, 4 H, HC5H5N), 7.90 (m, 
2 H,
 3
J = 8 Hz,
 3
J = 8 Hz, 
4
J = 2 Hz, HC5H5N), 8.63 (m, 
3
J = 8 Hz, 
4
J = 2 Hz, 4 H, HC5H5N). 
19
F{
1
H} NMR (376 MHz, CDCl3) δ = -81.7 (6 F), -118.8 (4 F), -128.1 (4 F). IR (KBr, cm
-1
) 
ν(OCO) 1650.9 vs, ν(CO) 1967.4 vs, (νCO) 1992.7 m, (νCO) 2041.6 vs. ESI-MS (positive mode): 
m/z = 935.58 [M + 2 H2O + H]
+
. Anal. Calc. for C22H10F14N2O8Ru2 ∙ C5H12 (970.59) C 33.41, 
H 2.28, N 2.89; Found: C 33.69, H 1.88, N 3.06 %. 
Ru2(CO)4(μ2-η
2
-O2C(CF2)2CF3)2(PPh3)2 (8b) 
Yield: 150 mg (76 %) 
1
H NMR (400 MHz, CDCl3): δ = 7.39-7.45 (m, 18 H, HPPh3), 7.48-7.55 
(m, 12 H, HPPh3). 
31
P{
1
H} NMR (162 MHz, CDCl3) δ = 15.23 ppm.
 19
F{
1
H} NMR (376 MHz, 
CDCl3) δ = -82.0 (6 F), -118.6 (4 F), -128.3 (4 F). IR (KBr, cm
-1) ν(OCO) 1658.9 vs, ν(CO) 
1966.4 vs, (νCO) 1991.1 m, (νCO) 2030.9 vs. ESI-MS (positive mode): m/z = 1183.96 [M - 3 
CO + H]
+
. Anal. Calc. for C48H30F14O8P2Ru2 (1264.81) C 45.58, H 2.39; Found: C 45.84, H 
2.56 %. 
Ru2(CO)4(μ2-η
2
-O2C(CF2)2CF3)2(PTA)2 (8c)  
Yield: 97 mg (59 %) 
1
H NMR (400 MHz, CDCl3): δ = 4.25 (br-m, 12 H, HPTA), 4.62 (m, 12 
H, HPTA). 
31
P{
1
H} NMR (162 MHz, CDCl3) δ = -54.68 ppm.
 19
F{
1
H} NMR (376 MHz, 
CDCl3) δ = -81.7 (6 F), -118.6 (4 F), -128.4 (4 F). IR (KBr, cm
-1) ν(OCO) 1663.0 vs, ν(CO) 
1967.8 vs, (νCO) 1991.6 m, (νCO) 2037.4 vs. ESI-MS (positive mode): m/z = 1055.90 [M + 
H]
+
. Anal. Calc. for C24H24F14N6O8P2Ru2 ∙ C2H5OH ∙ CH2Cl2 (1365.45) C 27.35, H 2.72, N 
7.09; Found: C 27.62, H 2.66, N 6.63 %. 
Ru2(CO)4(μ2-η
2
-O2C(CF2)10CF3)2(NC5H5)2 (9b) 
Yield: 153 mg (67 %) 
1
H NMR (400 MHz, CDCl3): δ = 7.45-7.49 (m, 4 H, HC5H5N), 7.90 (m, 
2 H,
 3
J = 8 Hz,
 3
J = 8 Hz, 
4
J = 2 Hz, HC5H5N), 8.62-8.64 (m, 4 H, HC5H5N). 
19
F{
1
H} NMR (376 
MHz, CDCl3) δ = -81.8 (6 F), -117.8 (4 F), -122.5 (4 F), -122.9 (20 F), -123.8 (8 F), -127.2 (4 
F). IR (KBr, cm
-1) ν(OCO) 1667.4 vs, ν(CO) 1964.0 vs, (νCO) 1984.2 m, (νCO) 2046.5 vs. ESI-MS 
(positive mode): m/z = 980.97 [M - C12F23O2 - C5H5N - CO + H]
+
. Anal. Calc. for 
C38H10F46N2O8Ru2 (1698.56) C 26.87, H 0.59, N 1.65; Found: C 26.58, H 0.72, N 2.04 %. 
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Ru2(CO)4(μ2-η
2
-O2C(CF2)10CF3)2(PPh3)2 (9b) 
Yield: 60 mg (54 %) 
1
H NMR (400 MHz, CDCl3): δ = 7.36-7.44 (m, 18 H, HPPh3), 7.46-7.50 
(m, 12 H, HPPh3). 
31
P{
1
H} NMR (162 MHz, CDCl3) δ = 15.24 ppm.
 19
F{
1
H} NMR (376 MHz, 
CDCl3) δ = -81.8 (6 F), -117.57 (4 F), -122.9 (24 F), -123.8 (8 F), -127.2 (4 F). IR (KBr, cm
-
1) ν(OCO) 1658.9 vs, ν(CO) 1966.8 vs, (νCO) 1991.3 m, (νCO) 2031.9 vs. ESI-MS (positive mode): 
m/z = 1692.86 [M - PPh3 - 4 CO + H]
+
. Anal. Calc. for C64H30F46O8P2Ru2 (2064.93) C 37.23, 
H 1.46; Found: C 37.19, H 1.55 %. 
Ru2(CO)4(μ2-η
2
-O2C(CF2)10CF3)2(PTA)2 (9c) 
Yield: 56 mg (26 %) 
1
H NMR (400 MHz, CDCl3): δ = 4.25 (br-s, 12 H, HPTA), 4.62 (m, 12 H, 
HPTA). 
31
P{
1
H} NMR (162 MHz, CDCl3) δ = -54.70 ppm.
 19
F{
1
H} NMR (376 MHz, CDCl3) 
δ = -81.8 (6 F), -117.6 (4 F), -122.6 (4 F), -122.8 (16 F), -123.0 (4 F), -123.8 (4 F), -124.0 (4 
F), -127.2 (4 F). IR (KBr, cm
-1) ν(OCO) 1662.3 vs, ν(CO) 1960.6 vs, (νCO) 1982.5 m, (νCO) 
2038.0 vs. ESI-MS (positive mode): m/z = 1856.77 [M + H]
+
. Anal. Calc. for 
C40H24F46N6O8P2Ru2 ∙ C2H5OH (1900.74) C 26.54, H 1.59, N 4.42; Found: C 26.59, H 1.57, 
N 4.31 %. 
Ru2(CO)4(μ2-η
2
-O2C(CH2)2CH3)2(PPh3)2 (10) 
Yield: 80 mg (52 %). 
1
H NMR (400 MHz, CDCl3): δ = 0.60 (t, 6 H, 
3
J = 7 Hz, CH3), 1.10-
1.17 (m, 4 H, CH2), 1.92 (t, 4 H,
 3
J = 7 Hz, CH2), 7.36-7.41 (m, 18 H, HPPh3), 7.54-7.57 (m, 
12 H, HPPh3). 
31
P{
1
H} NMR (162 MHz, CDCl3) δ = 14.11 ppm.
 
IR (KBr, cm
-1) ν(OCO) 1564.1 
vs, ν(CO) 1941.1 vs, (νCO) 1975.9 m, (νCO) 2018.4 vs. ESI-MS (positive mode): m/z = 987.04 
[M - CO + H]
+
. Anal. Calc. for C48H44O8P2Ru2 (1012.95) C 56.91, H 4.38; Found: C 56.41, H 
4.40 %. 
Ru2(CO)4(μ2-η
2
-O2C(CH2)10CH3)2(PPh3)2 (11) 
Yield: 108 mg (56 %). 
1
H NMR (400 MHz, CDCl3): δ = 0.89 (t, 6 H, 
3
J= 7 Hz, CH3), 1.00-
1.11 (m, 16 H, CH2), 1.22-1.29 (m, 20 H, CH2), 1.92 (t, 4 H, 
3
J= 7 Hz, CH2) 7.36-7.40 (m, 18 
H, HPPh3), 7.54-7.55 (m, 12 H, HPPh3). 
31
P{
1
H} NMR (162 MHz, CDCl3) δ = 14.21 ppm.
 
IR 
(KBr, cm
-1) ν(OCO) 1567.6 vs, ν(CO) 1952.4 vs, (νCO) 1981.5 m, (νCO) 2031.1 vs. ESI-MS 
(positive mode): m/z = 1238.33 [M]
+
. Anal. Calc. for C64H76O8P2Ru2 (1237.37) C 62.12, H 
6.19; Found: C 62.00, H 6.12 %. 
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6.6. Sawhorse-type diruthenium tetracarbonyl complexes derived from pyrenyl-
carboxylic acids (Chapter-3) 
6.6.1. Preparation of sawhorse-type diruthenium tetracarbonyl complexes (12 - 14) 
A solution of Ru3(CO)12 (100mg, 0.156 mmol) and three equivalents of the 
appropriate pyrene appended carboxylic acid (0.469 mmol) in dry tetrahydrofuran (20 mL), 
was heated at 110˚C in a pressure Schlenk tube for 15 h. Then, addition of three equivalents 
of the axial ligand [12a, 13a, 14a (L = NC5H5); 12b, 13b, 14b (L = PPh3)] under stirring at 
room temperature for 3 h, affords the final products. The complexes were isolated from the 
residue by precipitation from dichloromethane/hexane. In order to improve the purity, the 
crude products were subjected to chromatography on silica gel using a 
dichloromethane/pentane mixture (1:1) as eluent and the solid obtained thus were dried under 
vacuum. 
Ru2(CO)4(μ2-η
2
-O2CC16H9)2(C5H5N)2 (12a) 
Yield: 102 mg (68 %). 
1
H NMR (400 MHz, CD2Cl2): δ = 7.57-7.61 (m, 4 H, Har), 7.77 (d, 2 
H, 
3
J = 9 Hz, Har), 7.98-8.03 (m, 6 H, Har), 8.07-8.14 (m, 6 H, Har), 8.19 (d, 2 H, 
3
J = 8 Hz , 
Har), 8.52 (d, 2 H, 
3
J = 8 Hz, Har), 8.88 (d, 2 H, 
3
J = 9 Hz, Har), 9.14-9.15 (m, 4 H, Har) ppm. 
IR (CaF2, thf, cm
-1
) ν(OCO) 1567.55, ν(CO) 1944.03 vs, (νCO) 1974.57 m, (νCO) 2024.86 vs. UV-
Vis (1.0×10
-5
 M, CH2Cl2): λmax = 283, 355 nm. ESI-MS (positive mode): m/z = 935.58 [M - 
CO + H]
+
. Anal. Calc. for C48H28N2O8Ru2 (962.88) C 59.87, H 2.93, N 2.91; Found: C 59.77, 
H 3.18, N 2.80 %. 
Ru2(CO)4(μ2-η
2
-O2CC16H9)2(PPh3)2 (12b)  
Yield: 170 mg (82 %). 
1
H NMR (400 MHz, CD2Cl2): δ = 7.27-7.31 (m, 12 H, Har), 7.33-7.37 
(m, 8 H, Har), 7.69-7.76 (m, 14 H, Har), 7.83 (d, 2 H,
 3
J = 8 Hz, Har), 7.93-8.05 (m, 6 H, Har), 
8.04 (d, 2 H, 
3
J = 8 Hz, Har), 8.10 (d, 2 H, 
3
J = 8, Har), 8.65 (d, 2 H, 
3
J = 8 Hz, Har) ppm. 
31
P{
1
H} NMR (162 MHz, CD2Cl2) δ = 13.53 ppm.
 
IR (CaF2, thf, cm
-1
) ν(OCO) 1580.64, ν(CO) 
1952.68 vs, (νCO) 1980.64 m, (νCO) 2023.78 vs. UV-Vis (1.0×10
-5
 M, CH2Cl2): λmax = 282, 
352, 383 nm. ESI-MS (positive mode): m/z = 1330.07 [M + H]
+
. Anal. Calc. for 
C74H48O8P2Ru2 (1329.28) C 66.86, H 3.64; Found: C 66.82, H 3.68 %. 
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Ru2(CO)4(μ2-η
2
-O2CCH2C16H9)2(C5H5N)2 (13a) 
Yield: 98 mg (63 %). 
1
H NMR (400 MHz, CD2Cl2): δ = 4.17 (s, 4 H, HCH2), 6.56 (t, 4 H,
 3
J = 
8 Hz, Har), 7.27 (t, 2 H,
 3
J = 8 Hz, Har), 7.60 (d, 2 H, 
3
J = 8 Hz, Har), 7.70 (d, 2 H, 
3
J = 9 Hz, 
Har), 7.90-7.96 (m, 4 H, Har), 8.00-8.11 (m, 12 H, Har), 8.22 (d, 2 H, 
3
J = 7 Hz, Har) ppm. IR 
(CaF2, thf, cm
-1
) ν(OCO) 1584.91, ν(CO) 1941.33 vs, (νCO) 1972.55 m, (νCO) 2023.47 vs. UV/Vis 
(1.0×10
-5
 M, CH2Cl2): λmax = 278, 330, 347 nm. ESI-MS (positive mode): m/z = 935.59 [M - 
2 CO]
+
. Anal. Calc. for C50H32N2O8Ru2 (990.94) C 60.60, H 3.25, N 2.83; Found: C 60.33, H 
3.48, N 2.88 %. 
Ru2(CO)4(μ2-η
2
-O2CCH2C16H9)2(PPh3)2 (13b)  
Yield: 150 mg (71 %). 
1
HNMR (400 MHz, CD2Cl2): δ = 3.68 (s, 4 H, HCH2), 7.06-7.10 (m, 12 
H, Har), 7.20-7.27 (m, 20 H, Har), 7.60 (d, 2 H, 
3
J = 9 Hz, Har), 7.76-7.80 (m, 4 H, Har), 7.97-
8.08 (m, 6 H, Har), 8.15 ( d, 2 H, 
3
J = 7.4 Hz, Har), 8.21 (m, 2 H, Har) ppm. 
31
P{
1
H} NMR 
(162 MHz, CD2Cl2) δ = 15.18 ppm.
 
IR (CaF2, thf, cm
-1
) ν(OCO) 1579.49, ν(CO) 1952.58 vs, 
(νCO) 1979.58 m, (νCO) 2023.47 vs. UV-Vis (1.0×10
-5
 M, CH2Cl2): λmax = 278, 329, 346, 382 
nm. ESI-MS (positive mode): m/z = 1358.13 [M + H]
+
. Anal. Calc. for C76H52O8P2Ru2 · 
1.5C5H12 (1465.53) C 68.43, H 4.81; Found: C 68.85, H 4.42 %. 
Ru2(CO)4{μ2-η
2
-O2C(CH2)3C16H9}2(C5H5N)2 (14a) 
Yield: 110 mg (67 %). 
1
H NMR (400 MHz, CD2Cl2): δ = 2.03-2.09 (p, 4 H,
 3
J = 7 Hz, Har), 
2.47 (t, 4 H, 
3
J = 7 Hz, HCH2), 3.19 (t, 4 H, 
 3
J = 8 Hz, Har), 7.36-7.39 (m, 4 H, Har), 7.60 (d, 2 
H, 
3
J = 8 Hz, Har), 7.79-7.82 (m, 4 H, Har), 7.88-7.99 (m, 8 H, Har), 8.03-8.06 (m, 4 H, Har), 
8.13 (d, 2 H, 
3
J = 8 Hz, Har), 8.83-8.85 (m, 4 H, Har) ppm. IR (CaF2, thf, cm
-1
) ν(OCO) 1576.28, 
ν(CO) 1941.01 vs, (νCO) 1972.01 m, (νCO) 2023.21 vs. UV-Vis (1.0×10
-5
 M, CH2Cl2): λmax = 
278, 329, 345 nm. ESI-MS (positive mode): m/z = 1048.09 [M + H]
+
. Anal. Calc. for 
C54H40N2O8Ru2 (1047.04) C 61.94, H 3.85, N 2.68; Found: C 62.04, H 4.13, N 2.53 %. 
Ru2(CO)4{μ2-η
2
-O2C(CH2)3C16H9}2(PPh3)2 (14b) 
Yield: 139 mg (63 %).NMR (400 MHz, CDCl3): δ = 1.68 (p, 4 H, 
3
J = 8 Hz, CH2), 2.14 (t, 4 
H, 
3
J = 7, HCH2), 2.93 (t, 4 H, 
3
J = 8, HCH2), 7.24-7.27 (m, 18 H, Har), 7.48 (d, 2 H,
 3
J = 8, 
Har), 7.51-7.56 (m, 12 H, Har), 7.84 (d, 2 H, 
3
J = 8, Har), 7.89 (d, 2 H, 
3
J = 8, Har), 7.98-8.03 
(m, 8 H, Har), 8.08 (d, 2 H, 
3
J = 7, 2 H, Har), 8.15 (m, 2 H, Har) ppm. 
31
P{
1
H} NMR (162 
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MHz, CD2Cl2) δ = 14.09 ppm. IR (CaF2, thf, cm
-1
) ν(OCO) 1567.46, ν(CO)1951.78 vs, (νCO) 
1978.90 m, (νCO) 2022.89 vs. UV-Vis (1.0×10
-5
 M, CH2Cl2): λmax = 277, 329, 345, 383 nm. 
ESI-MS (positive mode): m/z = 1414.19 [M]
+
. Anal. Calc. for C80H60O8P2Ru2 (1413.44) C 
67.98, H 4.28; Found: C 67.95, H 4.34 %. 
 
6.7. Porphyrin derived sawhorse-type diruthenium tetracarbonyl complexes (chapter-
3) 
6.7.1. Preparation of sawhorse-type diruthenium tetracarbonyl complexes (15 - 18) 
Ru2(CO)4(μ2-η
2
-O2CC44H29N4)2(PPh3)2 (15) 
A solution of Ru3(CO)12 (16 mg, 0.026 mmol) and 5-(4-carboxyphenyl)-10,15,20-
triphenyl-21,23H-porphyrin (60 mg, 0.091 mmol) in dry thf (30 mL) were heated at 120 °C 
in a high pressure Schlenk tube for 18 h. After cooling to room temperature, PPh3 (20 mg, 
0.078 mmol) was added. The solution was stirred for 2 h and the product was isolated by 
precipitation from a dichloromethane/pentane mixture and dried under vacuum. The product 
was obtained as air-stable purple crystalline powder. 
Yield: 98 mg (59 %). 
1
H NMR (400 MHz, CDCl3) δ = -2.75 (s, 4 H, NH), 7.46-7.55 (m, 18 
H, HPPh3), 7.60 (d, 4 H, 
3
J = 8 Hz, C6H4COO), 7.77-7.84 (m, 18 H, Hporph), 7.86-7.90 (m, 12 
H, HPPh3), 8.01 (d, 4 H, 
3
J = 8 Hz, C6H4COO), 8.24-8.26 (m, 12 H, Hporph), 8.86-8.91 (m, 16 
H, Hporph) ppm. 
31
P{
1
H} NMR (162 MHz, CDCl3) δ = 15.99 ppm. IR (KBr, cm
-1) ν(NCN) 
1587.90, ν(OCO) 1545.04 s, ν(CO) 1952.73 vs, 1980.21 m, 2024.90 vs. Anal. Calc. for 
C130H88N4O8P2Ru2 ∙ 5 H2O (2244.33): C 69.57, H 4.40, N 4.99; found: C 69.24, H 4.55, N 
4.87. ESI-MS (positive mode): m/z = 2154.45 [M + H]
+
. 
{Ru2(CO)4(PPh3)2}2( μ2-η
2
-O2CC44H28N4CO2-η
2
-μ2) 2 (16) 
The same procedure was used for the preparation of 16 using Ru3(CO)12 (50 mg, 0.08 
mmol), 5,10-di-(4-carboxyphenyl)-15,20-diphenyl-21,23H-porphyrin (95 mg, 0.14 mmol) 
and PPh3 (13 mg, 0.23 mmol). In order to improve the purity, the raw product was subjected 
to chromatography on silica gel using a dichloromethane/pentane mixture as eluent and air-
stable purple crystalline powder was obtained. 
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Yield: 120 mg (50 %). 
1
H NMR (400 MHz, CDCl3) δ = -2.80 (s, 4 H, NH), 7.42-7.51 (m, 36 
H, HPPh3), 7.62 (d, 8 H, 
3
J = 7 Hz, C6H4COO), 7.77 (m, 12 H, Hporph), 7.82-7.85 (m, 24 H, 
HPPh3), 7.97 (d, 8 H, 
3
J = 7 Hz, C6H4COO), 8.22 (d, 8 H, 
3
J = 7 Hz, Hporph), 8.80-8.89 (m, 16 
H, Hporph) ppm. 
31
P{
1
H} NMR (162 MHz, CDCl3) δ = 17.42 ppm. IR (KBr, cm
-1) ν(NCN) 
1588.01, ν(OCO) 1545.93 s, ν(CO) 1950.99 vs, 1983.21 m, 2024.56 vs. Anal. Calc. for 
C172H120N8O16P4Ru4 (3078.98): C 67.01, H 3.92, N 3.63; found: C 67.18, H 4.22, N 3.48. 
ESI-MS (positive mode): m/z = 1278.61 [M/2 - PPh3 + 2 H]
2+
. 
Ru2(CO)4(μ2-η
2
-O2CC44H27N4Zn)2(PPh3)2 (17) 
The same procedure was used for the preparation of 17 using Ru3(CO)12 (19 mg, 0.03 
mmol), 5-(4-carboxyphenyl)-10,15,20-triphenylporphyrin-Zn (65 mg, 0.09 mmol) and PPh3 
(24 mg, 0.09 mmol). The product was isolated by precipitation from a dichloro-
methane/pentane mixture and dried under vacuum. The product was obtained as air-stable 
purple crystalline powder. 
Yield: 38 mg (56 %). 
1
H NMR (400 MHz, CDCl3) δ = 7.43-7.52 (m, 18 H, HPPh3), 7.56 (d, 4 
H, 
3
J = 8 Hz, C6H4COO), 7.77-7.84 (m, 18 H, Hporph), 7.86-7.90 (m, 12 H, HPPh3), 8.00 (d, 4 
H, 
3
J = 8 Hz, C6H4COO), 8.24 (d, 12 H, 
3
J = 7 Hz, Hporph), 8.93-8.98 (m, 16 H, Hporph) ppm. 
31
P{
1
H} NMR (162 MHz, CDCl3) δ = 17.87 ppm. IR (KBr, cm
-1
) ν(OCO) 1613.98 s, ν(CO) 
1950.00 vs, 1974.82 m, 2022.72 vs. Anal. Calc. for C135H94N8O8P2Ru2Zn2 ∙ 5 CH2Cl2 
(2705.66): C 59.93, H 3.50, N 4.14; found: C 59.60, H 3.60, N 4.08. ESI-MS (positive 
mode): m/z = 1555.14 [M - porph + H]
+
. 
{Ru2(CO)4(PPh3)2}2( μ2-η
2
-O2CC44H26N4ZnCO2-η
2
-μ2)2  (18) 
The same procedure was used for the preparation of 18 using Ru3(CO)12 (25 mg, 0.04 
mmol), 5,10-di(4-carboxyphenyl)-15,20-diphenyl-porphyrin-Zn (45 mg, 0.06 mmol) and 
PPh3 (30 mg, 0.12 mmol). In order to improve the purity, the raw product was subjected to 
chromatography on silica gel using dichloromethane/pentane mixture as eluent and air-stable 
purple crystalline powder was obtained. 
Yield: 35 mg (28 %). 
1
H NMR (400 MHz, CDCl3) δ = 7.41-7.51 (m, 36 H, HPPh3), 7.62 (d, 8 
H, 
3
J = 8 Hz, C6H4COO), 7.77 (m, 12 H, Hporph), 7.82-7.87 (m, 24 H, HPPh3), 7.98 (d, 8 H, 
3
J 
= 8 Hz, C6H4COO), 8.22 (d, 8 H, 
3
J = 7 Hz, Hporph), 8.90-8.99 (m, 16 H, Hporph) ppm. 
31
P{
1
H} 
 Chapter 6: Experimental Section 
 
 
 
130 
 
NMR (162 MHz, CDCl3) δ = 17.50 ppm. IR (KBr, cm
-1) ν(NCN) 1587.01, ν(OCO) 1545.54 s, 
ν(CO) 1950.69 vs, 1983.10 m, 2025.00 vs. Anal. Calc. for C172H120N8O18P4Ru4Zn2 ∙ 2 CH2Cl2 ∙ 
2 H2O (3411.64) C 61.26, H 3.55, N 3.28; found: C 61.01, H 3.83, N, 3.28. ESI-MS (positive 
mode): m/z = 1389.32 [M/2 - PPh3 + 2 Na + 2 H]
2+
. 
 
6.8. Cytotoxic chalcogenolato-bridged dinuclear (Ru, Rh, Ir) half-sandwich 
complexes (chapter-4) 
6.8.1. Preparation of chalcogenolato-bridged dinuclear complexes (19-27) 
Synthesis of [(η6-p-MeC6H4Pr
i
)2Ru2(μ-SC6H5)3]Cl (19), [(η
6
-p-MeC6H4Pr
i
)2Ru2(μ-
SeC6H5)3]Cl (20), [(η
5
-C5Me5)2Rh2(μ-SC6H5)3]Cl (22), [(η
5
-C5Me5)2Rh2(μ-SeC6H5)3]Cl (23), 
[(η5-C5Me5)2Ir2(μ-SC6H5)3]Cl (25) and [(η
5
-C5Me5)2Ir2(μ-SeC6H5)3]Cl (26). 
The dinuclear dichloro complexes (η6-p-MeC6H4Pr
i
)2Ru2(µ-Cl)2Cl2 (0.16 mmol, 100 
mg for 19 and 20), (η5-C5Me5)2Rh2(µ-Cl)2Cl2 (0.16 mmol, 100 mg for 22 and 23) or (η
5
-
C5Me5)2Ir2(µ-Cl)2Cl2 (0.13 mmol, 100 mg for 25 and 26) were dissolved in technical-grade 
ethanol (20 mL). An ethanolic solution (2.5 mL) of benzenethiol (0.50 mmol, 50 µl for 19; 
0.48 mmol, 49 µl for 22; 0.38 mmol, 38 µl for 25) or an ethanolic solution (2.5 mL) of 
benzeneselenol (0.49 mmol, 52 µl for 20; 0.48 mmol, 52 µl for 23; 0.38 mmol, 40 µl for 26) 
were added drop wise to the reaction mixture. Then the reaction was carried out at reflux for 
15 h. Then, ethanol was evaporated and the final dinuclear complexes (19, 20, 22, 23, 25 and 
26) were isolated from the residue by precipitation from a dichloromethane/diethyl ether 
mixture. In order to improve the purity, the crude products were subjected to column 
chromatography on silica gel using a 95:5 dichloromethane:ethanol mixture as eluent. The 
second fraction was collected, evaporated and the solid dried under vacuum. 
Synthesis of [(η6-p-MeC6H4Pr
i
)2Ru2(μ-TeC6H5)3]PF6 (21), [(η
5
-C5Me5)2Rh2(μ-TeC6H5)3]PF6 
(24) and [(η5-C5Me5)2Ir2(μ-TeC6H5)3]PF6 (27). 
The dinuclear dichloro complexes (η6-p-MeC6H4Pr
i
)2Ru2(µ-Cl)2Cl2 (0.13 mmol, 79 
mg for 21), (η5-C5Me5)2Rh2(µ-Cl)2Cl2 (0.16 mmol, 100 mg for 24) or (η
5
-C5Me5)2Ir2(µ-
Cl)2Cl2 (0.07 mmol, 58 mg for 27) were dissolved in technical-grade ethanol (25 ml) and 
added to an ethanolic solution of sodium tellurophenolate, which was prepared by the 
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treatment of diphenyl ditelluride (0.32 mmol, 132 mg for 21; 0.48 mmol, 197 mg for 24; 0.22 
mmol, 89 mg for 27) with sodium borohydride (0.37 mmol, 14 mg for 21; 0.48 mmol, 18 mg 
for 24; 0.22 mmol, 8 mg for 27).
127
 After being stirred for 15 h at room temperature, 1 eq. of 
potassium hexafluorophosphate was added to the reaction mixture and then the solution was 
stirred for another 2 h. The reaction mixture was filtered off to remove impurities and then 
evaporated. The products were isolated from the residue by precipitation from a 
dichloromethane/diethylether mixture. To improve the purity, the raw products were 
subjected to chromatography on silica gel using a 9:1 dichloromethane:ethanol mixture. The 
second fraction was collected, evaporated and the solid dried under vacuum. 
[(η6-p-MeC6H4Pr
i
)2Ru2(μ-SC6H5)3]Cl (19) 
Yield: 155 mg (93 %). 
1
H NMR (400 MHz, CDCl3): δ = 0.77 (d, 6 H,
 3
J = 7 Hz, HCH(CH3)2), 
0.88 (d, 6 H,
 3
J = 7 Hz, HCH(CH3)2), 1.61 (s, 6 H, HCH3), 1.92 (m, 2 H, HCH(CH3)2), 5.10 (d, 2 H,
 
3
J = 6 Hz, Hp-cymene), 5.13 (d, 2 H,
 3
J = 6 Hz, Hp-cymene), 5.23 (d, 2 H,
 3
J = 6 Hz, Hp-cymene), 5.52 
(m, 2 H, Hp-cymene), 7.36-7.41 (m, 9 H, Har), 7.89 (d, 6 H,
 3
J = 7 Hz, Har) ppm. 
13
C{
1
H} NMR 
(100 MHz, CDCl3): δ = 17.71 (CCH3), 21.95 (CCH(CH3)2), 22.53 (CCH(CH3)2), 30.58 (CCH(CH3)2), 
83.65 (Ru-Car), 84.76 (Ru-Car), 85.03 (Ru-Car), 85.37 (Ru-Car), 99.97 (Ru-Car), 107.39 (Ru-
Car), 128.45 (Car), 129.19 (Car), 132.57 (Car), 137.81 (Car) ppm. MS (positive mode): m/z = 
799.1 [M - Cl]
+
. Anal. Calc. for C38H43ClRu2S3 (833.54): C 54.76, H 5.20; Found: C 54.69, H 
5.32%. These data are in agreement with those reported by Mashima for [(η6-p-
MeC6H4Pr
i
)2Ru2(μ-SC6H5)3]PF6.
40
 
[(η6-p-MeC6H4Pr
i
)2Ru2(μ-SeC6H5)3]Cl (20) 
Yield: 105 mg (66 %). 
1
H NMR (400 MHz, CDCl3): δ = 0.74 (d, 6 H,
 3
J = 7 Hz, HCH(CH3)2), 
0.87 (d, 6 H,
 3
J = 7 Hz, HCH(CH3)2), 1.72 (s, 6 H, HCH3), 2.08 (m, 2 H, HCH(CH3)2), 5.19 (d, 2 H,
 
3
J = 6 Hz, Hp-cymene), 5.25 (d, 2 H,
 3
J = 6 Hz, Hp-cymene), 5.31 (d, 2 H,
 3
J = 6 Hz, Hp-cymene), 5.51 
(d, 2 H,
 3
J = 6 Hz, Hp-cymene), 7.31-7.36 (m, 9 H, Har), 7.75-7.79 (m, 6 H, Har) ppm. 
13
C{
1
H} 
NMR (100 MHz, CDCl3): δ = 18.21 (CCH3), 21.83 (CCH(CH3)2), 22.84 (CCH(CH3)2), 30.90 
(CCH(CH3)2), 82.41 (Ru-Car), 83.43 (Ru-Car), 83.65 (Ru-Car), 84.32(Ru-Car), 99.15 (Ru-Car), 
107.27 (Ru-Car), 128.51 (Car), 129.33 (Car), 130.34 (Car), 133.24 (Car) ppm. MS (positive 
mode): m/z = 939.1 [M - Cl]
+
. These data are in agreement with those reported by Mashima 
for [(η6-p-MeC6H4Pr
i
)2Ru2(μ-SeC6H5)3]PF6.
127
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[(η6-p-MeC6H4Pr
i
)2Ru2(μ-TeC6H5)3]PF6 (21) 
Yield: 74 mg (47 %). 
1
H NMR (400 MHz, CDCl3): δ = 0.77 (d, 6 H,
 3
J = 7 Hz, H HCH(CH3)2), 
0.90 (d, 6 H,
 3
J = 7 Hz, H HCH(CH3)2), 1.96 (s, 6 H, HCH3), 2.32-2.35 (m, 2 H, H HCH(CH3)2), 
5.41 (d, 2 H,
 3
J = 6 Hz, Hp-cymene), 5.48-5.51 (m, 4 H,
 
Hp-cymene), 5.63-5.64 (m, 2 H,
 
Hp-cymene), 
7.27-7.39 (m, 9 H, Har), 7.62-7.64 (m, 6 H, Har) ppm. 
31
P{
1
H} NMR (162 MHz, CD2Cl2) δ 
= -144.46 (m) ppm. 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 19.32 (CCH3), 22.04 (CCH(CH3)2), 
23.34 (CCH(CH3)2), 31.71 (CCH(CH3)2), 82.10 (Ru-Car), 82.70 (Ru-Car), 83.40 (Ru-Car), 84.20 
(Ru-Car), 99.81 (Ru-Car), 109.22 (Ru-Car), 128.92 (Car), 129.20 (Car), 136.70 (Car) ppm. ESI-
MS (positive mode): m/z = 1084.3 [M - PF6]
+
. Anal. Calc. for C38H43F6PRu2Te3 · 2 CH2Cl2 
(1399.52): C 34.33, H 3.38; Found: C 34.72, H 3.74%. These data are in agreement with 
those reported by Mashima for [(η6-p-MeC6H4Pr
i
)2Ru2(μ-TeC6H5)3]PF6.
127
 
[(η5-C5Me5)2Rh2(μ-SC6H5)3]Cl (22) 
Yield: 105 mg (77 %). 
1
H NMR (400 MHz, CDCl3): δ = 1.34 (s, 30 H, C5Me5), 7.33-7.37 (m, 
9 H, Har), 7.80-7.81 (m, 6 H, Har) ppm.
 13
C{
1
H} NMR (100 MHz, CH2Cl2): δ = 8.78 (CCH3), 
97.87 (Rh-Car), 128.83 (Car), 128.92 (Car), 132.49 (Car), 133.24 (Car) ppm. ESI MS (positive 
mode): m/z = 803.1 [M - Cl]
+
. Anal. Calc. for C38H45ClRh2S3 · 2 H2O (875.25): C 52.15, H 
5.64; Found C 51.87, H 5.69 %. 
[(η5-C5Me5)2Rh2(μ-SeC6H5)3]Cl (23) 
Yield: 90 mg (57 %). 
1
H NMR (400 MHz, CDCl3): δ = 1.49 (S, 30 H, HC5Me5), 7.31-7.34 (m, 
6 H, Har), 7.38-7.42 (m, 3 H, Har), 7.65-7.67 (m, 6 H, Har) ppm. 
13
C{
1
H} NMR (100 MHz, 
CDCl3): δ = 9.35 (CCH3), 97.77 (Rh-Car), 125.15 (Car), 128.98 (Car), 129.04 (Car), 134.03 (Car) 
ppm. ESI-MS (positive mode): m/z = 943.9 [M - Cl]
+
. Anal. Calc. for C38H45ClRh2Se3 · 2 
H2O (1015.94): C 44.92, H 4.86; Found C 45.03, H 4.83 %. 
[(η5-C5Me5)2Rh2(μ-TeC6H5)3]PF6 (24) 
Yield: 102 mg (51 %). 
1
H NMR (400 MHz, CD2Cl2): δ = 1.79 (s, 30 H, HC5Me5), 7.27-7.31 
(m, 6 H, Har), 7.42-7.47 (m, 3 H, Har), 7.57-7.59 (m, 6 H, Har) ppm. 
31
P{
1
H} NMR (162 
MHz, CD2Cl2) δ = -144.54 (m) ppm. 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 10.30 (CCH3), 
99.38 (Rh-Car), 128.97 (Car), 129.02 (Car), 129.23 (Car), 137.77 (Car) ppm. ESI-MS (positive 
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mode): m/z = 1091.6 [M - PF6]
+
. Anal. Calc. for C38H45F6PRh2Te3 (1235.34): C 36.95, H 
3.67; Found C 36.87, H 3.81 %. 
[(η5-C5Me5)2Ir2(μ-SC6H5)3]Cl (25) 
Yield: 100 mg (78 %). 
1
H NMR (400 MHz, CDCl3): δ =1.38 (s, 30 H, HC5Me5), 7.36-7.38 (m, 
9 H, Har), 7.75-7.78 (m, 6 H, Har) ppm.
 13
C{
1
H} NMR (100 MHz, CH2Cl2): δ = 8.50 (CCH3), 
91.52 (Rh-Car), 128.75 (Car), 129.35 (Car), 130.56 (Car), 132.99 (Car) ppm. ESI MS (positive 
mode): m/z = 982.2 [M - Cl]
+
. Anal. Calc. for C38H45ClIr2S3 · 2 H2O (1053.88): C 43.31, H 
4.69; Found C 43.31, H 4.58 %. 
[(η5-C5Me5)2Ir2(μ-SeC6H5)3]Cl (26) 
Yield: 91 mg (63 %). 
1
H NMR (400 MHz, CD2Cl2): δ = 1.52 (s, 30 H, HC5Me5), 7.33-7.42 (m, 
9 H, Har), 7.66-7.68 (m, 6 H, Har) ppm. 
13
C{
1
H} NMR (100 MHz, CD2Cl2): δ = 8.67 (CCH3), 
91.36 (Ir-Car), 124.65 (Car), 128.80 (Car), 128.96 (Car), 133.84 (Car) ppm. ESI-MS (positive 
mode): m/z = 1123.8 [M - Cl]
+
. Anal. Calc. for C38H45ClIr2Se3 · 2 H2O (1194.56): C 38.21, H 
4.13; Found C 38.60, H 4.21 %. 
[(η5-C5Me5)2Ir2(μ-TeC6H5)3]PF6 (27) 
Yield: 45 mg (43 %). 
1
H NMR (400 MHz, CD2Cl2): δ = 1.82 (s, 30 H, HC5Me5), 7.28-7.32 (m, 
6 H, Har), 7.38-7.43 (m, 3 H, Har), 7.57-7.59 (m, 6 H, Har)  ppm. 
31
P{
1
H} NMR (162 MHz, 
CD2Cl2) δ = -144.55 (m) ppm. 
13
C{
1
H} NMR (100 MHz, CD2Cl2): δ = 9.69 (CCH3), 93.16 
(Ir-Car), 129.07 (Car), 129.30 (Car), 137.34 (Car), 137.45 (Car) ppm. ESI-MS (positive mode): 
m/z = 1269.6 [M - PF6]
 +
. Anal. Calc. for C38H45F6Ir2PTe3 (1413.96): C 32.28, H 3.21; Found 
C, 32.34; H, 3.48 %. 
6.8.2. Preparation of mixed chalcogenolato-bridged dinuclear complexes (28-33). 
Synthesis of [(η6-p-MeC6H4Pr
i
)2Ru2(μ-SeC6H5)(μ-SCH2C6H4-p-Bu
t
)2]Cl (28), [(η
5
-
C5Me5)2Rh2(μ-SeC6H5)(μ-SCH2C6H5)2]Cl (30) and [(η
5
-C5Me5)2Ir2(μ-SeC6H5)(μ-
SCH2C6H5)2]Cl (32). 
The neutral dinuclear dichloro complexes (η6-p-MeC6H4Pr
i
)2Ru2Cl2(μ-SCH2C6H4-p-Bu
t
)2 
(0.07 mmol, 60 mg for 28), (η5-C5Me5)2Rh2Cl2(μ-SCH2C6H5)2 (0.13 mmol, 100 mg for 30) or 
(η5-C5Me5)2Ir2Cl2(μ-SCH2C6H5)2 (0.09 mmol, 88 mg for 32) were dissolved in technical-
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grade ethanol (20 mL). Then, an ethanolic solution (2.5 mL) of benzeneselenol (0.13 mmol, 
14 µl for 28; 0.25 mmol, 27 µl for 30; 0.18 mmol, 19 µl for 32) was added drop wise to the 
reaction mixture. The reaction was carried out at reflux for 18 h. After this period, ethanol 
was evaporated and the salts were isolated from the residue by precipitation from a 
dichloromethane/hexane solution. After filtration, the residue was washed several time with 
diethyl ether and hexane and dried under vacuum. 
Synthesis of [(η6-p-MeC6H4Pr
i
)2Ru2(μ-TeC6H5)(μ-SCH2C6H4-p-Bu
t
)2]PF6 (29), [(η
5
-
C5Me5)2Rh2(μ-TeC6H5)(μ-SCH2C6H5)2]PF6 (31) and [(η
5
-C5Me5)2Ir2(μ-TeC6H5)(μ-
SCH2C6H5)2]PF6 (33). 
The dinuclear dichloro complexes (η6-p-MeC6H4Pr
i
)2Ru2Cl2(μ-SCH2C6H4-p-Bu
t
)2 
(0.11 mmol, 100 mg for 29), (η5-C5Me5)2Rh2Cl2(μ-SCH2C6H5)2 (0.13 mmol, 100 mg for 31) 
or (η5-C5Me5)2Ir2Cl2(μ-SCH2C6H5)2 (0.13 mmol, 125 mg for 33) were dissolved in technical-
grade ethanol (25 mL) and added to an ethanolic solution of sodium tellurophenolate, which 
was prepared by the treatment of diphenyl ditelluride (0.11 mmol, 45 mg for 29; 0.13 mmol, 
52 mg for 31; 0.13 mmol, 52 mg for 33) with sodium borohydride (0.22 mmol, 8 mg for 29; 
0.25 mmol, 38 mg for 31; 0.26 mmol, 10 mg for 33).
127
 After being stirred for 15 h, 1 eq. of 
potassium hexafluorophosphate was added to the solution and the solution was stirred for 
another 2 h. The reaction mixture was filtered off to remove impurities and the solvent 
evaporated. The products were isolated from the residue by precipitation from a 
dichloromethane/diethyl ether mixture. To improve the purity, the raw products were 
subjected to chromatography on silica gel using a 9:1 dichloromethane:ethanol mixture. The 
second fraction was collected, evaporated and the solid dried under vacuum. 
[(η6-p-MeC6H4Pr
i
)2Ru2(μ-SeC6H5)(μ-SCH2C6H4-p-Bu
t
)2]Cl (28)  
Yield: 40 mg (59 %). 
1
H NMR (400 MHz, CD2Cl2): δ = 0.87 (d, 6 H,
 3
J = 7 Hz, HCH(CH3)2), 
0.96 (d, 6 H,
 3
J = 7 Hz, HCH(CH3)2), 1.36 (d, 18 H,
 3
J = 7 Hz, H(CH3)3), 1.82 (s, 6 H, HCH3), 
1.91-2.00 (m, 2 H, HCH(CH3)2), 3.49 (s, 2 H, HCH2), 3.52 (s, 2 H, HCH2), 4.58 (d, 2 H,
 3
J = 6 Hz, 
Hp-cymene), 4.85 (d, 2 H,
 3
J = 6 Hz, Hp-cymene), 5.06 (d, 2 H,
 3
J = 6 Hz, Hp-cymene), 5.20 (d, 2 H,
 3
J 
= 6 Hz, Hp-cymene), 7.29-7.52 (m, 11 H, Har), 7.79 (d, 2 H,
 3
J = 7 Hz, Har) ppm. 
13
C{
1
H} NMR 
(100 MHz, CDCl3): δ = 18.02 (CCH3), 22.23 (CCH(CH3)2), 22.84 (CCH(CH3)2), 31.06 (C(CH3)3), 
34.58 (CCH(CH3)2), 40.20 (CCH2), 41.49 (CCH2), 82.10 (Ru-Car), 82.88 (Ru-Car), 83.01 (Ru-Car), 
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83.52 (Ru-Car), 100.23 (Ru-Car), 106.76 (Ru-Car), 125.47 (Car), 128.52 (Car), 128.91 (Car), 
129.23 (Car), 133.44 (Car), 136.57 (Car), 136.92 (Car), 151.62 (Car) ppm. ESI-MS (positive 
mode): m/z = 986.4 [M - Cl]
+
. Anal. Calc. for C48H63ClRu2S2Se · CH2Cl2 (1105.09): C 53.23, 
H 5.93; Found C 53.62, H 6.20 %. 
[(η6-p-MeC6H4Pr
i
)2Ru2(μ-TeC6H5)(μ-SCH2C6H4-p-Bu
t
)2]PF6 (29) 
Yield: 86 mg (66 %). 
1
H NMR (400 MHz, CDCl3): δ = 0.80 (d, 6 H,
 3
J = 7 Hz, HCH(CH3)2), 
0.96 (d, 6 H,
 3
J = 7 Hz, HCH(CH3)2), 1.34 (d, 18 H,
 3
J = 7 Hz, H(CH3)3), 1.89 (s, 6 H, HCH3), 
2.00-2.08 (m, 2 H, HCH(CH3)2), 3.14 (s, 2 H, HCH2), 3.60 (s, 2 H, HCH2), 4.45 (d, 2 H,
 3
J = 6 Hz, 
Hp-cymene), 4.77 (d, 2 H,
 3
J = 6 Hz, Hp-cymene), 5.18 (d, 2 H,
 3
J = 6 Hz, Hp-cymene), 5.33 (d, 2 H,
 3
J 
= 6 Hz, Hp-cymene), 7.20-7.24 (m, 2 H, Har), 7.33-7.39 (d, 4 H, Har), 7.41-7.47 (m, 5 H, Har), 
7.72 (d, 2 H,
 3
J = 8 Hz, Har) ppm. 
31
P{
1
H} NMR (162 MHz, CD2Cl2) δ = -144.48 (m) ppm.
 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 18.45 (CCH3), 22.14 (CCH(CH3)2), 22.94 (CCH(CH3)2), 
31.06 (C(CH3)3), 34.60 (CCH(CH3)2), 43.45 (CCH2), 44.24 (CCH2), 82.04 (Ru-Car), 82.33 (Ru-Car), 
83.31 (Ru-Car), 100.46 (Ru-Car), 107.12 (Ru-Car), 107.72 (Ru-Car), 125.53 (Car), 128.90 (Car), 
129.18 (Car), 129.89 (Car), 136.12 (Car), 136.98 (Car),  137.16 (Car), 151.84 (Car) ppm. ESI-
MS (positive mode): m/z = 1034.6 [M – PF6]
+
. Anal. Calc. for C48H63F6PRu2S2Te · 2 CH2Cl2 
(1348.71): C 44.53, H 5.01; Found: C 44.83, H 4.80 %. 
[(η5-C5Me5)2Rh2(μ-SeC6H5)(μ-SCH2C6H5)2]Cl (30) 
Yield: 67 mg (58 %). 
1
H NMR (400 MHz, CD2Cl2): δ = 1.48 (s, 30 H, HCH3), 3.65 (s, 2 H, 
HCH2), 3.80 (s, 2 H, HCH2), 7.32-7.37 (m, 4 H, Har), 7.43-7.47 (m, 5 H, Har ), 7.61 (t, 4 H, 
3
J = 
8 Hz, Har), 7.70-7.72 (m, 2 H, Har) ppm. 
13
C{
1
H} NMR (100 MHz, CD2Cl2): δ = 9.12 (CH3), 
35.93 (CH2), 36.45(CH2), 98.11 (Rh-Car), 125.59 (Car), 127.47 (Car), 127.69 (Car), 128.62 
(Car), 128.90 (Car), 133.79 (Car),  139.56 (Car), 139.64 (Car) ppm. ESI-MS (positive mode): 
m/z = 879.7 [M - Cl]
+
. Anal. Calc. for C40H49ClRh2S2Se · 2 H2O (950.20): C 50.56, H 5.62; 
Found: C 50.29, H 5.81 %. 
[(η5-C5Me5)2Rh2(μ-TeC6H5)(μ-SCH2C6H5)2]PF6 (31) 
Yield: 107 mg (79 %). 
1
H NMR (400 MHz, CD2Cl2): δ = 1.57 (s, 30 H, HCH3), 3.39 (s, 2 H, 
HCH2), 3.91 (s, 2 H, HCH2), 7.28-7.31 (m, 2 H, Har), 7.34-7.38 (m, 2 H, Har ), 7.42-7.46 (m, 5 
H, Har ), 7.53 (d, 2 H, 
3
J = 8 Hz, Har), 7.62 (d, 2 H, 
3
J = 8 Hz, Har), 7.72-7.75 (m, 2 H, Har) 
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ppm.
 31
P{
1
H} NMR (162 MHz, CD2Cl2) δ = -144.56 (m) ppm. 
13
C{
1
H} NMR (100 MHz, 
CD2Cl2): δ = 9.59 (CCH3), 37.82 (CCH2), 39.19 (CCH2), 98.59 (Rh-Car), 127.39 (Car), 127.77 
(Car), 128.65 (Car), 129.01 (Car), 129.45 (Car), 137.32 (Car), 139.39 (Car), 139.82 (Car) ppm. 
ESI-MS (positive mode): m/z = 928.1 [M - PF6]
+
. Anal. Calc. for C40H49F6PRh2S2Te 
(1072.32): C 44.80, H 4.61; Found C 44.76, H 4.73 %. 
[(η5-C5Me5)2Ir2(μ-SeC6H5)(μ-SCH2C6H5)2]Cl (32) 
Yield: 65 mg (66 %). 
1
H NMR (400 MHz, CD2Cl2): δ = 1.49 (s, 30 H, HCH3), 3.86 (s, 2 H, 
HCH2), 4.03 (s, 2 H, HCH2), 7.32-7.39 (m, 4 H, Har), 7.43-7.47 (m, 5 H, Har ), 7.58 (t, 4 H, 
3
J = 
8 Hz, Har), 7.67-7.69 (m, 2 H, Har) ppm. 
13
C{
1
H} NMR (100 MHz, CD2Cl2): δ = 8.86 (CCH3), 
35.85 (CCH2), 37.26 (CCH2), 91.86 (Ir-Car), 123.28 (Car), 127.65 (Car), 127.85 (Car), 128.72 
(Car), 128.94 (Car), 129.16 (Car), 133.32 (Car), 138.98 (Car) ppm. ESI-MS (positive mode): m/z 
= 1057.9 [M - Cl]
+
. Anal. Calc. for C40H49ClIr2S2Se (1093.14): C 43.96, H 4.52; Found C 
43.32, H 4.93 %. 
[(η5-C5Me5)2Ir2(μ-TeC6H5)(μ-SCH2C6H5)2]PF6 (33) 
Yield: 132 mg (82 %). 
1
H NMR (400 MHz, CD2Cl2): δ = 1.59 (s, 30 H, HCH3), 3.65 (s, 2 H, 
HCH2), 4.12 (s, 2 H, HCH2), 7.27-7.31 (m, 2 H, Har), 7.35-7.39 (m, 2 H, Har ), 7.41-7.46 (m, 5 
H, Har), 7.50-7.52 (m, 2 H, Har), 7.58-7.60 (d, 2 H, Har), 7.70-7.72 (m, 2 H, Har) ppm.
 31
P{
1
H} 
NMR (162 MHz, CD2Cl2) δ = -144.55 (m) ppm. 
13
C{
1
H} NMR (100 MHz, CD2Cl2): δ = 
9.24 (CCH3), 39.76 (CCH2), 40.84 (CCH2), 92.47 (Ir-Car), 127.59 (Car), 127.97 (Car), 128.59 
(Car), 128.80 (Car), 129.50 (Car), 137.08 (Car), 138.93 (Car), 139.07 (Car) ppm. ESI-MS 
(positive mode): m/z = 1106.1 [M - PF6]
+
. Anal. Calc. for C40H49F6Ir2PS2Te (1250.95): C 
38.41, H 3.95; Found C 38.40, H 4.02 %. 
 
6.9. Sawhorse-type complexes containing biologically relevant acids (chapter-4) 
6.9.1. Preparation of sawhorse-type diruthenium tetracarbonyl complexes 34-36 
A solution of Ru3(CO)12 (100 mg, 0.156 mmol) and the carboxylic acid (0.470 mmol) 
in dry tetrahydrofuran (25 mL), was heated at 120 ˚C in a pressure Schlenk tube for 18 h. 
Then, addition of three equivalent of the axial ligand [34a, 35a (L = NC5H5); 34b, 35b, 36b 
 Chapter 6: Experimental Section 
 
 
 
137 
 
(L = PPh3); 34c, 35c (L = C43H29N5)] followed by stirring at room temperature for 3 h, 
affords the final products. The complexes are isolated from the residue by precipitation from 
dichlormethane/pentane. In order to improve the purity, the raw products were subjected to 
chromatography on silica gel using a dichloromethane/pentane mixture as eluent and the solid 
obtained was dried under vacuum. 
Ru2(CO)4(μ2-η
2
-O2CC12H18NO2S)2(NC5H5)2 (34a) 
Yield: 130 mg (79 %). 
1
H NMR (400 MHz, CDCl3): δ = 0.83 (t, 12 H,
 3
J = 7 Hz, HCH3), 1.46-
1.53 (m, 8 H, HCH2), 3.01 (t, 8 H, 
3
J = 8 Hz, HCH2), 7.56-7.60 (m, 4 H, Har), 7.72 (d, 4 H, 
3
J = 
8 Hz, Har), 7.96-7.98 (m, 6 H, Har), 8.90-8.92 (m, 4 H, Har). 
13
C{
1
H} NMR (100 MHz, 
CDCl3): δ = 11.12 (4 C, CH3), 21.95 (4 C, CH2), 50.00 (4 C, CH2), 125.12 (4 C, Car), 126.56 
(4 C, Car), 130.19 (4 C, Car), 136.42 (2 C, Car), 137.72 (2 C, Car), 142.44 (4 C, Car), 151.81 (2 
C, Car), 177.36 (2 C, CCOO), 203.74 (4 C, CCO). IR (KBr, cm
-1
) ν(OCO) 1558.17, ν(CO) 1946.64 
vs, (νCO) 1976.27 m, (νCO) 2026.98 vs. ESI-MS (positive mode): m/z = 935.58 [M - NC5H5 - 
CO + H]
+
. Anal. Calc. for C40H46N4O12Ru2S2 (1041.08) C 46.15, H 4.45, N 5.38. Found: C 
46.27, H 4.42, N 5.31 %. 
Ru2(CO)4(μ2-η
2
-O2CC12H18NO2S)2(PPh3)2 (34b) 
Yield: 159 mg (72 %). 
1
H NMR (400 MHz, CDCl3): δ = 0.86 (t, 12 H,
 3
J = 7 Hz, HCH3), 1.46-
1.52 (m, 8 H, HCH2), 3.01 (t, 8 H, 
3
J = 7 Hz, HCH2), 7.10 (d, 4 H, 
3
J = 8 Hz, Har), 7.39-7.49 
(m, 22 H, Har), 7.60-7.65 (m, 12 H, Har). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 11.14 (4 C, 
CCH3), 21.92 (4 C, CCH2), 49.89 (4 C, CCH2), 126.20 (4 C, Car),   128.57 (12 C, Car),  129.90 (6 
C, Car), 130.44 (4 C, Car),  133.13 (12 C, Car), , 133.71 (6 C, Car),  136.41 (2 C, Car), 142.46 (2 
C, Car), 179.16 (2 C, CCOO), 205.08 (4 C, CCO). 
31
P{
1
H} NMR (162 MHz, CDCl3) δ = 18.20 
ppm. IR (KBr, cm
-1
) ν(OCO) 1558.06, ν(CO) 1957.11 vs, (νCO) 1983.87 m, (νCO) 2026.80 vs. 
ESI-MS (positive mode): m/z = 1431.13 [M+Na]
+
. Anal. Calc. for C66H66N2O12P2Ru2S2 
(1407.45) C 56.32, H 4.73, N 1.99. Found: C 56.60, H, 4.90, N 2.00 %. 
Ru2(CO)4(μ2-η
2
-O2CC12H18NO2S)2(C43H29N5)2 (34c) 
Yield: 40 mg (57 %) 
1
H NMR (400 MHz, CDCl3): δ = -2.72 (s, 4 H, NH), 0.80 (t, 12 H,
 3
J = 
7 Hz, HCH3), 1.47-1.54 (m, 8 H, HCH2), 3.02 (t, 8 H, 
3
J = 8 Hz, HCH2), 7.78-7.86 (m, 22 H, 
Hporph and Har), 8.23-8.25 (m, 12 H, 
3
J = 8 Hz, Hporph), 8.31 (d, 4 H, 
3
J = 8 Hz, Har), 8.51 (d, 4 
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H, 
3
J = 6 Hz, Har), 8.90 (s, 8 H, Hporph), 9.02 (s, 8 H, Hporph), 9.40 (d, 4 H, 
3
J = 6 Hz, Hporph). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 11.10 (4 C, CCH3), 21.95 (4 C, CCH2), 50.02 (4 C, 
CCH2), 114.67 (8 C, Car), 120.92 (6 C, Car),126.74 (4 C, Car), 126.83 (4 C, Car), 127.90 (12 C, 
Car), 127.98 (16 C, Car), 130.43 (4 C, Car), 130.83 (12 C, Car), 130.94 (12 C, Car), 134.52 (6 C, 
Car), 136.62 (2 C, Car), 141.76 (4 C, Car), 150.00 (2 C, Car), 177.96 (2 C, CCOO), 204.01 (4 C, 
CCO). UV-Vis [1.0 × 10
-6
 M, CH2Cl2] λmax/nm (ε × 10
6 
M
-1
 cm
-1
) = 418 (3.251), 515 (0.230), 
551 (0.121), 590 (0.074), 646 (0.055). IR (KBr, cm
-1
): ν(porph N-H) 1214.92, ν(OCO) 1557.00, 
(νCO) 1979.01 vs, (νCO) 1976.27 m, (νCO) 2028.45 vs, (νC-H aro) 3056.83 m. ESI-MS (positive 
mode): m/z = 1501.23 [M -C43H29N5 +H]
+
. Anal. Calc. for C116H94N12O12Ru2S2 ∙ 2 H2O 
(2150.36) C 64.79, H 4.59, N 7.82, Found: C 64.70, H 4.64, N 7.65 %. 
Ru2(CO)4(μ2-η
2
-O2CC18H15ClNO2)(NC5H5)2 (35a) 
Yield: 60 mg (32 %) 
1
H NMR (400 MHz, CDCl3): δ = 2.12 (s, 6 H, HCH3), 3.47 (s, 4 H, 
HCH2), 3.67 (s, 6 H, HCH3), 6.64 (dd, 2 H,
 3
J = 9 Hz,
 4
J = 2 Hz, Har), 6.83 (d, 2 H,
 4
J = 2 Hz, 
Har), 6.93 (d, 2 H,
 3
J = 9 Hz, Har), 7.19 (dd, 4 H,
 3
J = 7 Hz,
 4
J = 2 Hz Har), 7.43 (d, 4 H,
 3
J = 8 
Hz, Har), 7.57 (d, 4 H,
 3
J = 8 Hz, Har), 7.73 (t, 2 H, 
3
J = 8 Hz, Har), 8.42 (d, 4 H, 
3
J = 5 Hz, 
Har).
 13
C{
1
H} NMR (100 MHz, CDCl3): δ = 13.21 (2 C, CCH3),  32.25 (2 C, CCH2), 55.44 (2 C, 
CCH3), 101.95 (2 C, Car), 111.14 (2 C, Car), 114.66 (2 C, Car), 115.13 (2 C, Car), 124.57 (4 C, 
Car), 129.01 (2 C, Car), 130.77 (4 C, Car), 131.03 (4 C, Car), 131.16 (2 C, Car), 134.00 (2 C, 
Car), 134.79 (2 C, Car), 137.11 (2 C, Car), 139.06 (2 C, Car), 151.63 (4 C, Car), 155.84 (2 C, 
Car), 168.23 (2 C, CCON), 183.66 (2 C, CCOO), 203.93 (4 C, CCO). IR (KBr, cm
-1
): ν(OCO) 
1581.79, (νCO) 1936.73 vs, (νCO) 1970.86 m, (νCO) 2022.40 vs. ESI-MS (positive mode): m/z 
= 1187.02 [M + H]
+
. Anal. Calc. for C52H40Cl2N4O12Ru2 (1185.94) C 52.66, H 3.40, N 4.72. 
Found: C 52.39, H 3.59, N 4.60 %. 
Ru2(CO)4(μ2-η
2
-O2CC18H15ClNO2)(PPh3)2 (35b) 
Yield: 277 mg (83 %) 
1
H NMR (400 MHz, CDCl3): δ = 1.76 (s, 6 H, HCH3), 3.31 (s, 4 H, 
HCH2), 3.63 (s, 6 H, HCH3), 6.68- (br-s, 2 H,
 3
J = 9 Hz, Har), 6.9 (d, 2 H,
 4
J = 2 Hz, Har), 7.01 
(d, 2 H,
 3
J = 9 Hz Har), 7.14-7.19 (m, 18 H, Har), 7.21 (d, 2 H, 
3
J = 7 Hz, Har), 7.32 (t, 6 H, 
3
J 
= 7 Hz, Har), 7.38-7.42 (m, 12 H, Har). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 12.95 (2 C, 
CCH3), 32.32 (2 C, CCH2), 55.48 (2 C, CCH3), 101.19 (2 C, Car), 111.35 (2 C, Car), 114.54 (2 C, 
Car), 114.92 (2 C, Car), 128.19 (18 C, Car), 128.78 (4 C, Car) 129.65 (2 C, Car), 130.89 (12 C, 
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Car), 133.34 (4 C, Car), 133.49 (6 C, Car), , 133.66 (2 C, Car), 133.84 (2 C, Car), 134.86 (2 C, 
Car), 138.68 (2 C, Car), 156.06 (2 C, Car), 167.98 (2 C, CCON), 185.77 (2 C, CCOO), 204.95 (4 
C, CCO). 
31
P{
1
H} NMR (162 MHz, CDCl3) δ = 12.99 ppm. IR (KBr, cm
-1
): ν(OCO) 1578.77, 
(νCO) 1950.87 vs, (νCO) 1980.63 m, (νCO) 2023.55 vs. ESI-MS (positive mode): m/z = 1575.12 
[M + Na]
+
. Anal. Calc. for C78H60Cl2N2O12P2Ru2 (1552.31) C 60.35, H 3.90, N 1.80, Found: 
C 60.08, H 4.08, N 1.81 %. 
Ru2(CO)4(μ2-η
2
-O2CC18H15ClNO2)(C43H29N5)2 (35c) 
Yield: 107 mg (86 %) 
1
H NMR (400 MHz, CDCl3): δ = -2.74 (s, 4 H, HNH), 2.41 (s, 6 H, 
HCH3), 3.67 (s, 6 H, HCH2), 3.84 (s, 4 H, HCH3), 6.64 (dd, 2 H,
 3
J = 9 Hz,
 4
J = 2 Hz, Har), 6.71 
(d, 2 H,
 3
J = 9 Hz, Har), 6.98 (d, 4 H,
 3
J = 8 Hz, Har), 7.15 (d, 2 H, 
4
J = 2 Hz, Har), 7.35 (d, 4 
H,
 3
J = 8 Hz, Har), 7.79-7.85 (m, 18 H, Hporph), 8.11 (d, 4 H, 
3
J = 6 Hz, Hporph), 8.25-8.27 (m, 
12 H, Hporph), 8.84-8.90 (m, 16 H, Hporph), 8.96 (d, 4 H, 
3
J = 5 Hz, Hporph). 
13
C{
1
H} NMR (100 
MHz, CDCl3): δ = 13.47 (2 C,CCH3), 32.53 (2 C, CCH2), 55.56 (2 C, CCH3), 102.56 (2 C, Car), 
110.79 (2 C, Car), 110.82 (2 C, Car), 114.67 (2 C, Car), 120.77 (8 C, Car), 126.72 (12 C, Car), 
126.79 (4 C, Car), 128.73 (2 C, Car), 130.41 (4 C, Car), 130.87 (4 C, Car), 131.40 (2 C, Car), 
133.70 (16 C, Car), 134.54 (2 C, Car), 135.29 (2 C, Car), 141.84 (2 C, Car), 149.90 (4 C, Car), 
152.00 (16 C, Car), 155.88 (2 C, Car), 168.12 (2 C, CCON), 184.43 (2 C, CCOO), 204.25 (4 C, 
CCO). UV-Vis [1.0 × 10
-6
 M, CH2Cl2] λmax/nm (ε × 10
6 
M
-1
 cm
-1
) = 418 (3.343), 515 (0.355), 
551 (0.171), 590 (0.109), 645 (0.083). IR (KBr, cm
-1
): ν(porph N-H) 1224.17, ν(OCO) 1580.28, 
(νCO) 1942.78 vs, (νCO) 1975.35 m, (νCO) 2025.14 vs, (νC-H aro) 3056.41 m. ESI-MS (positive 
mode): m/z = 616.25 [C43H29N5 + H]
+
. Anal. Calc. for C128H88Cl2N12O12Ru2 ∙ 3 H2O 
(2313.23) C 66.46, H 4.10, N 7.27, Found: C 66.55, H 4.03, N 7.19 %. 
Ru2(CO)4(μ2-η
2
-O2CC19H16FOS)(PPh3)2 (36b) 
Yield 54 mg (23 %) 
1
H NMR (400 MHz, DMSO): δ = 1.68 (s, 6 H, HCH3), 2.80 (s, 6 H, 
HCH3), 3.18 (s, 4 H, HCH2), 6.35 (dd, 2 H,
 3
J = 9 Hz, 
4
J = 2 Hz, HCH2), 6.65-6.70 (m, 2 H,
 
 Har), 
7.10-7.14 (m, 2 H, Har), 7.15 (s, 2 H, Har), 7.35-7.36 (m, 22 H, Har), 7.41-7.45 (m, 8 H, Har), 
7.61 (d, 4 H,
 3
J = 8 Hz, Har), 7.77 (d, 4 H,
 3
J = 8 Hz, Har). 
13
C{
1
H} NMR (100 MHz, CDCl3): 
δ = 9.87 (2 C, CCH3), 32.32 (2 C, CCH2), 43.86 (2 C,CCH3), 105.95 (2 C, Car), 110.41 (2 C, Car), 
123.28 (2 C, Car) 123.74 (4 C, Car), 127.01 (4 C, Car),  128.13 (18 C, Car), , 129.57 (2 C, Car), 
130.14 (2 C, Car), 133.09 (12 C, Car),   133.65 (6 C, Car), 133.77 (2 C, Car), 137.05 (2 C, Car), 
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139.87 (2 C, Car), 141.87 (2 C, Car), 145.22 (2 C, Car), 147.33 (2 C, Car), 164.39 (2 C, 
Car)184.93 (2 C, CCOO), 205.05 (4 C,CCO).
 31
P{
1
H} NMR (162 MHz, CDCl3) δ = 14.57 ppm. 
IR (KBr, cm
-1
): ν(OCO) 1580.41, (νCO) 1954.58 vs, (νCO) 1980.41 m, (νCO) 2025.10 vs. ESI-MS 
(positive mode): m/z = 997.56 [M - 2 PPh3 - CO + H]
+
. Anal. Calc. for C80H62F2O10P2Ru2S2 
(1549.56) C 62.01, H 4.03, Found: C 61.60, H 4.15 %. 
 
6.10. Photoactive sawhorse-type diruthenium tetracarbonyl complexes (chapter-4) 
6.10.1. Preparation of sawhorse-type diruthenium tetracarbonyl complexes (37-40) 
[Ru2(CO)4(μ2-η
2
-O2CC44H29N4)2(NC5H5)2] (37) 
A solution of Ru3(CO)12 (19 mg, 0.03 mmol) and 5-(4-carboxyphenyl)-10,15,20-
triphenyl-21,23H-porphyrin (65 mg, 0.09 mmol) in dry thf (25 mL) were heated at 120 ºC in 
a high pressure schlenk tube for 18 h. After cooling to room temperature, pyridine (7.4 µL, 
0.09 mmol) was added and the solution was stirred for 2 h. The product was isolated by 
precipitation from dichloromethane/pentane mixture and dried under vacuum. The product 
was obtained as air-stable purple crystalline powder.  
Yield: 35 mg (65 %).
 1
H NMR (400 MHz, CDCl3) δ = -2.76 (s, 4 H, NH), 7.65 (t, 4 H, 
3
J = 7 
Hz, Hpy), 7.74-7.81 (m, 18 H, Hporph), 7.96 (t, 2 H, 
3
J = 8 Hz, Hpy), 8.21-8.25 (m, 16 H, 
Hporph), 8.40 (d, 4 H, 
3
J = 8 Hz, Hporph), 8.85 (s, 8 H, Hporph), 8.86 (s, 8 H, Hporph), 9.23 (d, 4 H, 
3
J = 4 Hz, Hpy) ppm. IR (KBr, cm
-1
) ν(OCO) 1545.04 s, ν(NCN) 1587.90 s, ν(CO) 1942.72 vs, 
1976.26 m, 2026.28 vs, ν(C-H aro) 3054.66 m. Anal. Calc. for C104H68N10O8Ru2 ∙ 3 H2O 
(1841.88) C 67.82, H 4.05, N 7.60; found: C 67.60, H 3.88, N 7.47 %. ESI-MS (positive 
mode): m/z = 816.13 [M - 2 C5H5N + 2 H]
2+
. 
[Ru2(CO)4(μ2-η
2
-O2CC44H27N4Zn)2(NC5H5)2] (38) 
The same procedure as for 1 was used: Ru3(CO)12 (19 mg, 0.03 mmol), 5-(4-
carboxyphenyl)-10,15,20-triphenyl-porphyrin-Zn(II) (68 mg, 0.09 mmol), and pyridine (7.4 
µL, 0.09 mmol). The product was isolated by precipitation from a dichloromethane/pentane 
mixture and dried under vacuum. The product was obtained as air-stable purple crystalline 
powder. 
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Yield: 35 mg (61 %). 
1
H NMR (400 MHz, CDCl3) δ = 7.65 (t, 4 H, 
3
J = 7 Hz Hpy), 7.72-7.80 
(m, 18 H, Hporph), 7.96 (t, 2 H, 
3
J = 7 Hz, Hpy), 8.20-8.24 (m, 16 H, Hporph), 8.39 (d, 4 H, 
3
J = 
8 Hz, Hporph), 8.92 (s, 8 H, Hporph), 8.93 (s, 8 H, Hporph), 9.23 (d, 4 H, 
3
J = 4 Hz, Hpy) ppm. IR 
(KBr, cm
-1
) ν(OCO) 1560.83 s, ν(NCN) 1597.11 s, ν(CO) 1940.96 vs, 1973.77 m, 2024.02 vs, ν(C-H 
aro) 3056.63 m. Anal. Calc. for C104H64N10O8Ru2Zn2 ∙ 3CH2Cl2 ∙ H2O (2187.46) C 58.75, H 
3.32, N 6.40; found: C 58.51, H 3.48, N 6.42 %. ESI-MS (positive mode): m/z = 877.54 [M - 
2 C5H5N + 2 H]
2+
. 
[{Ru2(CO)4(NC5H5)2}2(μ2-η
2
-O2CC44H28N4CO2-η
2
-μ2)2] (39) 
The same procedure as used for the preparation of 1 was followed using Ru3(CO)12 
(48 mg, 0.075 mmol), 5,10-di-(4-carboxyphenyl)-15,20-diphenyl-21,23H-porphyrin (80 mg, 
0.114 mmol) and pyridine (18 µL, 0.23 mmol). In order to improve the purity, the raw 
product was subjected to chromatography on silica gel using dichloromethane/pentane 
mixture as eluent. The complex was obtained as an air-stable purple crystalline powder. 
Yield: 36 mg (20 %). 
1
H NMR (400 MHz, CDCl3) δ = -2.81 (s, 4 H, NH), 7.61 (t, 8 H, 
3
J = 7 
Hz, Hpy), 7.76-7.80 (m, 12 H, Hporph), 7.91-7.95 (m, 4 H, Hpy), 8.18-8.22 (m, 18 H, Hporph), 
8.38 (d, 8 H, 
3
J = 8 Hz, Hporph), 8.76-8.87 (m, 16 H, Hporph), 9.20 (d, 8 H, 
3
J = 4 Hz, Hpy) ppm. 
IR (KBr, cm
-1
) ν(OCO) 1546.98 s, ν(NCN) 1591.63 s, ν(CO) 1940.75 vs, 1974.49 m, 2024.96 vs, 
ν(C-H aro) 3047.61 m. Anal. Calc. for C120H76N12O16Ru4 ∙ C5H12 · H2O (2436.40) C 61.62, H 
3.72, N 6.90; found: C 61.60, H 3.82, N 6.37 %. ESI-MS (positive mode): m/z = 1095.12 [M 
- 2 C5H5N + 2 H]
2+
. 
[{Ru2(CO)4(NC5H5)2}2(μ2-η
2
-O2CC44H26N4ZnCO2-η
2
-μ2)2] (40) 
The same procedure as for 1 was used: Ru3(CO)12 (25 mg, 0.04 mmol), 5,10-di-(4-
carboxyphenyl)-15,20-diphenyl-porphyrin-Zn(II) (29 mg, 0.06 mmol) and pyridine (10 µL, 
0.12 mmol). In order to improve the purity, the raw product was subjected to chromatography 
on silica gel using dichloromethane/pentane mixture as eluent. Air-stable purple crystalline 
powder was isolated after evaporation of the solvent. 
Yield: 20 mg (21 %). 
1
H NMR (400 MHz, DMSO) δ = 7.35-7.38 (m, 8 H, Hpy), 7.74-7.77 (m, 
4 H, Hpy), 7.78-7.84 (m, 12 H, Hporph), 8.17-8.19 (m, 8 H, Hporph), 8.30 (d, 8 H, 
3
J = 8 Hz, 
Hporph), 8.46 (d, 8 H, 
3
J = 8 Hz, Hporph), 8.54-8.56 (m, 8 H, Hpy),  8.74-8.86 (m, 16 H, Hpy) 
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ppm. IR (KBr, cm
-1
) ν(OCO) 1543.98 s, ν(NCN) 1591.28 s, ν(CO) 1942.46 vs, 1974.82 m, 2026.10 
vs, ν(C-H aro) 3065.70 m. Anal. Calc. for C120H72N12O16Ru4Zn2 (2473.03) C 58.28, H 2.93, N 
6.80; Found: C 58.22, H 3.10, N 6.55 %. ESI-MS (positive mode): m/z = 1157.96 [M - 2 
C5H5N + 2 H]
2+
. 
 
6.11. Single-crystal X-ray structure analyses  
 All the crystals were mounted on a Stoe Image Plate Diffraction system equipped 
with a  circle goniometer, using Mo-Kα graphite monochromated radiation (λ = 0.71073 Å) 
with  range 0-200º. The structures were solved by direct methods using the program 
SHELXS-97, while the refinement and all further calculations were carried out using 
SHELXL-97.
172
 The H-atoms were included in calculated positions and treated as riding 
atoms using the SHELXL default parameters. The non-H atoms were refined anisotropically, 
using weighted full-matrix least-square on F
2
.
 
Crystallographic details are summarized in 
Table 14 - Table 23. ORTEP were used to draw the single crystal structures.
173
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Table 14. Crystallographic and structure refinement parameters for complex 1b. 
1b 
Chemical formula C54H56O8P2Ru2 
Formula weight 1097.07 
Crystal system  Triclinic 
Space group P-1 (No. 2) 
Crystal colour and shape  Yellow block 
Crystal size 0.23×0.19×0.16 
a (Å) 13.2493(13)  
b (Å) 14.4189(14) 
c (Å) 15.0855(15) 
α (°) 106.912(11) 
β (°) 93.503(12) 
γ (°) 109.986(11) 
V (Å
3
) 2549.6(4) 
Z 2 
T (K) 173(2) 
Dc (g·cm
-3
) 1.429 
μ (mm-1) 0.707 
Scan range (°) 2.17    26.18 
Unique reflections 9374 
Reflections used [I>2σ(I)] 6441 
Rint 0.0433 
Final R indices [I>2σ(I)]* 0.0370, wR2 0.0879 
R indices (all data) 0.0658, wR2 0.1115 
Goodness-of-fit 1.010 
Max, Min Δρ/e (Å-3) 0.836, -1.314 
 
* Structure was refined on F0
2
: wR2 = [Σ [w (F0
2
 - Fc
2
)
2]/ Σw(F0
2
)
2
]
1/2
, where w
-1
 = [Σ(F0
2
) + 
(aP)
2
 + bP] and P = [max(F0
2
, 0) + 2Fc
2
]/3. 
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Table 15. Crystallographic and structure refinement parameters for complex 2a. 
2a 
Chemical formula C32H44N2O8Ru2 
Formula weight 786.83 
Crystal system  Triclinic 
Space group P-1 (No. 2) 
Crystal colour and shape  Yellow block 
Crystal size 0.25×0.22×0.18 
a (Å) 10.6836(8) 
b (Å) 11.2916(9) 
c (Å) 15.8511(13) 
α (°) 69.609(6) 
β (°) 82.296(6) 
γ (°) 109.986(11) 
V (Å
3
) 1746.0(2) 
Z 2 
T (K) 173(2) 
Dc (g·cm
-3
) 1.497 
μ (mm-1) 0.913 
Scan range (°) 1.96    29.19 
Unique reflections 9140 
Reflections used [I>2σ(I)] 4338 
Rint 0.1547 
Final R indices [I>2σ(I)]* 0.0795, wR2 0.1691 
R indices (all data) 0.1783, wR2 0.1388 
Goodness-of-fit 0.929 
Max, Min Δρ/e (Å-3) 0.930, -0.839 
 
* Structure was refined on F0
2
: wR2 = [Σ [w (F0
2
 - Fc
2
)
2]/ Σw(F0
2
)
2
]
1/2
, where w
-1
 = [Σ(F0
2
) + 
(aP)
2
 + bP] and P = [max(F0
2
, 0) + 2Fc
2
]/3.s 
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Table 16. Crystallographic and structure refinement parameters for complex 3a. 
3a 
Chemical formula C32H48N2O8Ru2 
Formula weight 814.88 
Crystal system  Triclinic 
Space group P-1 (No. 2) 
Crystal colour and shape  Yellow block 
Crystal size 0.22×0.18×0.15 
a (Å) 10.6712(6) 
b (Å) 11.3078(7) 
c (Å) 16.3035(11) 
α (°) 78.011(5) 
β (°) 84.539(5) 
γ (°) 76.100(4) 
V (Å
3
) 1865.9(2) 
Z 2 
T (K) 173(2) 
Dc (g·cm
-3
) 1.450 
μ (mm-1) 0.858 
Scan range (°) 1.86    29.19 
Unique reflections 10080 
Reflections used [I>2σ(I)] 6410 
Rint 0.1053 
Final R indices [I>2σ(I)]* 0.0529, wR2 0.0837 
R indices (all data) 0.1041, wR2 0.0943 
Goodness-of-fit 0.928 
Max, Min Δρ/e (Å-3) 0.947, -0.857 
 
* Structure was refined on F0
2
: wR2 = [Σ [w (F0
2
 - Fc
2
)
2]/ Σw(F0
2
)
2
]
1/2
, where w
-1
 = [Σ(F0
2
) + 
(aP)
2
 + bP] and P = [max(F0
2
, 0) + 2Fc
2
]/3. 
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Table 17. Crystallographic and structure refinement parameters for complex 4a. 
4a 
Chemical formula C40H60N2O8Ru2 
Formula weight 899.04 
Crystal system  Triclinic 
Space group P-1 (No. 2) 
Crystal colour and shape  Yellow block  
Crystal size 0.16×0.13×0.11 
a (Å) 10.6008(14) 
b (Å) 10.9131(17) 
c (Å) 18.886(3) 
α (°) 94.899(13) 
β (°) 96.721(12) 
γ (°) 101.726(12) 
V (Å
3
) 2111.1(5) 
Z 2 
T (K) 173(2) 
Dc (g·cm
-3
) 1.414 
μ (mm-1) 0.765 
Scan range (°) 1.92    29.37 
Unique reflections 11378 
Reflections used [I>2σ(I)] 3606 
Rint 0.2887 
Final R indices [I>2σ(I)]* 0.1064, wR2 0.2178 
R indices (all data) 0.2762, wR2 0.2874 
Goodness-of-fit 0.862 
Max, Min Δρ/e (Å-3) 1.722, -1.187 
 
* Structure was refined on F0
2
: wR2 = [Σ [w (F0
2
 - Fc
2
)
2]/ Σw(F0
2
)
2
]
1/2
, where w
-1
 = [Σ(F0
2
) + 
(aP)
2
 + bP] and P = [max(F0
2
, 0) + 2Fc
2
]/3. 
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Table 18. Crystallographic and structure refinement parameters for complex 5a. 
5a 
Chemical formula C42H64N2O8Ru2 
Formula weight 927.09 
Crystal system  Triclinic 
Space group P-1 (No. 2) 
Crystal colour and shape  Yellow block 
Crystal size 0.24×0.21×0.16 
a (Å) 10.6356(7) 
b (Å) 11.1666(8) 
c (Å) 19.3877(15) 
α (°) 88.198(6) 
β (°) 89.544(6) 
γ (°) 76.654(6) 
V (Å
3
) 2239.3(3) 
Z 2 
T (K) 173(2) 
Dc (g·cm
-3
) 1.414 
μ (mm-1) 0.724 
Scan range (°) 1.88    29.19 
Unique reflections 12099 
Reflections used [I>2σ(I)] 7893 
Rint 0.1744 
Final R indices [I>2σ(I)]* 0.0680, wR2 0.1419 
R indices (all data) 0.1120, wR2 0.1574 
Goodness-of-fit 0.967 
Max, Min Δρ/e (Å-3) 0.687, -1.219 
 
* Structure was refined on F0
2
: wR2 = [Σ [w (F0
2
 - Fc
2
)
2]/ Σw(F0
2
)
2
]
1/2
, where w
-1
 = [Σ(F0
2
) + 
(aP)
2
 + bP] and P = [max(F0
2
, 0) + 2Fc
2
]/3. 
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Table 19. Crystallographic and structure refinement parameters for complexes 8a. 
8a 
Chemical formula C22H10F14N2O8Ru2 
Formula weight 898.46 
Crystal system  Monoclinic 
Space group C 2/c (no. 15) 
Crystal colour and shape  Yellow block 
Crystal size 0.24 x 0.20 x 0.17 
a (Å) 15.630(3) 
b (Å) 17.900(4) 
c (Å) 10.860(2) 
β (°) 106.41(3) 
V (Å
3
) 2914.6(10) 
Z 4 
T (K) 293(2) 
Dc (g·cm
-3
) 2.048 
μ (mm-1) 1.175 
Scan range (°) 2.28 <  < 26.10 
Unique reflections 2797 
Observed refls [I>2σ(I)] 1918 
Rint 0.0441 
Final R indices [I>2σ(I)]* 0.0440, wR2 0.1231 
R indices (all data) 0.0616, wR2 0.1304 
Goodness-of-fit 0.998 
Max, Min Δρ/e (Å-3) 1.053, -0.531 
  
 
* Structure was refined on F0
2
: wR2 = [Σ [w (F0
2
 - Fc
2
)
2]/ Σw(F0
2
)
2
]
1/2
, where w
-1
 = [Σ(F0
2
) + 
(aP)
2
 + bP] and P = [max(F0
2
, 0) + 2Fc
2
]/3. 
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Table 20. Crystallographic and structure refinement parameters for complexes 10. 
10 
Chemical formula C48H44O8P2Ru2 
Formula weight 1012.91 
Crystal system  Monoclinic 
Space group C 2/c (no. 15) 
Crystal colour and shape  Yellow block 
Crystal size 0.25 x 0.23 x 0.18 
a (Å) 24.7037(11) 
b (Å) 9.5100(3) 
c (Å) 18.9324(9) 
β (°) 102.530(4) 
V (Å
3
) 4341.9(3) 
Z 4 
T (K) 173(2) 
Dc (g·cm
-3
) 1.550 
μ (mm-1) 0.824 
Scan range (°) 1.69 <  < 29.22 
Unique reflections 5854 
Observed refls [I>2σ(I)] 4532 
Rint 0.0842 
Final R indices [I>2σ(I)]* 0.0491, wR2 0.0876 
R indices (all data) 0.0734, wR2 0.0944 
Goodness-of-fit 1.044 
Max, Min Δρ/e (Å-3) 0.896, -0.799 
  
 
* Structures were refined on F0
2
: wR2 = [Σ[w (F0
2
 - Fc
2
)
2] / Σw (F0
2
)
2
]
1/2
, where w
-1
 = [Σ(F0
2
) + 
(aP)
2
 + bP] and P = [max(F0
2
, 0) + 2Fc
2
]/3. 
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Table 21. Crystallographic and structure refinement parameters for complexes 13b. 
13b 
Chemical formula C76H52O8P2Ru2 
Formula weight 1357.26 
Crystal system  Triclinic 
Space group P -1 (no. 2) 
Crystal colour and shape  Yellow block 
Crystal size 0.17 x 0.16 x 0.12 
a (Å) 9.9733(4) 
b (Å) 10.8151(5) 
c (Å) 28.7024(13) 
α (°) 89.544(3) 
β (°) 87.422(4) 
γ (°) 78.134(3) 
V (Å
3
) 3026.7(2) 
Z 2 
T (K) 173(2) 
Dc (g·cm
-3
) 1.489 
μ (mm-1) 0.612 
Scan range (°) 1.92 < < 29.21 
Unique reflections 16278 
Observed refls [I>2σ(I)] 12255 
Rint 0.0687 
Final R indices [I>2σ(I)]* 0.0444, wR2 0.0755 
R indices (all data) 0.0721, wR2 0.0817 
Goodness-of-fit 1.025 
Max, Min Δρ/e (Å-3) 0.565, - 0.657 
 
* Structures were refined on F0
2
: wR2 = [Σ[w (F0
2
 - Fc
2
)
2] / Σw (F0
2
)
2
]
1/2
, where w
-1
 = [Σ(F0
2
) + 
(aP)
2
 + bP] and P = [max(F0
2
, 0) + 2Fc
2
]/3 
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Table 22. Crystallographic and structure refinement parameters for complexes 14b. 
14b · 2C6H5Me 
Chemical formula C94H76O8P2Ru2 
Formula weight 1597.63 
Crystal system  Monoclinic 
Space group C 2/c (no. 15) 
Crystal colour and shape  Yellow block 
Crystal size 0.24 x 0.20 x 0.19 
a (Å) 36.0388(15) 
b (Å) 9.1563(3) 
c (Å) 28.5506(9) 
α (°) 90 
β (°) 126.953(2) 
γ (°) 90 
V (Å
3
) 7528.7(5) 
Z 4 
T (K) 173(2) 
Dc (g·cm
-3
) 1.409 
μ (mm-1) 0.504 
Scan range (°) 1.79 <  < 29.19 
Unique reflections 10175 
Observed refls [I>2σ(I)] 7424 
Rint 0.1236 
Final R indices [I>2σ(I)]* 0.0558, wR2 0.0752 
R indices (all data) 0.0911, wR2 0.0816 
Goodness-of-fit 1.055 
Max, Min Δρ/e (Å-3) 0.546, -1.274 
 
* Structures were refined on F0
2
: wR2 = [Σ[w (F0
2
 - Fc
2
)
2] / Σw (F0
2
)
2
]
1/2
, where w
-1
 = [Σ(F0
2
) + 
(aP)
2
 + bP] and P = [max(F0
2
, 0) + 2Fc
2
]/3 
 
 
 
 
 Chapter 6: Experimental Section 
 
 
 
152 
 
Table 23. Crystallographic and structure refinement parameters for complex 34a · 0.5 C6H6. 
34a · 0.5 C6H6 
Chemical formula C43H49N4O12Ru2S2 
Formula weight 1080.12 
Crystal system  Triclinic 
Space group P -1 (no. 2) 
Crystal colour and shape  Yellow block 
Crystal size 0.23 x 0.19 x 0.16 
a (Å) 10.4848(6) 
b (Å) 15.3189(11) 
c (Å) 18.2466(12) 
α (°) 72.648(5) 
β (°) 84.706(5) 
γ (°) 73.398(5) 
V (Å
3
) 2680.6(3) 
Z 2 
T (K) 173(2) 
Dc (g·cm
-3
) 1.338 
μ (mm-1) 0.697 
Scan range (°) 1.58 <  < 29.26 
Unique reflections 14483 
Observed refls [I>2σ(I)] 9716 
Rint 0.1231 
Final R indices [I>2σ(I)]* 0.0910, wR2 0.1523 
R indices (all data) 0.1472, wR2 0.1734 
Goodness-of-fit 1.131 
Max, Min Δρ/e (Å-3) 0.847, - 1.939 
 
* Structure was refined on F0
2
: wR2 = [Σ[w (F0
2
 - Fc
2
)
2] / Σw (F0
2
)
2
]
1/2
, where w
-1
 = [Σ(F0
2
) + 
(aP)
2
 + bP] and P = [max(F0
2
, 0) + 2Fc
2
]/3. 
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List of abbreviations 
thf  = tetrahydrofuran 
CCl4  = carbon tetrachloride 
CH2Cl2 = dichloromethane 
bpy  = 2,2’-bipyridine 
biisoq  = 1,1’-biisoquinoline 
dppe   = 1,2-bis(diphenylphosphino)ethane 
cyclop  = 1,2-bis(diphenylphosphinomethyl)cyclohexane 
diop  = 4,5-bis(diphenyl-phosphinomethyl)-2,2-dimethyl-1,3-dioxolane 
scCO2  = supercritical carbon dioxide 
STP  = standard temperature and pressure 
TOF  = catalytic turnover frequencies 
TON  = catalytic turnover number 
BARF  = tetrakis-{3,5-bis(trifluoromethyl)phenyl}borate 
CF3SO3 = trifluoromethanesulfonate 
binap  = 2,2’-bis(diphenylphosphino)-1,1’-binaphthyl 
dmpe  = (CH3)2P(CH2)2P(CH3)2 
dppe  = (C6H5)2P(CH2)2P(C6H5)2 
dfppe  = {CF3(CF2)5(p-C6H4)}2P(CH2)2P{(p-C6H4)(CF2)5CF3}2 
PTA  = 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane  
PPh3   = triphenylphosphine  
pyr   = pyridine 
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C60  = fullerene  
bpy  = 4,4’-bipyridine  
bpe  = 1,2-bis(4-pyridyl)ethylene  
5,10-dpp = 5,10-bis(4-pyridyl)-15,20-di-phenyl-21H,23H-porphyrin  
5,15-dpp = 5,15-bis(4-pyridyl)-10,20-diphenyl-21H,23H-porphyrin   
ESI-MS = electrospray mass spectrometry 
UV-Vis = ultraviolet-visible spectroscopy 
DOSY  = diffusion ordered spectroscopy 
NAMI-A = imidazolium trans-[imidazoledimethylsulfoxide-tetrachlororuthenate(III)] 
KP1019 = indazolium-trans-[tetrachlorobis(1H-indazole)ruthenate(III)] 
RAPTA-C = [(η6-p-MeC6H4Pr
i
)Ru(PTA)Cl2] 
RM175 = [(C6H5Ph)Ru(en)Cl][PF6] 
en  = ethane-1,2-diamine 
Me  = methyl group 
dpp  = 2,3-bis(2-pyridyl)pyrazine 
IR  = infrared spectroscopy 
MTT  = 3-(4,5-dimethyl-2-thiazoyl)-2,5-diphenyltetrazolium bromide 
IC50  = drug concentration necessary for 50% inhibition of cell survival 
LD50  = laser light dose necessary to inhibit 50 % cell survival 
DMSO  = dimethyl sulfoxide 
FDA  = food and drug administration 
PDT  = Photodynamic therapy 
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